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ABSTRACT 
Mini-matrix multiple unit dosage forms (MUDFs) of diclofenac sodium and S(+) 
ibuprofen have been prepared. Normal tabletting techniques were used to form the 
mini-matrices prior to their enclosure in hard gelatin capsules. Four natural hydrophilic 
gums, namely xanthan, karaya, locust bean and carrageenan gums as well as 
hydroxypropyl methylcellulose (HPMC) were used as the principle release-retarding 
agents. Various excipients - lactose, Encompress®, cellulose acetate phthalate (CAP), 
Veegum F® and Avicel PH101® - were added in different proportions to further modify 
drug release. 
The diclofenac sodium mini-matrices (4.5 mm in diameter) were produced by 
the wet granulation method. The release profiles from several encapsulated mini-
matrices in phosphate buffer solution (pH 7.0) showed that xanthan, karaya and locust 
bean gums could sustain the release of diclofenac sodium while the carrageenan gum 
did not produce a satisfactory sustaining effect. The rank order of decreasing swelling 
rate in both axial and radial dimensions was xanthan > karaya > locust bean gum and 
each of these gums showed almost Fickian swelling behaviour. The solvent 
penetration rates were consistent with the swelling rates. However, the order of 
decreasing drug release and erosion rates was locust bean> xanthan > karaya gum. 
For each of these gums, the release behaviour was anomalous indicating that both 
Fickian drug diffusion and polymer relaxation were involved in the release process. 
The dominant mechanism depended on the nature and content of the gum, as well as 
the stage in the dissolution period. The study involving xanthan gum showed that the 
diclofenac sodium release rate declined linearly with a progressive increase in the gum 
content, without changing the release behaviour. However, for high drug: xanthan gum 
ratio (2:1), the release kinetics changed to Super Case II. Solubility differences 
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between the excipients did not affect the release rate, but increasing proportions of 
each excipient produced a faster release rate with the release mechanism changing 
from anomalous to Case II and then to Super Case II transport. Mini-matrices 
containing HPMC produced faster drug release than those containing the three natural 
gums. There was no synergistic effect between xanthan and locust bean gums on the 
release of diclofenac sodium from mini-matrices. Variation in the stirring speed (used 
in the dissolution apparatus) and matrix volume had little effect on drug release, 
whereas the pH of the dissolution medium greatly affected the release of diclofenac 
sodium. 
Following on from the studies involving diclofenac sodium, xanthan and karaya 
gums were used to produce mini-matrices of S(+) ibuprofen. Excipients with good 
compressibility characteristics such as lactose, Encompress® and Avicel PH101® were 
needed in the formulations. At pH 7, higher drug release rates were obtained with 
karaya gum (Super Case II mechanism) compared with xanthan gum (anomalous 
behaviour). Solubility differences between the excipients slightly affected the release 
rate. Compression forces (11 - 26 kN) slightly affected the crushing strength. The mini-
matrices were relatively stable to variation in temperature (5 - 37°C) and relative 
humidity (10 - 75%) over a 2 month time period. 
These studies have shown that near zero-order release of diclofenac sodium 
and S(+) ibuprofen can be achieved using encapsulated mini-matrices formulations. 
The release mechanisms and release rates can be adjusted by variation of the type 
and content of gums and/or excipients. 
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CHAPTER 1 
INTRODUCTION 
1.1 ORAL SUSTAINED-RELEASE DRUG DELIVERY SYSTEMS 
Oral delivery is the most acceptable route for delivery of drug to patients, 
whether this be in the form of liquid or solid preparations. By this route, the tablet and 
the capsule are the most commonly prescribed dosage forms because they offer a 
convenient form of drug administration, provide dosage uniformity, are stable over 
extended and diverse storage conditions and can be produced on high-speed 
equipment (Lieberman et a!. 1990; Deshpande et a!. 1996). 
Normal drug dosing may follow a "sawtooth" kinetic profile (Figure 1.1). During 
the early periods of dosing there may be insufficient drug to generate a favourable 
biological response. The following doses may lead to a toxic level (over the desired 
therapeutic level), which then falls to a subclinical level, and on subsequent dosing 
rises to dangerously high level, falling again to ineffective concentrations, in continuous 
cycles of excessive-ineffective levels. Several technical advancements have been 
developed in order to control the rate of drug delivery, sustain the duration of 
therapeutic activity, eliminate dangerous side effects, and/or target the delivery of drug 
to a tissue (Martin 1993; Chien 1992; Lee and Robinson 1979; Lordi 1986). 
The term "sustained release" is used to describe a drug delivery system that 
delays and/or prolongs the release of drug. It also implies delayed therapeutic action 
and sustained duration of therapeutic effect. The term "controlled release" has a 
meaning that goes beyond the scope of sustained drug action. It also implies a 
predictability and reproducibility in the drug release kinetics. In other words, sustained-
release dosage forms provide medication over an extended time period whereas 
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controlled release systems attempt to control drug concentrations in the target tissue 
(Chien 1992; Ansel et al. 1995). But Lordi (1986) states that the terms "sustained 
release", "sustained action", "prolonged action", "controlled release", "extended action", 
"timed release", "depot" and "repository" dosage forms all describe the same delay in 
release of drug. 
Toxic level 
Therapeutic range 
Subtherapeutic level 
o 8 18 Z4 3Z 40 48 
Time (hour) 
Figure 1.1. Undesirable sawtooth kinetic profile under conditions of normal dosing. 
1.2 DESIGNS OF ORAL SUSTAINED-RELEASE DRUG DELIVERY 
SYSTEMS 
Two general methods have been developed for implementation of practical 
sustained-release dosage form designs: 1) methods based on modification of the 
physical and/or chemical properties of the drug and 2) methods based on modification 
of the drug release rate characteristics of the dosage that effect bioavailability (Lordi 
1986). 
Controlled-release drug delivery systems based on dosage form modification 
can be classified into three categories. 
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1. Rate-preprogrammed drug delivery systems. The release of drug molecules 
from the delivery systems has been preprogrammed at specific rate profiles. This is 
accomplished by system design, which controls the molecular diffusion of drug 
molecules in and/or across the barrier medium within or surrounding the delivery 
system. 
2. Activation-modulated drug delivery systems. The release of drug molecules 
from the delivery systems is activated by some physical, chemical, or biochemical 
processes and/or facilitated by the energy supplied externally. The rate of drug release 
is then controlled by regulating the process applied or energy input. 
3. Feedback-regulated drug delivery systems. The release of drug molecules 
from the delivery systems is activated by a triggering agent, such as a biochemical 
substance, in the body and also regulated by its concentration via some feedback 
mechanism. The rate of drug release is controlled by the concentration of triggering 
agent detected by a sensor in the feedback-regulated mechanism. 
All three categories of controlled-release drug delivery systems consist of the 
following common structural features: 1) drug reservoir compartment, 2) rate-
controlling element, and 3) energy source. 
The rate-preprogrammed drug delivery system can be viewed as the first 
generation of controlled-release drug delivery systems, providing the technological 
basis for the later development of activation-modulated drug delivery systems, as the 
second generation, and of feedback-regulated drug delivery systems, as the third 
generation. 
Rate-preprogrammed drug delivery systems are constructed from the two basic 
types of controlled-release drug delivery systems (Chien 1992). 
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1) Polymer membrane permeation-controlled drug delivery systems. 
In this system the drug reservoir compartment is encapsulated inside a 
polymeric membrane, which acts as a rate-controlling element and the release of drug 
is controlled by its permeation through the rate-controlling membrane (Figure 1.2). 
+---- Polymer membrane 
~.J+-- Drug core I reservoir 
Figure 1.2. Polymer membrane permeation-controlled drug delivery systems. 
2) Polymer matrix diffusion-controlled drug delivery systems. 
In this system the drug substance is homogeneously dispersed throughout a 
polymer matrix, which acts as rate-controlling element, and the release of drug is thus 
controlled by its diffusion through the rate-controlling polymer matrix (Figure 1.3). This 
system was used in this study in the form of a hydrophilic matrix. 
Drug embedded In polymer matrix 
Figure 1.3. Polymer matrix diffusion-controlled drug delivery systems. 
1.2.1 Properties of drugs used In sustained-release formulations 
In general, the drugs best suited for incorporation into a sustained release 
product should have certain characteristics. 
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1) They should exhibit neither very slow nor very fast rates of absorption and 
excretion. Drugs with slow rates of absorption and excretion are usually inherently 
long-acting and their preparation into sustained-action type dosage forms is not 
necessary. Similarly, a drug with a short half life, i.e., < 1 hours, should not be 
formulated into a sustained release product because such a delivery system would 
require unacceptably large release rates and doses. 
2) They should be uniformly absorbed from the gastrointestinal tract. Drugs 
absorbed poorly or at varying and unpredictable rates are not good candidates for 
sustained-release products, because their drug release and therefore drug absorption 
will fluctuate, depending upon the position of the drug in the gastrointestinal tract and 
the dosage form's rate of movement within the tract. 
3) They should be administered in relatively small doses. Drugs with large 
single doses frequently are not suitable for the preparation of the sustained-action 
product because the individual dosage unit needed to maintain the extended 
therapeutic blood level of the drug would have to be too large for the patient to easily 
swallow. 
4) They should possess a good margin of safety. Those drugs which are 
potent in very small doses or possess very narrow or small therapeutic indices are 
poor candidates for formulation into controlled-release formulations because of 
technological limitations of precise control over release rates. 
5) They should be used in the treatment of chronic rather than acute 
conditions. Drugs for acute conditions generally require more physician control of the 
dosage than that provided by sustained-release products (Ansel et al. 1995; Lordi 
1986). 
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1.2.2 Hydrophilic matrix (HM) 
The hydrophilic matrix (a polymer matrix diffusion-controlled drug delivery 
system) is defined as an homogeneous mixture of substances, substantially 
comprising polymers which are slowly dissolved in water. They are converted into a 
well defined form by compression or encapsulation. When a HM tablet is in contact 
with water or aqueous based dissolution media such as the gastro-intestinal juices, the 
hydrophilic polymers form a gelatinous surface layer, through which water slowly 
penetrates, hydrating and swelling the polymer. Then the polymer in the gel form, 
gradually goes into solution, first the outermost layer and thereafter the inner layers, 
until it is totally dissolved. The active substance is slowly released by two 
contemporaneous mechanisms, namely diffusion through the gelatinous layer and gel 
erosion. While the first of these release mechanisms prevails when the drug is very 
soluble in the dissolution medium, the second prevails in case of poorly soluble drugs 
(Calanchi et al. 1987). 
HM tablets have been used extensively to produce sustained drug delivery by 
the gastro-intestinal (GI) route (Huber and Christenson 1968; Lapidus and Lordi 1968 
and Mockel and Lippold 1993) because they are relatively simple, inexpensive, 
versatile and utilise conventional processing equipment. Various types of swellable 
polymers have been used to produce hydrophilic matrices for sustained release 
formulations. Hydroxypropyl methylcellulose (HPMC) alone or in combination with 
other polymers, is frequently used as mentioned in the reviews by Hogan (1989) and 
Alderman (1984). It has been used mostly in the form of matrix tablets and matrix 
pellets (Tapia et aI., 1993). 
Drug release from a hydrophilic matrix is determined by a diverse range of 
factors that can be classified into 3 main categories: a) polymer variables, b) 
formulation and manufacturing, and c) environmental conditions. The mechanisms of 
6 
drug release from a HPMC matrix were extensively investigated (Sung et al. 1996; 
Wan et al. 1993; Pham and Lee 1994). In the case of polymer variables, the effect of 
polymer content (Ford et al. 1985a; Ford et al. 1985b; Hogan 1989; Panomsuk et al. 
1995b; Kabanda et al. 1994; Michell et al. 1993; Sung et al. 1996; Xu and Sunada 
1995) and type (Sheu et al. 1992; Lapidus and Lordi 1968; Panomsuk et al. 1995b; 
Kabanda et al. 1994; Sung et al. 1996) on drug release was considered. Polymer 
molecular weight (often expressed as solution viscosity) is generally accepted to be a 
controlling factor (Chang and Parrot 1991). However, this is only valid when dealing 
with a single type of polymer. Also important are the rheological properties of the 
polymer. In the case of formulation and manufacturing, the effect of drug type (Ford et 
al. 1987), drug particle size (Ford et al. 1985a; Ford et al. 1985b; Hogan 1989), drug 
content (Mitchell et al. 1993; Xu and Sunada 1995), excipient type (Lapidus and Lordi 
1968; Ford et al. 1987; Hogan 1989; Panomsuk et al. 1995b; Kabanda et al. 1994; 
Feely and Davis 1988a; Feely and Davis 1988b; Sheskey et al. 1995), compression 
force (Ford et al. 1985a; Kabanda et al. 1994; Vazquez et al. 1992) and matrix size 
and shape (Ford et al. 1987; Hogan 1989; Panomsuk et al. 1995b) on drug release 
has been investigated. Environmental conditions, for example, the effect of added salt, 
dissolution medium pH (Sheu et al. 1992) and temperature (Larpidus and Lordi 1968) 
on drug release has also been investigated. It can be concluded from these works that 
in a properly developed formulation, HPMC is a good matrix material for sustaining 
drug release. However, there is a report that certain ionic salts and drugs, e.g., 
diclofenac sodium, cause failure of sustained release of HPMC matrices because they 
substantially depress the thermal gelation temperature of HPMC (Rajabi-Siahboomi et 
al. 1993). In addition, one study showed burst release of propranolol hydrochloride 
from HPMC matrix at low content of drug (20 mg per 150 mg HPMC) (Mitchell et al. 
1993). Therefore other hydrophilic materials have been examined to overcome these 
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problems. Among these, xanthan gum is an interesting sUbstance (Talukda and 
Plaizier-Vercammen 1993; Talukda and Kinget 1995; Lu et al. 1991; Dhopeshwarkar 
and Zatz 1993; Talukdar et al. 1996). It is a high molecular weight 
heteropolysaccharide. The viscosity of its gel is nearly independent of pH, ionic 
strength and temperature (see also Chapter 2). Xanthan gum is compatible with 
virtually all salts. For these reasons, it has been chosen for production of diclofenac 
sodium and S(+) ibuprofen matrices in this study. The other three hydrophilic gums 
used were karaya gum, locust bean gum and carrageenan. 
1.2.3 Mechanisms of drug release 
Modelling of controlled release of drugs from polymeric devices has been the 
subject of considerable research over the past 20 years. Korsmeyer et al. (1983) 
derived a simple relationship which described drug release from a polymeric system 
M, = ktn ................................................... (1.1) 
Ma 
where M, / Ma is the fraction of drug released, t is the release time, k is a kinetic 
constant (with units of r") incorporating structural and geometric characteristics of the 
release device and n is the release exponent indicative of the mechanism of release. 
This equation can be used to analyze the first 60% of a release curve where the 
release is linearly related to (I, regardless of geometric shape. 
Sinclair and Peppas (1984) and Peppas (1985) have also shown that two 
competing release mechanisms, a Fickian diffusional release and a Case-II 
relaxational release, are the limits of this phenomenon. Fickian diffusional release 
occurs by the usual molecular diffusion of the drug due to a chemical potential 
gradient. Case-II relaxational release is the drug transport mechanism associated with 
stresses and state-transition in hydrophilic glassy polymers which swell in water or 
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biological fluids. This term also includes polymer entanglement and erosion. Table 1.1 
describes the limits of this analysis for cylindrical shape e.g. a tablet. The value of the 
exponent for case-II transport mechanism is twice that of pure Fickian diffusional 
mechanism. 
Table 1.1. Diffusion exponent and solute release mechanism for cylindrical shape. 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n<0.89 Anomalous (non-Fickian) diffusion 
0.89 Case II transport 
n>0.89 Super Case II transport 
Following a heuristic approach first developed by Alfrey et al. (1966) for the 
case of solvent transport in a polymer, the two phenomena controlling the release can 
be considered as additive. Therefore, Equation 1.1 may be extended (Peppas and 
Sahlin 1989) 
where the first term of the right-hand side is the Fickian contribution, the second term 
being the Case-II relaxational contribution. The coefficient m is the purely Fickian 
diffusion exponent for a device of any geometric shape which exhibits controlled 
release. This coefficient was given for any shape, including cylinders, tablets and films 
by a diagram (Figure 1.4). 
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Figure 1.4. Diffusional exponent, m, of Equation 1.2 for Fickian diffusional drug 
release from mini-matrices as a function of their aspect ratio; a ratio of diameter (2a) to 
thickness of the tablet (I) (From Peppas and Sahlin 1989. Int J Pharm, 57,169-172.). 
Equation 1.2 can be rewritten as: 
M, = k)I"'[l +~1"'] ....................................... (1.3) 
Ma k) 
The percentage of drug release due to the Fickian mechanism, F, is clearly 
calculated as: 
F= 1 
k 1+-21"' 
k) 
................................................ (1.4) 
which leads to the ratio of relaxational over Fickian contributions as: 
R k2", 
-=-1 .................................................... (1.5) 
F k) 
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Therefore, Equations 1.2 and 1.3 indicate that solute release from any device, 
irrespective of its geometric shape, can be written in terms of a Fickian and a 
relaxational contribution. If the Fickian contribution can be expressed as a function of 
f', then the relaxational contribution can be expressed as a function of fm. By 
comparison of Equations 1.1 and 1.2 it is concluded that m=n when the relaxational 
mechanism is negligible. 
Although the constant k in Equation 1.1 is one of the measures of the drug 
release rate, it should not be used for comparison because there are different kinetics 
in different test conditions. Therefore, to characterize the drug release rate in different 
experimental conditions, mean dissolution time (MDT) was calculated from dissolution 
data according to Mockel and Lippold (1993) using Equation 1.6. 
MDT = _n_k-y' ........................................... (1.6) 
n+l 
For calculation of the release rate of the drug, the data in this study were 
subjected to the Higuchi equation (Higuchi 1961): 
Q = (2ADCst)M ............................................. (1.7) 
where Q is the percentage of drug release at time t, A is the total concentration of drug 
in the mini-matrix, D is the diffusion coefficient of the drug in the mini-matrix and Cs is 
the solubility of drug in the mini-matrix. This equation may be reduced to a simple 
equation as: 
Q = aIM + c .................................................... (1.8) 
Equation 1.8, for release data dependent on the square root of time, would give 
a straight line release profile, where a is a ..Jtime dissolution rate constant and c is a 
constant. The lag period, prior to the commencement of release, is defined as (-cla)2. 
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1.3 ADVANTAGES AND DISADVANTAGES OF SUSTAINED-RELEASE 
DRUG DELIVERY SYSTEMS 
1.3.1 Advantages of sustained-release drug delivery systems 
Sustained drug delivery systems are convenient items. They accomplish more 
efficiently what conventional dosage forms accomplish with real clinical benefits. Some 
of the potential benefits to be gained from sustained drug delivery are now considered. 
1) Enhanced patient compliance and convenience. Patient compliance is a 
chronic problem for all self-administered drugs and is a suffiCiently compelling reason 
in itself to warrant a prolonged-action delivery system. It is a very important component 
of successful drug therapy. With less frequency of dose administration the patient is 
less apt to neglect taking a dose. Rate-controlled products deliver more than a single 
dose of medication and thus are taken less often than conventional forms. 
2) Reduction in amount of drug required. The net effect of reduction in drug use 
is usually a decrease or elimination of systemic or local side effects. Other advantages 
are to gain less potentiation or reduction of drug activity with chronic use and minimize 
drug accumulation with chronic dosing. 
3) Improved efficiency in treatment. This is the most important reason for 
sustained drug delivery. Proper drug delivery should lead to a more prompt cure or 
control of the condition at hand as well as better management of acute and chronic 
conditions. This effect has many therapeutic and non-therapeutic ramifications 
including perhaps a financial saving to the patient in terms of lost work days, less 
hospitalization, fewer visits to the physician, etc. 
4) Reduction in health care costs, i.e., economy. This economy should be 
viewed in a broad sense, since the unit cost of most sustained and/or controlled drug 
delivery systems is usually greater than conventional dosage forms because of the 
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special nature of these products. However, when measured against the total cost 
savings in health care it seems reasonable to assume that many of these products are 
already economical to the patient and the savings should be even greater (Lee and 
Robinson 1979; Ansel et al. 1995; Lordi 1986; Calanchi et al. 1987). 
1.3.2 Disadvantages of sustained-release drug delivery systems 
Disadvantages of these systems must also be considered. 
1) Administration of sustained release medication does not permit the prompt 
termination of therapy. Immediate changes in drug need during therapy, such as might 
be encountered if significant adverse effect are noted, cannot be accommodated. 
2) The physician has less flexibility in adjusting dosage regimens. This is fixed 
by the dosage form design. 
3) Sustained release forms are designed for the normal population, i.e., on the 
basis of average drug biologic half-lives. Consequently, disease states that alter drug 
disposition, significant patient variation, and so forth are not accommodated. 
4) Economic factors must also be assessed, since more costly processes and 
equipment are involved in manufacturing sustained release forms (Lordi 1986). 
1.4 MULTIPLE UNIT DOSAGE FORMS (MUDFs) 
Multiple units dosage forms (MUDFs) or multiparticulate dosage forms are 
those in which a single dose of a therapeutic agent is administered subdivided into 
many small dosage units. For oral administration, sufficient units to comprise a single 
therapeutic dose is usually enclosed in a hard gelatin capsule, a disintegrating tablet or 
in a sachet. MUDFs are widely used for oral pharmaceuticals and whilst occasionally 
13 
they may provide immediate release products, by far their major use is as controlled 
release devices providing delayed or sustained release of drug (Melia 1994). 
Some of the common technologies used in the pharmaceutical industry for the 
production of oral MUDFs are extrusion/spheronisation, non-pareil coating, 
granulation, tabletting, microencapsulation, spray coating, ion-exchange complexation 
and macromolecular complexation. The decision to choose a particular technology for 
the production is influenced by many factors. Some of the principle factors are listed 
below. 
• Drug: dose, stability, physicochemical characteristics, pharmacokinetic profile, 
compatibility with excipients. 
• Dosage form: drug release profile, in vivo performance, therapeutic efficacy, 
stability. 
• Manufacturing: equipment availability, capital expenditure, existing expertise, 
production costs, time and ease of manufacture, batch to batch reproducibility. 
• Other: patent protection, patient acceptability, product image. 
1.4.1 Advantages of MUDFs 
With a move towards 12 or 24 hourly dosing regimes, sustained release 
preparations must contain greater amounts of drug than the conventional dose form 
equivalent and consequently the size of the monolithic unit is increased. MUDFs allow 
much greater dosing flexibility. Incompatible drugs or excipients may be co-
administered. 
One of the major problems associated with large single controlled release units 
above a certain size is the variability in the gastric emptying patterns which are 
displayed both in fasted and fed subjects. MUDFs have much more reproducible 
gastriC emptying patterns leading to more reproducible bioavailability of certain drugs. 
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The report from Digranes and co-workers (1984) showed that food affects the 
absorption of erythromycin pellets less than it affects erythromycin stearate enteric-
coated tablets. Erythromycin pellets also produced better reproducibility in absorption 
than the enteric-coated tablets both within and between subjects (Graffner et al. 1986). 
The absorption of erythromycin from enteric-coated pellets given 1 hour before food is 
better and more reliable than film-coated erythromycin stearate or enteric-coated 
erythromycin base (Josefsson et al. 1986). The erythromycin enteric-coated pellets 
also gave a higher maximum drug concentration than the film coated erythromycin 
stearate tablet (Josefsson et al. 1982). A study of acetylsalicylic acid showed that 
encapsulated enteric-coated granules gave more uniform plasma levels and less inter-
and intra-individual variation than enteric-coated tablets (Edgar et al. 1984). In the 
stomach the mixing of the MUDFs with food may avoid the high localised drug 
concentration associated with release from a large, single monolithic device. 
In a patient with normal bowel function, the transit of pellets through the colon 
is very much slower than with large single units. Pellets are better suited for delivery of 
drugs to the large bowel as larger units pass through more quickly due to a 
phenomenon called colonic streaming. In addition where the colon contents are more 
fluid such as secretory diarrhoea, the sieving function of the ascending colon is lost 
and all materials travel at the same rate. In these cases the use of high density pellets 
may prolong residence in the ascending colon. 
If a single monolithic dosage form unexpectedly disintegrates within the 
gastrointestinal tract, for example, as a result of the patient inadvertently chewing a 
controlled release dosage form, then it will release its payload as a bolus causing 
'dose dumping' of the drug. In MUDFs, failure of the unit is unlikely to cause disruption 
of all the particulates thus the dosage released will be minimal. For this reason MUDFs 
are associated with a reduced risk of toxicity. 
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Administering a drug as a multiparticulate reduces the probability of localised 
mucosal damage to the gastrointestinal tract. If a capsule or tablet sticks in the 
oesophagus or within the stomach or intestine, then the contents will be released onto 
a small area of the gut wall (Melia et al. 1994). 
1.4.2 Disadvantages of MUDFs 
If the technology chosen is new to a pharmaceutical company, then the 
disadvantages of using a MUDFs are primarily those of the cost and time in its 
development and introduction. Investment will be required in new plant, capital 
equipment and modifications to existing pilot and factory production staff and for them 
to develop "hands on" experience in product manufacture. Considerable time will be 
required to develop, commission and validate the production process, in which some 
unit processes may be unfamiliar, this is in addition to the normal time associated with 
developing the new controlled release product. 
Unforeseen difficulties may also arise in stability testing and quality control of 
the new product as a result of lack of a knowledge base and experience in the new 
technology. Even if the technology and expertise is well established, production costs 
and time for manufacture are often higher for MUDFs than for tablets. Many of these 
problems may be circumvented if development and/or manufacture of a product is 
subcontracted to a specialist company which offers expertise in a particular technology 
(Melia et al. 1994). 
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1.4.3 Technologies used in the production of MUDFs 
1.4.3.1 Extrusion/spheronisation 
Extrusion/spheronisation is one of the principle manufacturing methods used 
for production of multiple unit sustained-release dosage forms. The two main unit 
processes are used to produce spherical, drug-loaded "cores" of uniform diameter 
(0.5-2.0 mm), which can then be film-coated and filled into hard gelatin capsules 
(Hodsdon and Melia 1994). It is a mechanical method for mass-production of 
spheroidal particles from a wet powder mass; in effect, an automated version of the old 
traditional method of pill production by hand (Rowe 1983). Successful extrusion is 
highly dependent on the interplay between the formulation, the equipment and the 
processing conditions. Smooth extrudates will produce spheres of uniform particle size 
whilst extrudates having uneven density or surface roughness will result, at best, in 
wider particle size distributions and, at worst, may not successfully spheronise at all. 
1.4.3.2 Non-pareil coating 
Non-pareil seed coating or multilayer coating is the other main method used for 
production of multiple unit sustained-release dosage forms. It has a supporting inert 
core (non-pareil seed), ideally, a spherical granule of diameter 0.7 to 2.0 mm, coated 
with a homogeneous layer of active drug and excipients. Multilayer formulations may 
be more complex and a number of layers may be required to provide a drug release 
profile suitable for the required pharmacological profile (Alighieri et al. 1994). The 
rotating coating pan is the most extensively utilised type of equipment for the 
production of multilayer formulations. Careful choice of process control is needed to 
ensure product reproducibility. 
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1.4.3.3 Granulation 
The granules are produced in a similar way to conventional tablet granules, but 
they are coated with a release-controlling polymer. Ideally, the granule must be 
mechanically strong, well densified and resistant to impact-attrition and abrasion. 
These properties are essential in order to withstand the physical stresses of film 
coating and any subsequent processing (e.g. encapsulation, tabletting) required to 
produce the final dosage. Granule morphology is also important because it determines 
the level of polymer coating that is necessary to achieve uniform granule coverage. 
1.4.3.4 Microencapsulation 
The polymer is dissolved in an organic solvent, and drug is added to form a 
solution or suspension. The emulsifier is dissolved in a second liquid that is immiscible 
with the drug-polymer solution. The drug-polymer mixture is emulsified into the second 
surfactant-containing liquid phase to form a dispersion of drug-polymer solvent 
droplets. The solvent is then removed by evaporation, heat or vacuum might be used if 
necessary. The microsphere size can be controlled by using different mixing 
techniques. The completed drug polymer microspheres usually have a matrix structure 
with the drug homogeneously dispersed throughout the polymer. 
1.4.3.5 Tab/ettlng 
The methods mentioned could be both time consuming and costly to develop. 
Investment might be required in new equipment. Difficulties in quality control to assure 
product reproducibility may also arise and this is the important point to be considered. 
Tabletting is considered a good technique for preparing MUDFs. 
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Recent investigations (Munday et al. 1991; Colombo et al. 1985) have 
evaluated the potential of mini-matrices contained within hard gelatin capsules as 
controlled release oral multiparticulate formulations. In order to get a true 
multiparticulate dosage form, offering the benefits and advantages, it is necessary for 
the tablets to be as small as possible. For practical purposes, tablets between 2 mm 
and 5 mm diameter are used (Meyer et al. 1985). Tablets larger than this could not be 
contained in a hard gelatin capsule in any great number and tablets smaller than 2 mm 
would be extremely difficult to manufacture. Studies have shown that tablets of this 
general size have a similar gastric emptying pattern to standard pellet formulation 
(Feely et al. 1985). 
Most types of tablet (directly compressed, wet granulated, coated, layered etc.) 
can, in theory, also be produced at this smaller scale. Compression is conducted on 
standard tablet presses, but often punches containing up to four or even eight punch 
tips are utilised to increase production rates. These tablets can be filled into capsules 
using the same processes and equipment used to fill pellets. 
There are a number of benefits to be gained from the use of tablets. Tablet 
technology is widely understood, diverse and offers less constraints than, for example 
extrusion or spheronisation. Sustained-release tablets can be produced which employ 
a variety of different release mechanisms, e.g., diffusion, erOSion, osmotic, etc., unlike 
pellets which principally rely on diffusion through a rate controlling polymer coating. 
Since most companies have a tabletting capacity, multiparticulate products may also 
be produced without the need for extra capital expenditure. In addition, the mini-
matrices would have flexibility in dose adjustment. The dose could be tailored to meet 
the precise requirements of a particular patient, i.e., adjustment of the precise number 
of uniform mini-matrices to be enclosed in a capsule. The dose titration might be 
difficult with beads and pellets because the amount of drug in each particle is not 
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exactly known, and with granules, the irregular size and shape make dose titration 
even less precise. 
The disadvantages of mini-matrix formulations are that any problems 
associated with producing a standard size tablet, e.g., poor flow, segregation, capping, 
lamination, picking, etc., are likely to be amplified when producing a small tablet. 
Hence consideration of drug loading, excipient selection and formulation are key 
factors for a successful finished product (Feely and Sims 1994). 
Oiclofenac sodium hydrophilic matrix tablets using HPMC (Talukdar et al. 1996; 
Sheu et al. 1992), ethyl cellulose (Chattaraj and Oas 1996) or xanthan gum (Talukdar 
et al. 1996) as matrix materials had been studied. In order to achieve the benefits from 
both hydrophilic matrix and multiple unit dosage forms, the formulation of diclofenac 
sodium and also S(+) ibuprofen in the form of mini-matrix MUOFs is the main work in 
this study. 
1.5 TABLET MANUFACTURE 
The three basic methods for the preparation of compressed tablets are the wet 
granulation method, the dry granulation method and direct compression. 
1.5.1 Wet granulation 
Wet granulation is a widely employed method for the production of compressed 
tablets. For the powder mixture to flow evenly and freely from the hopper into the dies, 
it is usually necessary to convert the powder mixture to free-flowing granules by a 
process known as granulation. This is accomplished by adding a liquid binder or an 
adhesive to the powder mixture, passing the wetted mass through a screen of the 
desired mesh size, drying the granules, then passing them through a second screen of 
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smaller mesh to reduce further the size of the granules. The binding agent present in 
the tablets also contributes to the adhesion of the granules to one another, maintaining 
the integrity of the tablet after compression. 
1.5.2 Dry granulation 
In this method the granules are formed by compacting large masses of the 
mixture and subsequently crushing and sizing these pieces into smaller granules. By 
this method, either the active ingredient or the diluent must have cohesive properties in 
order for the large masses to be formed. This method is especially applicable to 
materials that cannot be prepared by the wet granulation method due to their 
degradation by moisture or to the elevated temperatures required for drying 
1.5.3 Direct compression 
Some granular chemicals possess free flowing as well as cohesive properties 
that enable them to be compressed directly in a tablet machine without the 
requirement of either wet or dry granulation. The tablet excipients used must be 
materials with properties of fluidity and compressibility (Ansel et al. 1995). 
1.6 IN VITRO ASSESSMENT OF ORAL SOLID DOSAGE FORMS 
In addition to the physical appearance and the uniformity of dosage unit, the 
most widely accepted reference method to assess the quality of the final product is the 
in vivo bioavailability testing; measuring drug levels in body fluids at various times after 
ingestion. However, this method has limitations. First, the body fluid drug levels do not 
necessarily correlate quantitatively with pharmacological response. Second, the data 
tend to be study-specific; the data from one set of patients and study conditions may 
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not be comparable to those of another set of patients and study conditions. Third, it is 
expensive and time consuming. So, the bioavailability test is used for reference 
purposes rather than for routine monitoring. 
The pharmaceutical industry has sought a rapid, inexpensive and precise 
means of measuring the pharmacological effectiveness of different formulations and 
batches of solid oral dosage forms. The in vitro dissolution test is used, i.e., the rate 
that the drug passes from the dosage forms into the solution is determined under 
controlled conditions. This test attempts to simulate the digestive process in a 
simplistic way. It is understood that this technique should not be used to make in vivo 
predictions unless the parameter chosen permit a correlation with bioavailability data. 
Caution must be exercised in selecting dissolution methodology for evaluating and 
optimizing formulations and for monitoring batch consistency (Dash et al. 1988). Under 
proper investigation, it is possible to create dissolution methodology which is so 
sensitive that it can detect differences which are not meaningful from a bioequivalence 
standpoint. 
1.7 OBJECTIVES OF THIS STUDY 
Most of the sustained-release diclofenac sodium products commercially 
available are the enteric-coated tablets. Several reports showed that this kind of tablet 
have failed to provide therapeutic plasma levels (Levy and Jusko 1967; Wagner et al. 
1973). Some showed delay in absorption compared with immediate release 
preparations (Leonard an Levy 1965) or with the fed state (Fischer et al. 1985). A 
potential factor influencing the onset of tablet disintegration is the delayed gastric 
emptying time (Wilding et al. 1992), resulting from food intake. 
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In order to overcome the bioavailability problems outlined above, a tabletted 
mini-matrix formulation containing diclofenac sodium was produced and a precise 
number of mini-matrices enclosed in a hard gelatin capsule was used as a MUDF. 
In addition, no oral S(+) ibuprofen products, neither immediate nor sustained 
release products, are available in the market. Many studies showing that the dose of 
S(+) ibuprofen can be reduced by 25-50% compared to the dose of racemic ibuprofen 
(Romero et al. 1991; Stock et al. 1991; Klein et al. 1992). Racemic ibuprofen is 
handled differently in patients with impaired liver function, suggesting that metabolic 
inversion of the inactive R(-) ibuprofen to the active S(+) ibuprofen may be affected by 
cirrhosis (Li et al. 1993). Hepatic elimination of ibuprofen is also impaired. Direct 
administration of S(+) ibuprofen may be advantageous because the metabolic load to 
the human body is reduced, the R(-) ibuprofen is potentially toxic and patients are 
more likely to comply with the smaller doses of S(+) ibuprofen (Li et al. 1993; Stock et 
al. 1991). The formulation of S(+) ibuprofen in the form of mini-matrix MUDFs is 
therefore worthy of investigation. 
The overall objective of this study was to prepare diclofenac sodium and S(+) 
ibuprofen oral sustained-release mini-matrix MUDFs. The physico-chemical properties 
of the drugs; diclofenac sodium and S(+) ibuprofen, and hydrophilic gums used in the 
formulation were investigated. Diclofenac sodium was the first model drug used to 
prepare mini-matrix MUDFs using the tabletting technique. The in vitro release profiles 
of these products were studied using the dissolution apparatus. The results were fitted 
with various equations to investigate the mechanism of drug release. The effect of 
certain factors; gum type, gum concentration, added excipients, swelling, solvent 
penetration front, erosion, etc., on drug release were also examined. The knowledge 
gained from these experiments was used to prepare S(+) ibuprofen mini-matrix 
MUDFs. The release profiles and mechanisms of S(+) ibuprofen products were also 
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studied. The stress storage test was applied with the S(+) ibuprofen finished product. 
The in vitro release profiles of commercially available products of diclofenac sodium 
and racemic ibuprofen were investigated and compared with the prepared products. 
The compatibility between model drugs and excipients (used in the successful 
preparations) were performed using DSC. 
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CHAPTER 2 
MATERIALS 
2.1 NATURAL HYDROPHILIC GUMS AND SYNTHETIC HYDROPHILIC 
POLYMER 
Natural hydrophilic gums; xanthan gum, karaya gum, locust bean gum and 
carrageenan gum, were purchased from Sigma Chemical Company (St. Louis, USA). 
Synthetic hydrophilic polymer, hydroxypropyl methylcellulose (HPMC), was purchased 
from Dow Chemical (Michigan, USA). The polymer and gums were the principal 
materials used to form mini-matrices and their physical properties are summarized in 
Table 2.1. 
2.1.1 Xanthan gum 
Xanthan gum is a high molecular-weight natural carbohydrate. It is a 
polysaccharide produced in a pure culture fermentation by the micro-organism 
Xanthomonas campestris, an organism originally isolated from the rutabaga plant 
(Cottrell et al. 1980). It occurs as a cream or white-coloured, odourless, free-flowing, 
fine powder (Daskalakis 1994). 
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Table 2.1. Physical properties of four natural hydrophilic gums and HPMC. 
Property 
M.W. 
Solubility 
Viscosity 
Rheology 
Effect of 
temperature 
on viscosity 
Effect of pH 
on viscosity 
Xanthan gum Karaya gum Locust bean gum Carrageenan HPMC 
2x10b --- - --~ ---- 3.1xW .-- No sharp M.w~, 2.6-3.2x10:'·--1-150x10<r 
for Kappa and 3.3-7.9x105 for 
Lambda-carrageenan 
Soluble in cold and warm 
water, insoluble in ethanol 
and ether 
1000 centipoises8 (1 Pa.s.) 
Pseudoplastic 
Stable at temperature range 
10-70·C 
Stable at pH range 6-9, pH 
range 1-11 slightly affects 
viscosity 
Soluble in water 
Non-Newtonian 
Boiling reduces the 
viscosity 
Addition of acid or alkali 
reduces the viscosity 
Soluble in water, full hydration 
when heated at 80·C for 10 min 
Pseudoplastic 
Thins out reversibly when heat is 
applied and degrades irreversibly 
with time when elevated 
temperature is maintained 
pH range 3-11 slightly affects 
viscosity 
Soluble in hot water (>75·C), Soluble in cold water, mixtures of 
solubility depends on the type ethanol/methanol and 
of carrageenan 
Thixotropic 
ViSCOSity reduces 
progressively when 
temperature increases 
Rate of hydration more rapid 
at low pH, considerably slower 
at pH 6 and above 
dichloromethane, insoluble in hot 
water, chloroform, ether 
0.005-75 Pa.s.b , depends on the 
type of HPMC 
Pseudoplastic 
Viscosity reduces when 
temperature increases, reversible 
sol to gel transformation upon 
heating and cooling, respectively 
Stable at pH range 3-11 
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Table 2.1. Physical properties of four natural hydrophilic gums and HPMC. (continued) 
Property Xanthan gum Karaya gum 
Incompatibility Cationic surfactants, Electrolyte e.g. Na~a~T, 
polymers, and preservatives, AICI3 , A12(S04h 
polyvalent metal ions (under 
highly alkaline condition), 
borate «300 ppm), oxidising 
agent, sodium CMC, dried 
AI(OHhgel 
a; 1 % aqueous solution, measured at 60 rpm, 2S
v 
C. 
b; 2% aqueous solution, measured at 20·C. 
Locust bean gum 
Some inorganic cations, basic 
salts, high concentration of 
calcium salt (under alkaline 
condition) 
Carrageenan HPMC 
High and low concentration of Some oxidizing agents 
divalent cations decreases 
and increases viscosity, 
respectively 
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2.1.1.1 Chemical structure 
M+ = Na, K, 1J2Ca 
Figure 2.1. The repeating-unit structure of xanthan gum. 
Xanthan gum is a heteropolysaccharide, containing mannose, glucose and 
glucuronic acid (as a mixed potassium, sodium and calcium salt). The molecular 
weight is approximately 2x106 and has been reported to be as high as 13 - 50x106. 
These differences in measurement are probably caused by association phenomena 
occurring between polymer chains. Figure 2.1 illustrates the repeating-unit structure of 
xanthan gum. Each repeating block has five sugar units: two glucose, two mannose 
and one glucuronic acid. The polymer backbone is made up of ~D-glucose units linked 
through the 1 and 4 positions, and is therefore identical in structure to cellulose. 
Trisaccharide side chains on alternating anhydroglucose units distinguish xanthan gum 
from cellulose. Each side chain comprises a glucuronic acid residue between two 
mannose units. Most of the terminal D-mannose residues carry a pyruvic acid residue 
linked ketalically to the 4 and 6 positions. The non-terminal D-mannose unit on the side 
chain has an acetyl group at the 6 position. The pyruvate and glucuronate groups 
account for the anionic nature of the polymer (Jansson et al. 1975; McNeely and Kang 
1973; Cottrell et al. 1980). 
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The shielding of the backbone of xanthan gum by its side chain could explain 
its extraordinary resistance to enzymes. Also unique among the natural gums are the 
unvarying chemical structure and the uniformity of chemical and physical properties of 
xanthan gum (Cottrell et al. 1980, Daskalakis 1994, Fitzpatrick 1995). 
2.1.1.2 Physical properties 
Solubility. Xanthan gum is practically insoluble in ethanol and ether, and 
soluble in cold or warm water (Daskalakis 1994). A 1% aqueous solution has pH 6-8 
and a viscosity of about 1000 centipoises (1 Pa.s.) when measured at 60 rpm with a 
Brookfield model LVF viscometer at 25·C. Aqueous solutions of xanthan gum are 
highly pseudoplastic (McNeely and Kang 1973). 
Effect of temperature. The viscosity of its aqueous solution is nearly 
independent of temperature over a wide temperature range. Between 10 and 70·C, a 
xanthan gum solution having a viscosity of 1000 cps will decrease in viscosity by not 
more than 100 cps (McNeely and Kang 1973). 
Effect of pH. The viscosity of aqueous solutions of xanthan gum is nearly 
independent of pH, between pH 6 and 9, and shows only minor variation in viscosity 
over a pH range of 1 to 11 (McNeely and Kang 1973). 
Compatibility. Xanthan gum has unusually good compatibility with high 
concentration of many salts and it will dissolve directly in moderate concentrations of a 
wide range of salts. Xanthan gum is compatible with most synthetic and natural 
viscosity-increasing agents (McNeely and Kang 1973). 
Incompatibility. Xanthan gum is an anionic material and is not usually 
compatible with cationic surfactants, polymers and preservatives since precipitation 
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Occurs. Anionic and amphoteric surfactants at concentrations above 15% cause 
precipitation of xanthan gum from a solution (Daskalakis 1994). 
Under highly alkaline conditions polyvalent metal ions, such as calcium, cause 
gelation or precipitation; this may be inhibited by the addition of a glucoheptonate 
sequestrant (McNeely and O'Connell 1966). Long-chain quaternary ammonium salts or 
amines with more than eight carbon atoms in the main chain may precipitate it 
(Rogovin and Albrecht 1964). The presence of low levels of borate «300 ppm) can 
also cause gelation. This may be avoided by increasing the borate ion concentration or 
by lowering the pH of a formulation to less than pH 5. The addition of ethylene glycol, 
sorbitol, or mannitol may also prevent this gelation. 
Xanthan gum solutions are stable in the presence of up to 60% water-miscible 
organic solvents such as acetone, methanol, ethanol or propan-2-01. However, above 
this concentration precipitation or gelation occurs (Daskalakis 1994). 
Xanthan gum is also incompatible with oxidising agents, some tablet film-
coatings (Evans and Fenton-May 1986), carboxymethylcellulose sodium (Walker and 
Wells 1982), dried aluminium hydroxide gel (Zatz et al. 1986) and some active 
ingredients such as amitriptyline, tamoxifen and verapamil (Bumphrey 1986). 
Stability to heat. Xanthan gum is remarkably resistant to degradation by heat. 
Long exposures to temperature as high as 80°C appear to have little effect on xanthan 
gum solutions. The resistance to degradation by heat is improved by the presence of 
salts (McNeely and Kang 1973). 
2.1.1.3 Reaction with locust bean gum 
Locust bean gum reacts strongly in solution with xanthan polysaccharide. The 
viscosity of xanthan gum solutions is considerably increased, or gelation occurs, in the 
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presence of locust bean gum, guar gum and magnesium aluminium silicate (Kovac 
1973). This effect is most pronounced in deionized water and reduced by the presence 
of salt. This interaction may be desirable in some instances and can be exploited to 
reduce the amount of xanthan gum used in a formulation. 
2.1.1.4 Applications 
Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics, and foods as a suspending and stabilizing agent (Bumphrey 1986; Evans 
and Fenton-May 1986). Recently, it has been reported that xanthan gum can be used 
alone or in the combination with other gums as an effective excipient for sustained-
release formulations (Lu et al. 1991; Dhopeshwarkar and Zatz 1993; Talukdar and 
Plaizier-Vercammen 1993). 
2.1.2 Karaya gum 
Karaya gum or sterculia gum is a complex water-soluble polysaccharide. It is a 
hydrophilic colloid prepared from the exudate of Sterculia urens Roxb and other 
species of Sterculia (Department of Health 1993). It is a finely ground white powder 
with a faint odour of acetic acid (Budavari 1996). 
2.1.2.1 Chemical structure 
Karaya gum is a partially acetylated polymer of galactose, rhamnose and 
glucuronic acid with a high molecular weight. It contains approximately 8% acetyl 
groups and around 37% uronic acid residues (Meer 1980). 
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2.1.2.2 Physical properties 
Karaya gum absorbs water very rapidly to form viscous mucilages at low 
concentration. The adhesive property of karaya gum is not related to its viscosity (Meer 
1980). 
Effect of temperature. The viscosity of a fully hydrated karaya gum solution 
decreases when the temperature is gradually raised from 20 to 85°C. Boiling reduces 
the viscosity of karaya gum solution, particularly when it is held at this temperature for 
more than 2 minutes. A higher maximum viscosity is obtained by cold hydration of 
karaya gum than is afforded by hot hydration (Goldstein and Alter 1973). The reduction 
in viscosity that is obtained by cooking karaya gum suspensions, especially under 
pressure, is accompanied by an increase in the solubility of the gum. Under these 
conditions, it forms a smooth, homogeneous, translucent, colloidal dispersion 
(Goldstein and Alter 1973). 
Effect of concentration. In dilute solutions of karaya gum, the viscosity 
increases linearly as the concentration increases up to about 0.5%. Thereafter, karaya 
gum dispersions exhibit non-Newtonian flow characteristics (Goldstein and Alter 1973). 
Effect of pH. Karaya gum maintains its solubility with changes in pH; the 
viscosity decreases upon addition of acid or alkali. Higher viscosities and pH stability 
OVer a wider range are obtainable when the gum is hydrated prior to pH adjustment. 
The solution colour lightens in acidic media and darkens in alkaline solutions because 
of the presence of tannins (Meer 1980). 
Incompatibility. The viscosity of karaya gum dispersions decreases when 
electrolytes, such as sodium, calcium, and aluminium chlorides and aluminium 
sulphate, are added (Meer 1980). 
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Stability. The viscosity of karaya gum suspensions remains constant for 
several days. Increased stability can be provided by the addition of preservatives. 
Karaya gum experiences a loss in viscosity when stored in the dry state; the loss is 
greater for a powdered material than for the crude gum (Money 1951). This decrease 
is most noticeable in the first few weeks after the gum has been ground, especially if it 
is stored under conditions of high humidity and temperature. Cold storage inhibits this 
degradation. It has been suggested that the decrease in viscosity is related to the loss 
of acetic acid (Meer 1980; Goldstein and Alter 1973). 
2.1.2.3 Applications 
Karaya gum is used as a bulk laxative and for adjusting faecal consistency. It 
has adhesive properties and is used in the fitting of ileostomy and colostomy 
appliances and in dental fixative powders. It is also used as an emulsifier and stabiliser 
in foods (Reynold 1996). 
2.1.3 Locust bean gum 
Locust bean gum is the ground kernel endosperms of the tree pod of Ceratonia 
siliqua L., Leguminosae (St John's bread). Its molecular weight is about 310,000. It is a 
yellow-green powder, odourless and tasteless but acquires a leguminous taste when 
bOiled in water (Budavari 1996). 
2.1.3.1 Chemical structure 
Locust bean gum is a carbohydrate polymer containing galactose and mannose 
as the structural building blocks. The ratio of the two components may vary slightly 
depending on the origin of the seed, but the gum is generally considered to contain 
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one galactose unit for every four mannose units (Seaman 1980). Its structure is a 
linear chain of f3-D-mannopyranosyl units linked 1, 4 with single-membered a-D-
galactopyranosyl units occurring as side branches. The a-D-galactopyranosyl units are 
linked 1, 6 with the main chain. The side branches are not spaced uniformly (Seaman 
1980). 
2.1.3.2 Physical Properties 
Solubility. Locust bean gum has limited solubility in water at ambient 
temperature. The gum will hydrate and develop its properties when its solutions are 
heated. It will reach full hydration when heated for 10 minutes at 80·C. Upon cooling, it 
remains in solution in dissociated, extended molecular form, where it can serve as a 
thickener or chemical reagent (Seaman 1980). 
Effect of temperature and pH. Its solutions exhibit pseudoplastic flow 
behaviour. They thin out reversibly when heat is applied and degrade irreversibly with 
time when an elevated temperature is maintained. The solutions resist shear 
degradation but will degrade progressively under high shear (Seaman 1980). 
Because it is a neutral polysaccharide, pH range from 3-11 has little effect on 
viscosity (Rol 1973). 
Compatibility. Strong reactions are obtained with solutions of certain inorganic 
cations. The addition of a high concentration of calcium salt, under alkaline conditions, 
will cause a gel to form. If dry powder is added to the salt solution, the gum will not 
hydrate and thicken (Seaman 1980). Neutral salts will not precipitate the gum (Bryant 
1941), but certain basic salts, such as basic lead acetate, will cause precipitation 
(Williams 1928). It is also precipitated by tannin (RoI1973). 
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2.1.3.3 Applications 
It is used as stabiliser, thickener and binder in food and cosmetics (Budavari 
1996). 
2.1.4 Carrageenan gum 
Carrageenans are water-soluble gums which occur in certain species of red 
seaweeds of the Gigartinaceae, Solieriaceae, Phyllophoraceae, and Hypneaceae 
families. They are cream-coloured to light brown powders (Guiseley et al. 1980). 
2.1.4.1 Chemical structure 
Kappa 
Lambda 
Figure 2.2. Chemical structure of carrageenan gum. 
Carrageenan gum consists chiefly of potassium, sodium, calcium, magnesium, 
and ammonium sulfate esters of galactose and 3,6-anhydrogalactose copolymers 
(Figure 2.2). These hexoses are alternately linked a-1,3 and J3-1,4 in the polymer. The 
prevalent copolymers in the hydrocolloid are designated kappa-, iota-, and lambda-
carrageenan. Kappa-carrageenan is mostly the alternating polymer of D-gaJactose-4-
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sulfate and 3,6-anhydro-D-galactose. Iota-carrageenan is similar, except that the 3,6-
anhydrogalactose is sulfated at carbon 2. Between kappa-carrageenan and iota-
carrageenan there is a continuum of intermediate compositions differing in degree of 
sulfation at carbon 2. In lambda-carrageenan, the alternating monomeric units are 
mostly D-galactose-2-sulfate (1,3-linked) and D-galactose-2,6-disulfate (1,4-linked). 
The ester sulfate content for carrageenan ranges from 18% to 40%. In addition, it 
contains inorganic salts that originate from the process of recovery from the extract 
(USP XXIII 1994). 
Carrageenans do not have sharply defined molecular weights, but rather have 
average molecular weights representing a distribution of molecular species identical in 
structure but of varying chain length (Guiseley et al. 1980). Molecular weight values of 
2.6-3.2x105 and 3.3-7.9x105 have been reported for kappa- and lambda-carrageenans 
(Goring and Young 1955; Cook et al. 1951; Masson and Caines 1954; Smith et al. 
1955). Molecular weights are dependent upon the extraction conditions used (Towle 
1973). 
2.1.4.2 Physical properties 
Solubilities. The carrageenans are soluble in hot (>75°C) water. The solubility 
in water is influenced by several factors, including temperature, the presence and type 
of counter-ion associated with the polymer, the presence of other water-soluble 
organic compounds and salts, and the type of carrageenan. Most important in 
controlling water solubility is the hydrophilicity of the molecule, related to the sulfate 
half-ester groups, and the galactopyranosyl unit, as opposed to the presence of the 
more hydrophobic 3,6-anhydrogalactopyranosyl unit. Thus, lambda-carrageenan, 
being void of 3,6-anhydrogalactopyranosyl units and having a high percentage of 
sulfate ester groups, is cold-water soluble in all salt forms. Kappa-carrageenan, having 
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less hydrophilic sulfate ester groups and containing a larger proportion of hydrophobic 
3,6-anhydrogalactopyranosyl units, is cold-water soluble only in the sodium salt form. 
In the presence of hydrophobic cations, such as potassium ion, the delicate balance of 
solubility versus insolubility is tipped and gel formation ensues. Thus, a spectrum of 
solubility exists, depending upon the balance of hydrophilicity versus hydrophobicity 
inherent in the primary structure of various carrageenans. That the primary structure 
alone is responsible for the solubility characteristics of various carrageenan is, 
however, an overSimplification. Other factors, such as the location of groups on the 
polymer chain and the molecular conformation, are also deciding factors in determining 
solubility characteristics (Towle 1973). 
Hydration of carrageenan is more rapid at low pH. The rate of hydration is 
considerably slower at pH 6 and above (Stoloff 1950). Acid-catalysed hydrolysis of 
glycosidic linkages becomes significant at low pH, especially at pH 3.0 and below. This 
depolymerization process is much faster at higher temperatures, and for this reason 
there are practical limitations beyond which the increased rate of hydration offered by 
lower pH and higher temperature is offset by a significant drop in solution viscosity 
(Towle 1973). 
Dilute aqueous dispersions of carrageenan are viscous, the viscosity being 
dependent on concentration, temperature, the presence of other solute molecules, the 
type of carrageenan, and the molecular weight. As the concentration of carrageenan 
solution is increased, the viscosity increases nearly logarithmically (Towle 1973). 
Effect of temperature. The viscosity of carrageenan solutions decreases 
progressively with increases in temperature. This change is generally reversible 
provided that heating at or near the stability optimum at pH 9 and that conditions are 
such that no thermal degradation occurs (Towle 1973). 
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Incompatibility. Salts of monovalent cations have little effect on the viscosity 
of carrageenan solutions. Divalent cations, however, tend to reduce the viscosity 
significantly at higher concentration, but may produce a viscosity increase at low levels 
(Towle 1973). 
Solutions of carrageenan gum display non-Newtonian, thixotropic flow 
characteristics, typified mainly by a decrease in viscosity with increasing shear or 
agitation (Masson and Goring 1955) and a return to normal viscosity with ceasation of 
agitation. 
2.1.4.3 Applications 
Carrageenans are used as thickening, suspending, and gelling agents. Typical 
applications are as thickener or binder in toothpaste, a suspending agent for cocoa in 
chocolate milk, and a gelling agent for milk puddings, water-gel desserts, and air-
freshener gels (Towle 1973). They are also used to induce experimental inflammation 
in laboratory animals (8udavari 1996). 
2.1.5 Hydroxypropyl methylcellulose (HPMC) 
HPMC is a synthetic water-soluble hydrocolloid derived from the etherification 
of cellulose. It is an odourless and tasteless, white or creamy-white coloured fibrous or 
granular powder (Harwood and Johnson 1994). 
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2.1.5.1 Chemical structure 
n 
Figure 2.3. Chemical structure of HPMC. 
Where R is H, CH3, or [CH3CH(OH)CH2J. The degree of substitution (OS) for 
methyl groups ranges from 0.9 to 1.8 and the molar substitution (MS) of hydroxypropyl 
groups ranges from 0.1 to 1.0 (Greminger Jr and KrumeI1980). 
2.1.5.2 Physical properties 
Solubility. HPMC is soluble in cold water and insoluble in hot water, practically 
insoluble in chloroform, ethanol (95%), and ether but soluble in mixtures of ethanol and 
dichloromethane, and mixtures of methanol and dichloromethane (Harwood and 
JOhnson 1994). Altering the amounts of methyl and hydroxypropyl substitution affects 
the solubility properties of the cellulose ether (Greminger Jr and Krumel 1980). 
Commercial products are available in a wide range of viscosities varying from 0.005 to 
75 Pa.s. as measured on 2% w/w solutions at 20°C (Greminger Jr and KrumeI1980). 
Effect of temperature and pH. A solution of HPMC generally shows 
pseudoplastic non-thixotropic flow properties at 20°C (Greminger Jr and KrumeI1980). 
Solutions are stable between pH 3-11. Increasing the temperature reduces the 
viscosity of solutions. HPMC undergoes a reversible sol to gel transformation upon 
heating and COOling respectively. The gel point is 50-90°C, depending upon the grade 
of material (Harwood and Johnson 1994). 
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Incompatibilities. HPMC is incompatible with some oxidizing agents. Since it 
is non-ionic, HPMC will not complex with metallic salts and ionic organics to form 
insoluble precipitates (Harwood and Johnson 1994). 
2.1.5.3 Applications 
HPMC is widely used in oral and topical pharmaceutical formulations. In oral 
products, it is primarily used as a tablet binder (Chowhan 1980), in film-coating (Rowe 
1977; Rowe 1980; Banker et al. 1981; Okhamafe and York 1982; Alderman and 
Schulz 1989; Pate II 1990) and as an extended release tablet matrix (Hardy et al. 1982; 
Hogan 1989; Shah et al. 1989; Wilson and Cuff 1989; Dahl et al. 1990). 
It is also used as a suspending and thickening agent in topical formulations, 
particularly ophthalmic preparations. It is also used as an emulsifier, suspending and 
stabilizing agent in topical gels and ointments. 
In addition, it is used as an adhesive in plastic bandages and as a wetting 
agent for hard contact lenses. It is also widely used in cosmetics and food products 
(Harwood and Johnson 1994). 
2.2 MODEL DRUGS 
Diclofenac sodium, a poorly water soluble model drug, was purchased from 
Sigma Chemical Company (St. Louis, USA). S(+) ibuprofen, pH dependent soluble 
model drug, was a gift from Boots Pharmaceuticals (Nottingham, UK). 
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2.2.1 Diclofenac sodium 
Chemical structure: 
Figure 2.4. Chemical structure of diclofenac sodium. 
Chemical names: 
2-[(2,6-Dichlorophenyl) amino] benzeneacetic acid monosodium salt, 
[0-(2,6-Dichloroanilino) phenyl] acetic acid sodium salt, or 
Sodium [0-[(2,6-dichlorophenyl) amino] phenyl] acetate. 
Molecular weight: 318.1 
CAS 1S307 -79-6 
2.2.1.1 Physical properties 
Diclofenac sodium is an odourless, white to off-white crystalline, slightly 
hygroscopic powder. 
Melting point: 283-28S"C for diclofenac sodium and 1S6-1S8"C for diclofenac 
(Lund 1994). 
Dissociation constant: pKa 4.7 in HCI-Na2HP04 buffer solution (Hertzfeldt and 
Kummel 1983). 
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Solubility 
Effect of pH and temperature 
The aqueous solubility of diclofenac sodium is dependent on pH; solubility is 
poor at low values of pH but when the pH rises above the pKa, rapid increases in 
solubility occur. Herzfeldt and Kummel (1983) established a solubility for diclofenac 
sodium, at room temperature, of less than 4x10-4% w/v at pH 1.2 to 3, whereas in the 
pH range 4 to 7.5 solubilities are shown in Table 2.2. At 25°C and pH 2 the solubilities 
of diclofenac sodium has been reported to be 1.5x10-6 M (Fini et al. 1986). 
Table 2.2. Aqueous solubilities of diclofenac sodium at various pH values, at room 
temperature. 
pH Solubility (% w/v) 
4.0 0.0021 
5.0 0.0086 
6.0 0.059 
7.0 0.187 
7.5 0.169 
Effect of additives 
The presence of cations (sodium ions or potassium ions) markedly affects the 
solubility of diclofenac sodium. Nishihata et al. (1988) reported solubilities for 
diclofenac sodium in 0.1 M sodium phosphate buffer (pH 7.2) at room temperature and 
at 50°C of 13.4 mM and 45.7 mM, respectively. The addition of ethanol 10% wlw to the 
buffer solution, as a cosolvent, increased the solubility of diclofenac sodium to 51.4 
mM at room temperature. As the concentration of either hydroxypropyl-~cyclodextrin 
or hydroxypropyl-y-cyclodextrin was increased (up to about 70 mM) the solubility of 
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diclofenac sodium, in phosphate buffer pH 7.4 at 25·C, also increased from 30 mM to 
85 mM (Backensfeld et al. 1991). 
Stability 
Crushed diclofenac sodium tablets and diclofenac sodium powder were 
reported to be stable after storage at 40·C in 50% relative humidity for 28 days. But at 
90·C, 55% relative humidity for 20 days the degradation product; 1-[2,6-
dichlorophenyl]-2-indolin-2-one; was detected (Kubula et al. 1993). 
The suppository formulation was also stable for 24 months at room temperature 
(Budukova et al. 1989). Diclofenac sodium in biological fluid (serum) can be kept 
frozen (-20·C) for at least 2 weeks without degradation (EI-Sayed et al. 1988). 
2.2.1.2 Pharmacokinetics 
Diclofenac sodium is rapidly absorbed when given as an oral solution, rectal 
suppository, or by intramuscular injection. It is absorbed more slowly when given as 
enteric-coated tablets, especially when this dosage form is given with food. Although 
orally-administered diclofenac is almost completely absorbed, it is subject to first-pass 
metabolism so that about 50% of the drug reaches the systemic circulation in the 
unchanged form. Diclofenac is also absorbed percutaneously. At therapeutic 
concentrations it is more than 99% bound to plasma proteins. Diclofenac penetrates 
synovial fluid where concentrations may persist even when plasma concentrations fall; 
diclofenac has been detected in breast milk. The terminal half-life is about 1 to 2 hours. 
Diclofenac is metabolised to 4'-hydroxydiclofenac, 5-hydroxydiclofenac, 3'-
hydroxydiclofenac and 4',5-dihydroxydiclofenac. It is then excreted in the form of 
glucuronide and sulphate conjugates, mainly in the urine (about 65%) but also in the 
bile (about 35%) (Fowler et al. 1983; Maggi et al. 1990). 
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2.2.1.3 Use and administration 
Diclofenac, a phenylacetic acid derivative, is a non-steroidal anti-inflammatory 
drug (NSAID). It is used mainly as the sodium salt for the relief of pain and 
inflammation in various conditions: musculoskeletal and joint disorders such as 
rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis; peri-articular disorders 
such as bursitis and tendinitis; soft-tissue disorders such as sprains and strains; and 
other painful conditions such as renal colic, acute gout, dysmenorrhoea, and following 
some surgical procedures (Todd and Sorkin 1988). 
The usual dose by mouth is 75 to 150 mg of diclofenac sodium daily in divided 
doses. In children the suggested dose by mouth or rectal for juvenile chronic arthritis is 
1 to 3 mg per kg body-weight daily in divided doses (Small 1989). 
2.2.1.4 Adverse effects 
The commonest side effects occurring during therapy with non-steroidal anti-
inflammatory drugs (NSAIDs) are generally gastro-intestinal disturbances. These are 
usually mild and reversible but in some patients peptic ulcer and severe gastro-
intestinal bleeding have been reported. These adverse effects on the gastro-intestinal 
tract may be associated with inhibition of the form of cyclo-oxygenase known as cyclo-
oxygenase-1 (Cox-1). NSAIOs that are highly selective inhibitors of the form known as 
Cox-2 may have less gastro-intestinal toxicity. 
Central nervous system (CNS) related side-effects include headache, 
dizziness, nervousness, tinnitus, depression, drowsiness, and insomnia. 
Hypersensitivity reactions may occur occasionally and include fever, ashma, and 
rashes. Hepatotoxicity and aseptic meningitis which occur rarely may also be 
hypersensitivity reactions. Some patients may experience visual disturbances. 
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Haematological adverse effects include anaemias, thrombocytopenia, 
neutropenic, eosinophilia, and agranulocytosis. Inhibition of platelet aggregation is 
reversible (Reynold 1996). 
2.2.2 S(+) Ibuprofen 
Chemical structure: 
Figure 2.5. Chemical structure of ibuprofen. 
Chemical names: 
2-(4-ISobutylphenyl)propionic acid or 
a.-Methyl-4-(2-methylpropyl) benzeneacetic acid. 
Molecular weight: 206.3 
2.2.2.1 Physical properties 
A white or almost white powder or crystals with a characteristic odour. 
Melting point: 53·C -55·C. 
Solubility 
Aqueous solubility in phosphate buffer pH 7.7 at 3tC is 6.0 mg/ml. Its solubility 
in aqueous media is higher than racemic ibuprofen at pH higher than 4.5. The heat of 
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solution is slightly exothermic at pH 7.7. Intrinsic dissolution rate in USP simulated 
intestinal fluid at 3ic is 8.1 Ilg/sec cm2 (smaller than that of racemic ibuprofen) 
(Romero and Rhodes 1991). Solubility in aqueous buffer solution at pH 1.5 was twice 
that of racemic ibuprofen at 20· and 38·C (Burger et al. 1996). 
Crystal and molecular structure 
Ibuprofen has a chiral centre and can exist in two enantiomeric forms (Freer et 
al. 1993; McConnell 1974). According to Hutt and Caldwell (1983), on administration of 
the racemic mixture, the pharmacologically inactive R(-)-enantiomer is converted to the 
active S(+)-enantiomer. A stereoselective assay is therefore necessary for 
pharmacokinetic studies. 
Stability 
Dondoni et al. (1986) used TLC and GLC to identify several products of the 
oxidative degradation of racemic ibuprofen. In the absence of oxygen, racemic 
ibuprofen was found to be stable, even at high temperatures (105· to 110·C), for at 
least four days. 
Incompatibility 
Interactions between racemic ibuprofen and stearic acid, stearyl alcohol, 
calcium stearate, and magnesium stearate have been investigated by Gordon and co-
workers (1984). Using differential scanning calorimetry, mixtures were heated at a rate 
of 1.5·C per minute over the temperature range 30·C to 110·C. The formation of a 
simple eutectic mixture in each case indicated the incompatibility of the stearates with 
racemic ibuprofen. The effect of these interactions on the chemical stability of racemic 
ibuprofen was not determined. 
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Investigations of solid-state mixtures of racemic ibuprofen and magnesium 
oxide stored at 55·C and 40·C indicated formation of the magnesium salt of ibuprofen 
(Kararli et al. 1989). No significant interaction was noted at 30·C for up to 80 days. 
Racemic ibuprofen showed no chemical degradation in the presence of magnesium 
oxide at 55·C. Solid-state interactions (at SS·C) were also reported between racemic 
ibuprofen and magnesium hydroxide, sodium bicarbonate, potassium carbonate, or 
calcium oxide, but not between ibuprofen and magnesium chloride or aluminium 
hydroxide. 
2.2.2.2 Pharmacokinetics 
Ibuprofen is absorbed from the gastro-intestinal tract and peak plasma 
concentrations occur about 1 to 2 hours after ingestion. It is extensively bound (>99%) 
to plasma proteins (Paliwal et al. 1993) and has a plasma half-life of about 1.77 hours 
[5(+) ibuprofen (Cheng et al. 1994)] or 1.8 hours [racemic ibuprofen (Li et al. 1993)]. 
5(+) ibuprofen has higher Cmax, AUC, mean residence time and renal clearance values 
compared to racemic ibuprofen (Geisslinger et al. 1993). It is rapidly excreted in the 
urine mainly as metabolites and their conjugates. About 1 % is excreted in urine as 
unchanged ibuprofen and about 14% as conjugated ibuprofen. There appears to be 
little if any excretion in breast milk. 
Ibuprofen contains a chiral carbon atom on the propionic acid side-chain, and 
therefore exists as two enantiomers. The anti-inflammatory, analgesic and antipyretic 
activities of ibuprofen, as determined by in vitro inhibition of prostaglandin synthesis, 
resides almost exclusively in the 5(+) ibuprofen; 160 times more potent than R(-) 
ibuprofen (Adams et al. 1976). In vivo R(-) ibuprofen is inverted to the S(+) enantiomer 
(Hutt and Caldwell 1983) to the extent of 57-69% for oral doses (Cheng et al. 1994; 
lee et al. 1985) and 69% for IV doses (Cheng et al. 1994) in humans. The bioinversion 
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of R(-) ibuprofen administered orally is mainly systemic (Cheng et al. 1994; Hall et al. 
1993). 
Experiments in rats indicate that the liver contributes to the optical 
isomerization of R(-) ibuprofen to S(+) ibuprofen (Jeffrey et al. 1991). The mechanism 
probably involves the stereoselective formation of a coenzyme A thioester with the R( -) 
enantiomer, which subsequently is racemised and hydrolyzed to release the S(+) 
enantiomer (Hutt and Caldwell 1983; Knihinicki et al. 1991). A large inter-individual 
variability in the ratio of S{+) to R(-) ibuprofen average concentration at steady-state 
were observed and probably accounts for the known lack of correlation between 
racemic ibuprofen concentration and therapeutic efficacy (Oliary et al. 1992). 
Interestingly, this unidirectional conversion not only has therapeutic implications but 
might have toxicological consequences, since in rats R{-) ibuprofen forms potentially 
toxic hybrid triglycerides resulting in adipose depots of slowly eliminated drug (Williams 
et al. 1986). 
Many studies have shown that the dose of S(+) ibuprofen can be reduced from 
25-50% compared to the dose of racemic ibuprofen (Romero et al. 1991; Stock et al. 
1991; Klein et al. 1992). Racemic ibuprofen is handled differently in patients with 
impaired liver function, suggesting that metabolic inversion of the inactive R(-) 
ibuprofen to the active S{+) ibuprofen may be affected by cirrhosis (Li et al. 1993). 
Hepatic elimination of ibuprofen is also impaired. Direct administration of S(+) 
ibuprofen may be advantageous because the metabolic load to the human body is 
reduced, the R(-) ibuprofen is potentially toxic and the patients are more likely to 
comply with the smaller doses of S(+) ibuprofen (Li et al. 1993; Stock et al. 1991). 
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2.2.2.3 Use and administration 
Ibuprofen has analgesic, anti-inflammatory, and antipyretic properties although 
its anti-inflammatory properties may be weaker than those of some other non-steroidal 
anti-inflammatory drugs. It is an inhibitor of cycle-oxygenase. 
Ibuprofen is used in mild to moderate pain in conditions such as 
dysmenorrhoea, migraine, postoperative pain, ankylosing spondylitis, osteoarthritis, 
and rheumatoid arthritis including juvenile rheumatoid arthritis, peri-articular disorders 
such as bursitis and tenosynovitis, and soft-tissue disorder such as sprains and 
strains. It is also used to reduce fever. 
The usual dose by mouth is 1.2 to 1.8 g daily in divided doses although 
maintenance doses of 0.6 to 1.2 g daily may be effective in some patients. If necessary 
the dose may be increased to 2.4 g daily and some sources have suggested that up to 
3.2 g daily may be given although others state that 2.4 g daily should not be exceeded. 
If gastro-intestinal disturbances occur, ibuprofen should be given with food or milk. 
2.2.2.4 Adverse effects 
Its adverse effects are similar to the adverse effects of diclofenac (described in 
2.2.1.4). Ibuprofen may be better tolerated than other NSAIDs. 
2.3 Exclplents 
Lactose (Borculor Whey Products, Holland), dicalcium phosphate 
(Encompress®, Forum Chemical, Surrey, UK), cellulose acetate phthalate (CAP, 
Eastman, Newcastle, UK), magnesium aluminium silicate (Veegum F®, R.T. 
Vanderbilt, Norwalk, USA) and microcrystalline cellulose (Avicel®PH101, Honeywill and 
Stein, Surrey, England) were used as the release regulating excipients. 
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Magnesium stearate (BOH, Poole, UK), talc (Fisher, Leicestershire, UK) and 
hydrogenated cottonseed oil (Lubritab®, Forum, Surrey, England) were used as 
lubricants. 
2.4 Buffers, liquids and solutions 
Sodium hydroxide and potassium dihydrogen orthophosphate (both were 
purchased from BOH, Poole, UK) were used to prepare phosphate buffer solutions pH 
range 6-8 (USP XXIII 1994). Hydrochloric acid (Fisher, Leicestershire, UK) and 
potassium chloride (BOH, Poole, England) were used to prepare hydrochloric acid 
buffer solution pH 1.2 (USP XXIII 1994). Sodium phosphate (Fisons, Loughborough, 
UK) and citric acid (Fisher, Leicestershire, UK) were used to prepare citrate-phosphate 
buffer solution pH range 3-5.5 (Wade 1980). 
Potassium hydroxide (Philip Harris, Shenstone, England), magnesium chloride 
(Fisher, Leicestershire, UK) and sodium chloride (Fisons, Laughborough, UK) were 
used to prepare saturated solutions for controlling the relative humidity in the 
chambers (Wade 1980). 
Methanol (Rathburn, Walkerburn, Scotland), ethanol (Haymans, Essex, UK), n-
propanol (Fisons, Laughborough, UK), butanol and acetone (both were purchased 
from Fisher, Leicestershire, UK) were used as solvents for preparing supersaturated 
diclofenac sodium solutions. 
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CHAPTER 3 
PREFORMULATION STUDIES 
3.1 INTRODUCTION 
Preformulation is the first learning phase of all new drugs. It focuses on the 
physico-chemical properties of the compound that could affect drug performance and 
development of an efficacious dosage form. A thorough understanding of these 
properties may ultimately provide a rational for formulation design. 
This part of the research is intended to study the physico-chemical properties of 
the model drugs; diclofenac sodium and S(+) ibuprofen, that might affect the 
formulation, the release mechanism and release rate of the drugs from the matrices. 
Some useful properties that had been published were also gathered in this chapter. 
The properties of the natural hydrophilic gums: xanthan gum, karaya gum, locust bean 
gum and carrageenan gum that related to the performance of the mini-matrices, such 
as particle size distribution and viscosity, were investigated. 
3.2 MATERIALS 
Natural hydrophilic gums: xanthan gum (X), karaya gum (K), locust bean gum 
(lB) and carrageenan (C). 
Model drugs: diclofenac sodium (D) and S(+) ibuprofen (I). 
Excipients: lactose (l), dicalcium phosphate (E, Encompress~), cellulose 
acetate phthalate (CAP), magnesium aluminium silicate (V, Veegum F~) and 
microcrystalline cellulose (A, Avicel~). 
lubricants: magnesium stearate, talc and hydrogenated cottonseed oil 
(lubritab~). 
SI 
Buffers, liquids and solutions: sodium hydroxide and potassium dihydrogen 
orthophosphate were used to prepare phosphate buffer solutions pH 7.0 (USP XXIII 
1994), 0.1 M HCI was used as solvent to prepare gum mucilages, and water, 
methanol, ethanol, propanol, butanol and acetone were used as solvents to prepare 
supersaturated diclofenac sodium solutions. 
3.3 Methods 
3.3.1 Crystallinity and polymorphism 
3.3.1.1 Preparation of dlclofenac sodium crystals 
Supersaturated solutions of diclofenac sodium in various solvents; water, 
methanol, ethanol, propanol, butanol and acetone, were prepared using a water bath. 
The supersaturated solutions were left to recrystallize by slow cooling (at room 
temperature) and fast cooling (using an ice bath). The resulting crystals were kept in a 
desiccator containing silica gel until required. The melting point and evidence for 
polymorphism of diclofenac sodium crystals were investigated by differential scanning 
calorimetry. The morphology of these crystals were studied using the scanning 
electron microscope (SEM). 
3.3.1.2 Differential scanning calorimetry (DSe) 
Diclofenac sodium crystals were thermally characterised by using a differential 
scanning calorimeter (Perkin Elmer, DSC 7, USA). The samples (2-10 mg) were 
weighed directly into flat bottomed aluminium sample pans. These samples were 
heated in a nitrogen atmosphere. The heat flow rate of 20'C/min was monitored as a 
function of temperature from 40 to 360·C. The thermograms were recorded. 
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3.3.1.3 Scanning electron microscope (SEM) 
The diclofenac sodium crystals were coated with gold (Polaron sputter coater 
model SC7640) and scanned using a Cambridge instruments scanning electron 
microscope (model S908). 
3.3.2 Particle size study 
The gum powders (xanthan gum, karaya gum, locust bean gum and 
carrageenan) were sent to Knoll Pharmaceuticals (Nottingham, UK.) for particle size 
determination using image analysis (Microscale, Cambridge, England). Each gum was 
dispersed in liquid paraffin before measuring the size. The photomicrographs were 
taken and particle size distribution of each gum was plotted. 
3.3.3 Viscosity study 
A 2% w/w mucilage of natural hydrophilic gums; xanthan gum, karaya gum, 
locust bean gum and carrageenan, in 0.01 M HCI pH 1.2 and 0.05 M phosphate buffer 
solution pH 7.0 were prepared. The gum powders were dispersed in the acid or buffer 
solutions by continuous stirring using magnetic stirrers. The mucilages were left 
overnight at room temperature for complete hydration of the gums. 2% wlw mucilages 
of 1:1 natural hydrophilic gums and model drugs; diclofenac sodium or S(+) ibuprofen, 
and 1: 1: 1 natural hydrophilic gums, model drugs and lactose in 0.05 M phosphate 
buffer solution pH 7.0 were also prepared by the same procedure. The rheology of 
these mucilages was examined at 37" C using a Carri-Med controlled stress rheometer 
(England). 
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3.3.4 Solubility study 
3.3.4.1 pH solubility profile 
The solubility of diclofenac sodium and S{+) ibuprofen at various pH values was 
determined. Excess drug powders were added to the medium in the double jacketed 
beaker, connected to the water bath (3iC). The mixtures were stirred with a magnetic 
stirrer and left to equilibrate for 24 hours. The initial medium used was a dilute acid 
(0.1 M HCI) pH 1.2 and a certain amount of dilute alkali (0.1 M NaOH) was added 
successively to produce the required pH. A sample (3 ml) was then removed, filtered 
using a Whatman® filter paper number 1, and the absorbance of the filtrate was 
measured using a UV spectrophotometer (Shimadzu, UV160A, Japan). For diclofenac 
sodium a wavelength of 275 nm was used for pH ~ 5 and a wavelength of 273 nm was 
used for pH < 5. For S{+) ibuprofen a wavelength of 231 nm was used at all pH values. 
The solubilities of the drugs were plotted against pH. 
3.3.4.2 Intrinsic dissolution rate 
Flat face pure diclofenac sodium discs weighing 350 mg and diameter 11 mm 
were prepared by direct compression. The powder was manually compressed by a 
Manesty F3 Single punch tablet machine {Manesty Machine Ltd., Liverpool, England}. 
After removal of the die from the machine, the tablet was placed in the 11 mm 
diameter die such that the surface of the tablet was level to the surface of the die. The 
other end of the die was sealed with hard paraffin in order to control the contact 
surface area of the drug. This die was placed in 1000 ml 0.05 M phosphate buffer pH 
7.4 maintained at 3i C in a water bath. The dissolution medium was stirred with a 
paddle (BP 1993 dimensions) at 100 rpm and at the distance of 25±2 mm above the 
exposed tablet surface. The solution {3 ml} was then taken out every 5 minutes for 65 
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minute duration, filtered using Whatman® filter paper number 1, and the absorbance of 
the filtrate was measured using a UV spectrophotometer (Shimadzu, UV160A, Japan) 
at wavelength 275 nm. The amount of diclofenac sodium dissolved per surface area 
was calculated and plotted against time. 
3.4 RESULTS AND DISCUSSION 
3.4.1 Crystallinity and polymorphism 
3.4.1.1 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry is a thermal analysis method that is valuable in 
pharmaceutical research and quality control for the characterization and identification 
of compounds, determination of purity, polymorphism, solvent and moisture content, 
stability and compatibility with excipients. The theory of DSC is to measure the heat 
loss or gain resulting from physical or chemical changes within a sample as a function 
of temperature. The endothermic (heat-absorbing) processes are referred to fusion, 
boiling, sublimation, vaporization, desolvation, solid-solid transition and chemical 
degradation. Crystallization and degradation are usually exothermic process. 
Quantitative measurements of these processes have many applications in 
preformulation studies including purity, polymorphism, solvation, degradation and 
eXCipient compatibility. 
Diclofenac sodium crystals recrystallized from various solvents were white to 
off-white in colour. The thermograms, i.e. the plot of the difference in energy input 
required to maintain the sample and the reference at exactly the same temperature 
against the sample temperature, of all diclofenac sodium crystals had similar profiles 
with little difference in melting point (extrapolated onset, the temperature 
corresponding to the intersection of the pre-transition baseline with the extrapolated 
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leading edge of the endotherm or exotherm of that transition). These indicated no 
evidence of polymorphism of diclofenac sodium crystals recrystallized from various 
solvents and at different cooling rates. The thermogram of slow cooling diclofenac 
sodium crystal from water is shown in Figure 3.1 as a typical example. The 
thermogram showed an endotherm peak at 29S.SoC, with the onset at 292.SoC followed 
by an exotherm. These endotherm and exotherm peaks indicate melting and 
decomposition of diclofenac sodium, respectively. In addition, there was a broad 
endotherm in the range of 30-10S·C. This endotherm indicates the evaporation of 
water from the surface of the sample. The endotherm peak and onset (melting point) of 
each crystal are shown in Table 3.1. 
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Figure 3.1. DSC thermogram of diclofenac sodium crystal after recrystallization at a 
slow rate from water showing the endotherm peak at 29S.SoC and onset temperature at 
292.SoC (heat flow rate 20·C/min). 
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Table 3.1. DSC thermogram characteristics of diclofenac sodium crystals recrystallized from various solvents and at different cooling rates. 
The commercial sample of diclofenac sodium had a melting point at 288. i C and peak of transition at 298. 7°C. 
Solvent Fast cooling Slow cooling 
Melting point (C) Peak of transition (C) Melting point (C)--Peak of transition (C) 
Water 292.5 298.8 
Methanol 297.6 301.5 291.6 298.2 
Ethanol 293.8 299.1 293.6 298.1 
Acetone 290.5 297.1 292.5 297.5 
n-Propanol 293.6 301.8 295.5 303.2 
Butanol 295.9 300.5 295.1 300.2 
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3.4.1.2 Scanning electron microscope (SEM) 
SEM is used as a tool for imaging the surface of a material. It has a high 
resolution capacity, around 0.00001 mm compared to 0.001 mm for a light microscope. 
The morphology of diclofenac sodium and diclofenac sodium crystals recrystallized 
from various solvents and at different cooling rates are shown in Figures 3.2-3.10. 
When a crystal precipitates from a supersaturated solution, the first event that occurs 
is the creation of a nucleus. This nucleus then grows. If growth is of equal rate in all 
directions, then a fairly cubical-looking shape will occur. If the growth is inhibited in one 
direction, then a plate will occur, and if it is inhibited in two directions, then a needle will 
be the result. Such shape differences do not imply different crystal systems, but are 
called crystal habits. 
The molecular particles of diclofenac sodium (as received from the company) 
(Figure 3.2) were amorphous. The diclofenac sodium crystals recrystallized from water 
by fast and slow cooling rates had plate-like shapes (Figures 3.3 and 3.4). As the 
polarity of the solvents decreased (from methanol to ethanol, acetone, propanol and 
butanol) the shape of the crystals gradually changed from irregular plates (in methanol 
and ethanol, fast cooling, Figures 3.5 and 3.6) to a mixture of irregular plates and 
tabular crystals (in acetone, fast cooling, Figure 3.7), a mixture of tabular and needle-
like crystals (in propanol, fast cooling, Figure 3.8) and needle-like crystals (in butanol, 
fast and slow cooling, Figures 3.9 and 3.10) respectively. 
The arrangement of diclofenac sodium crystals recrystallized from water 
(Figures 3.3 and 3.4) and butanol (Figures 3.9 and 3.10) showed that the COOling rate 
did not affect the shape of the crystals but did affect the arrangement of the crystals. In 
a slow COOling environment, the crystals were slowly built up resulting in more regular 
crystals than in fast cooling. The cooling rate affected the size of the crystals 
recrystallized from water and butanol in different ways. The size of slow cooling 
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crystals recrystallized from water was larger than fast cooling crystals and vice versa 
for the crystals recrystallized from butanol. 
Figure 3.2. SEM photomicrograph of diclofenac sodium as received from the 
company. Magnification: 515x. Voltage: 10 kV. 
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Figure 3.3. SEM photomicrograph of diclofenac sodium crystal recrystallized from a 
supersaturated solution of diclofenac sodium in water (dielectric constant at 20·C = 80) 
in a fast cooling environment. Magnification: 500x. Voltage: 10 kV. 
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Figure 3.4. SEM photomicrograph of diclofenac sodium crystal recrystallized from a 
supersaturated solution of diclofenac sodium in water (dielectric constant at 20·C = 80) 
in a slow cooling environment. Magnification: 500x. Voltage: 10 kV. 
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Figure 3.5. SEM photomicrograph of diclofenac sodium crystal recrystallized from a 
supersaturated solution of diclofenac sodium in methanol (dielectric constant at 20'C = 
33) in a fast cooling environment. Magnification: 500x. Voltage: 10 kV. 
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Figure 3.6. SEM photomicrograph of diclofenac sodium crystal recrystallized from a 
supersaturated solution of diclofenac sodium in ethanol (dielectric constant at 20'C = 
25) in a fast cooling environment. Magnification: 500x. Voltage: 10 kV. 
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Figure 3.7. SEM photomicrograph of diclofenac sodium crystal recrystallized from a 
supersaturated solution of diclofenac sodium in acetone (dielectric constant at 20·C = 
21) in a fast cooling environment. Magnification: 500x. Voltage: 10 kV. 
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Figure 3.8. SEM photomicrograph of diclofenac sodium crystal recrystallized from a 
supersaturated solution of diclofenac sodium in propanol (dielectric constant at 20'C = 
18.62) in a fast cooling environment. Magnification: 500x. Voltage: 10 kV. 
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Figure 3.9. SEM photomicrograph of diclofenac sodium crystal recrystallized from a 
supersaturated solution of diclofenac sodium in butanol (dielectric constant at 20·C = 
17.1) in a fast cooling environment. Magnification: 515x. Voltage: 10 kV. 
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Figure 3.10. SEM photomicrograph of diclofenac sodium crystal recrystallized from a 
supersaturated solution of diclofenac sodium in butanol (dielectric constant at 20·C = 
17.1) in a slow cooling environment. Magnification: 500x. Voltage: 10 kV. 
3.4.2 Particle size study 
The photomicrographs of xanthan gum, karaya gum, locust bean gum and 
carrageenan are shown in Figures 3.11-3.14 respectively. Xanthan gum, karaya gum 
and locust bean gum have an irregular shape with different particle sizes. Xanthan 
gum has a larger particle size than locust bean gum and karaya gum respectively. 
Carrageenan has a fibrous-like shape. The histogram of particle size distribution of 
each gum is shown in Figures 3.15-3.18. A logarithmic plot of particle size distribution 
of these four gums is shown in Figure 3.19. The plot showed that particle size 
distributions of carrageenan and locust bean gum were very close (Figure 3.19). The 
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mean sizes are 252.5,123.4, 121.3 and 60.9 ~lm for xanthan gum, carrageenan , locust 
bean gum and karaya gum respectively. 
_200J1m 
Figure 3.11. Photomicrograph of xanthan gum powder from image analysis. 
Figure 3.12. Photomicrograph of karaya gum powder from image analysis. 
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Figure 3.13. Photomicrograph of locust bean gum powder from image analysis. 
Figure 3.14. Photomicrograph of carrageenan gum powder from image analysis. 
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Figure 3.15. Histogram of particle size distribution of xanthan gum from image 
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Figure 3.16. Histogram of particle size distribution of karaya gum from image analysis. 
70 
25 -
20 ' 
... 
J: 15 -C) 
'a; 
~ 
>. I .c 
~ 10 -'-0 
5 ~ 
0 
N 0 lO ;l; 0 r-- 0 N lO M <0 N C'! lO C'! ~ 0 lO 
c:i Ll'i N 0 :;; ~ ~ N .,; N N N M ~ co ~ ~ <0 ~ 
particle size (microns) 
Figure 3.17. Histogram of particle size distribution of locust bean gum from image 
analysis. 
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Figure 3.18. Histogram of particle size distribution of carrageenan gum from image 
analysis. 
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Figure 3.19. A logarithmic plot of particle size distribution of four natural hydrophilic 
gums against % by weight under size. 
3.4.3 Viscosity study 
The gum mucilages studied exhibited pseudoplastic flow, except for the 2% w/v 
karaya gum mucilage containing S(+) ibuprofen. The rheograms began at the origin 
and were non-linear, i.e. the shear rate did not increase linearly with the shear stress. 
The curved rheograms resulted from a shearing action on the long-chain molecules of 
the gums. As the shearing stress was increased, the normally disarranged molecules 
began to align their long axes in the direction of flow. This orientation reduced the 
internal resistance of the gum and allowed a greater rate of shear at each successive 
shearing stress. In addition, some of the solvent associated with the molecules may be 
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released, resulting in an effective lowering of the concentration and the size of the 
dispersed molecules. These effected a lowering of the apparent viscosity. 
Objective comparisons between different pseudoplastic systems are more 
difficult than with either Newtonian or plastic systems. Several approaches have been 
used to obtain meaningful parameters that will allow different pseudoplastic materials 
to be compared. The empirical power law (Ostwald-de Waele equation) has been used 
most frequently for pseudoplastic and dilatant systems (Whorlow 1992). 
cr =kyn .......................................................... (3.1) 
Where cr is the shearing stress, k is a viscosity coefficient and y is the rate of 
shear. The particular viscosity coefficient (k) defined in this equation is a constant 
characteristic of a particular material, but dissimilar to Newtonian and plastic 
viscosities. The exponent n is an index of the deviation from Newtonian flow behaviour. 
The exponent n is unity for Newtonian systems, <1 for pseudoplastic systems and >1 
for dilatant systems. The more n differs from unity, the more non-Newtonian is the flow 
behaviour. Following rearrangement, Equation 3.1 may be rewritten in the logarithmic 
form: 
log a = n log y + log k ........................................ (3.2) 
A plot of log cr versus log y yielded a straight line of slope = n and intercept = 
log k. The viscosity coefficient (k), shear rate index (n) and correlation coefficient of 2% 
w/v mucilage of gums; xanthan gum, karaya gum, locust bean gum or carrageenan, 
1: 1 gums and drugs; diclofenac sodium or S( +) ibuprofen, and 1: 1: 1 gums, drugs and 
lactose in 0.05 M phosphate buffer solution pH 7.0 were calculated according to 
Equation 3.1 and shown in Table 3.2. For comparison purposes, the histogram of the 
viscosity index (k) of these mucilages are also shown in Figure 3.20. 
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The rheogram of 2% w/v S(+) ibuprofen and karaya gum mucilage fitted well 
with the Herschel-Bulkley model, cr = cr y + Icy n ; where cry = yield value. Above the 
yield stress, the flow curve was non-linear. This mucilage had viscosity coefficient (k) = 
0.0009, shear rate index (n) = 1.215, dynamic yield (cry) = 7 Nm-2 and correlation 
coefficient (r) = 0.9941. The shear rate index (n) was more than 1 indicating the 
dilatant or shear thickening system. 
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Table 3.2. Viscosity parameters from the rheograms of 2% w/v mucilages of gums, 
model drugs and gums, and model drugs, gums and lactose using Equation 3.1 to 
derive the viscosity coefficient (k) and shear rate index (n). 
2% w/v mucilage of Viscosity coefficient 
(k) 
X 
DandX 
D, Xand L 
I andX 
I, Xand L 
K 
Dand K 
D, Kand L 
I and K 
I, K and L 
LB 
D and LB 
D, LB and L 
I and LB 
I, LB and L 
C 
47.56 
14.20 
6.09 
14.36 
5.97 
0.78 
0.34 
0.12 
0.18 
15.77 
1.41 
0.32 
1.25 
0.34 
0.21 
Shear rate index 
(n) 
0.13 
0.16 
0.22 
0.16 
0.22 
0.57 
0.49 
0.55 
0.52 
0.45 
0.60 
0.67 
0.60 
0.65 
0.50 
Correlation coefficient 
(r) 
0.9922 
0.9931 
0.9931 
0.9954 
0.9936 
0.9998 
0.9867 
0.9928 
0.9860 
0.9792 
0.9932 
0.9985 
0.9936 
0.9992 
0.9964 
X; Xanthan gum, K; Karaya gum, LB; Locust bean gum, C; Carrageenan, 0; 
Diclofenac sodium, I; S(+) ibuprofen and L; Lactose. 
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Figure 3.20. Viscosity coefficients of 2% w/v gums, gums and drugs, and gums, drugs 
and lactose. X; Xanthan gum, K; Karaya gum; LB; Locust bean gum , C; Carrageenan, 
0; Diclofenac sodium, I; S(+) ibuprofen and L; Lactose. 
The percentage decrease in the viscosity coefficient when drugs, or drugs and 
lactose are used to substitute a portion of the gums are shown in Table 3.3. The 
viscosity coefficients of 2% w/v xanthan gum, karaya gum, locust bean gum and 
carrageenan mucilages in 0.05 M phosphate buffer solution pH 7.0 were 47 .56, 0.78, 
15.77 and 0.21 respectively. The viscosity coefficients of xanthan gum mucilages were 
decreased about 70% when 50% of the xanthan gum was substituted with diclofenac 
sodium or S(+) ibuprofen. For karaya gum, the viscosity coefficients decreased by 56% 
when 50% of the karaya gum was substituted with diclofenac sodium. Although this 
decrease in viscosity coefficient was less than for xanthan gum, the initial viscosity 
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coefficient of a 2% w/v solution of karaya gum was very low (0.78) compared with 
xanthan gum (47.56). For locust bean gum, the viscosity coefficients were decreased 
by 91 and 92% when 50% of the locust bean gum was substituted with diclofenac 
sodium and S(+) ibuprofen respectively. When diclofenac sodium or S(+) ibuprofen, 
lactose and gums were combined in equal parts (1:1:1), the viscosity coefficients were 
decreased by approximately 87, 78-84 and 98% for xanthan gum, karaya gum and 
locust bean gum respectively. The experiment was not continued with carrageenan 
because its initial viscosity coefficient was very low (0.21). 
Table 3.3. Percentage decrease in the viscosity coefficient when drugs (diclofenac 
sodium and S(+) ibuprofen), or drugs and lactose were used to substitute some of the 
gum in a 2% w/v solution in 0.05 M phosphate buffer pH 7.0. 
Composition of % decrease of viscosity coefficient 
2% w/v solution xanthan gum karaya gum locust bean gum 
0: gum 1:1 70.1 56.0 91.0 
I: gum 1:1 69.8 92.0 
O:L: gum 1:1:1 87.2 84.4 98.0 
I:L: gum 1:1:1 87.4 77.5 97.9 
*0; Oiclofenac sodium, I; S(+) ibuprofen, L; Lactose. 
When xanthan gum was substituted with the two different drugs, diclofenac 
sodium or S(+) ibuprofen, the percentage decrease in viscosity coefficient was not 
significantly different; 70.1 % compared to 69.8%. The result with locust bean gum was 
similar but the reduction was greater; 91.0% and 92.0% for diclofenac sodium and S(+) 
ibuprofen respectively. For karaya gum, the flow behaviour changed from 
pseudoplastic to Herschel-Bulkley when the gum was substituted with S(+) ibuprofen. 
S(+) ibuprofen is soluble in 0.05 M phosphate buffer pH 7.0. The solubility was 
approximately 20 mg/ml. The affinity of water with S(+) ibuprofen might be higher than 
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with karaya gum resulting in not enough water to hydrate the gum. Hence, the flow 
behaviour was changed and the viscosity coefficient was very low. 
The degree of reduction in viscosity coefficient was significantly different when 
karaya gum was mixed with diclofenac sodium and lactose (84.39%) or S(+) ibuprofen 
and lactose (77.53%). On the other hand, the degree of reduction in viscosity under 
similar circumstances for xanthan gum and locust bean gum was not significantly 
different (see Table 3.3). This indicated that karaya gum flow behaviour and viscosity 
coefficient were both sensitive to substitution with drugs. Xanthan gum should be the 
best candidate for formulating both drugs because the flow behaviour is less sensitive 
to substitution with the two drugs, and the degree of reduction in viscosity coefficient 
was less than locust bean gum. 
The viscosity coefficients of 2% w/v xanthan gum, karaya gum and locust bean 
gum mucilage in 0.1 M HCI pH 1.2 were lower than in 0.05 M phosphate buffer pH 7.0 
by 39.0, 83.3 and 29.0% respectively. In acid medium, these gums underwent 
hydrolysis resulting in lower viscosity (Cottrell et al. 1980; Meer 1980). On the other 
hand, the viscosity coefficient of carrageenan in 0.1 M HCI was much higher (86.6%) 
than in 0.05 M phosphate buffer pH 7.0 because the hydration of carrageenan is more 
rapid at low pH. These results were consistent with findings of Stoloff (1950), in which 
it was shown that the rate of hydration is considerably slower at pH 6 and above. 
3.4.4 Solubility study 
3.4.4.1 pH solubility profile 
The pH solubility profiles of diclofenac sodium and S(+) ibuprofen are shown in 
Figures 3.21 and 3.22. For diclofenac sodium (Figure 3.21), the solubility at pH<5.2 
was very low, and increased slightly from pH 5.2 to 6.5. The solubility rapidly increased 
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from pH 6.5 to 8. For S(+) ibuprofen (Figure 3.22) , the solubility at pH<4 was very low, 
and increased slightly from pH 4 to 5.7. The solubility rapidly increased from pH 5.7 to 
8. 
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Figure 3.21. pH solubility profile of diclofenac sodium powder at 3t C. 
7.00 8.00 
79 
2500 T 
I 
2000 + 
- I ~ ~ 1500 t 
o 
11000 J 
I: 
o 
U 
500 
o 
0.00 1.00 2.00 3.00 4.00 
pH 
5.00 6.00 
Figure 3.22. pH solubility profile of S(+) ibuprofen powder at 3i c. 
3.4.4.2 Intrinsic dissolution rate (lDR) 
7.00 8.00 
The plot of the amount of diclofenac sodium dissolved per unit surface area 
against time at 37°C in 0.05 M phosphate buffer medium pH 7.4 is shown in Figure 
3.23. The lOR, calculated from the slope of this chart, is 0.92 mg/cm2min. 
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Figure 3.23. Amount of diclofenac sodium dissolved (mg/cm2) against time (min) at 
37°C in 0.05 M phosphate buffer medium pH 7.4, speed of rotation 100 rpm. 
Similar work carried out by Romero and Rhodes (1991) reported an intrinsic 
dissolution rate for S(+) ibuprofen of 0.486 mg/cm2min using 500 ml USP simulated 
intestinal fluid at 37±0.8°C, speed of rotation 100 rpm. It has been reported that a lOR 
of < 1 mg/cm2min for a drug would be likely to produce bioavailability problems 
because absorption would be dissolution rate limited (Kaplan 1972). The lOR of S(+) 
ibuprofen was lower than that of diclofenac sodium. However, comparison should be 
made with caution because the experimental conditions were different in each case. In 
general, the higher the lOR, the better the in vivo performance, e.g., bioavailability, 
could be expected. 
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3.5 CONCLUSION 
Diclofenac sodium crystals recrystallized from various solvents and at different 
cooling rates were white to off-white in colour with a melting point of 293.8±2. fc. 
There was no evidence of polymorphism under these recrystallisation conditions. The 
type of the solvents affected the shape of the crystals while the cooling rate affected 
the arrangement of the crystals. 
Xanthan gum, locust bean gum and karaya gum had irregularly shaped 
particles with mean sizes of 252.5, 121.3 and 60.9 /J.m respectively. Carrageenan had 
a fibrous-like shape with a mean size of 123.4 /J.m. 
The gum mucilages exhibited pseudoplastic flow. The rheology patterns were 
still the same when these gums were partially substituted with the model drugs and 
lactose, except when karaya gum and S(+) ibuprofen were combined in the ratio of 
1: 1. The viscosity coefficients decreased to various degrees for each gum, in 
accordance with the decrease of gum concentration. The flow behaviour of xanthan 
gum was least sensitive to the type of substituted drug and the degree of reduction in 
viscosity coefficient was less than locust bean gum. Xanthan gum would be a good 
candidate in formulating diclofenac sodium and S(+) ibuprofen hydrophilic matrices. 
The solubility of both drugs greatly depended on the pH of the medium. The 
higher the medium pH, the greater the solubility. 
The intrinsic dissolution rate of diclofenac sodium in 0.05 M phosphate buffer 
pH 7.4 at 3tC was 0.92 mg/cm2min. The intrinsic dissolution rate of S(+) ibuprofen in 
USP simulated intestinal fluid at 37°C was 0.486 mg/cm2min (Romero and Rhodes 
1991). These two values cannot be compared because of the different experimental 
condition used. 
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CHAPTER 4 
HYDROPHILIC MINI-MATRICES CONTAINING DICLOFENAC 
SODIUM AND NATURAL GUMS: PREPARATION AND 
EVALUATION OF IN VITRO RELEASE 
4.1 INTRODUCTION 
Diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAIO), is a drug of 
choice for chronic arthritis. Its short half-life, about 1-2 hours (Fowler et al. 1983), 
makes it a good candidate for sustained-release formulation. The multiple units dosage 
forms (MUDFs) were chosen for this study in order to achieve uniform plasma levels 
(Edgar et al. 1984) and reproducible bioavailability (Graffner et al. 1986) (see also 
Chapter 1). The mini-matrices were the units enclosed in the hard gelatin capsules of 
the MUDFs. The production of mini-matrices uses a tabletting technique that is widely 
understood, diverse and offers less constraints than, for example extrusion or 
spheronisation. It does not require extra capital expenditure because most companies 
already have a tabletting capacity. In addition, the mini-matrices also have dosing 
flexibility. The aim of this chapter is to prepare diclofenac sodium mini-matrix MUDFs 
and subsequently evaluate their in vitro release profiles. 
4.2 MATERIALS 
Natural hydrophilic gums: xanthan gum (X), karaya gum (K), locust bean gum 
(LB), and carrageenan gum (C). 
Synthetic hydrophiliC polymer: hydroxypropyl methylcellulose (HPMC). 
Model drug: diclofenac sodium (0). 
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Excipients: lactose (L), dicalcium phosphate (E, Encompress®), cellulose 
acetate phthalate (CAP), and magnesium aluminium silicate 01, Veegum F®). 
Lubricant: magnesium stearate. 
Buffers, liquids and solutions: sodium hydroxide and potassium dihydrogen 
orthophosphate were used to prepare phosphate buffer solutions pH 6, 6.5, 7, 7.4 and 
8 (USP XXIII 1994), sodium phosphate and citric acid were used to prepare citrate-
phosphate buffer solution pH 3, 4, 5 and 5.5 (Wade 1980). 
4.3 METHODS 
4.3.1 Tablet manufacture 
All materials were passed through a mesh sieve with an aperture of 250 J.lm 
before use. Mini-matrices were prepared by the wet granulation method. The 
composition of the formulations are presented in Tables 4.1 and 4.2. All materials, with 
the exception of lubricant (magnesium stearate), were thoroughly mixed in a tumbling 
mixer for 5 minutes and then wetted in a mortar with 50% vlv ethanol (except for 
formula 2 which was wetted with 70% vlv ethanol). The wet mass was then passed 
through a 500 J.lm mesh sieve and dried at a temperature not greater than 60' C for 18 
hours (except for formula 2 which was dried at room temperature). The dried granules 
were then rescreened through a 300 J.lm mesh sieve, lubricated with magnesium 
stearate 1% wlw and compressed into flat-faced mini-matrices of diameter 4.5 mm, 
weighing 30 mg (except as indicated in Table 4.1), and containing 15 mg of dlclofenac 
sodium. Diclofenac sodium: xanthan gum in the ratio of 1: 1 (Formulation 1, Table 4.1) 
was also compressed to 3 and 5.5 mm diameter tablets, weighing 20 and 40 mg and 
containing 10 and 20 mg of diclofenac sodium respectively, in order to study the effect 
of tablet volume on drug release. An instrumented Manesty F3 single punch tablet 
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machine (Manesty Machines Ltd., liverpool, England) was used to compress the mini-
matrices. Since the influence of compression pressure on the drug release rate from 
hydrophilic matrices is reported to be negligible (Hogan 1989; Huber and Christenson 
1968; Lapidus and Lordi 1968; Ford et a!. 1985a; Talukdar and Plaizier-Vercammen 
1993), the effect of the pressure was not studied here. However the mini-matrices 
produced were in the range of 15-44 N crushing strength depending on the 
composition in the formulas. The crushing strength of 20 tablets was individually 
measured (Erweka TBH 28 Tablet Hardness Tester, F.R.G.). The mean crushing 
strength and standard deviation were calculated. Six mini-matrices containing a total 
dose of 90 mg of diclofenac sodium were encapsulated in size 1 hard gelatin capsules 
to produce a MUDF. 
Table 4.1. Composition (%) of the mini-matrices containing diclofenac sodium and four 
hydrophilic gums or HPMC. 
Diclofenac sodium 
Xanthan gum 
Karaya gum 
Locust bean gum 
Carrageenan 
18 
49.5 
49.5 
28 38 
49.5 49.5 
49.5 
49.5 
Formulation 
4 8 58 68 
49.5 49.5 49.5 
24.75 
24.75 
49.5 
HPMC K4M 49.5 
7D 8c 9° 
66 39.6 33 
33 59.4 66 
Magnesium stearate 1 1 1 1 1 1 1 1 1 
Weight of each mini-matrix: 830.2±1.1 mg; D22.5±1.0 mg; c37 .5±1.0 mg; d45.O±1.0 mg. 
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Table 4.2. Composition (%) of the mini-matrices containing diclofenac sodium, xanthan 
gum and various excipients. 
Formulation 
10A-Oi 11A-Oi 12A-Oi 13A-Oi 14A-Oi 
Oiclofenac sodium 49.5 49.5 49.5 49.5 49.5 
Xanthan gum 41.25 33 24.75 16.5 8.25 
Excipients (lactose, 8.25 16.5 24.75 33 41.25 
Encompress®, CAP and 
Veegum F®) 
Magnesium stearate 1 1 1 1 1 
"A, e, C and 0 series for each formulation number contain lactose, Encompress®, CAP 
and Veegum F® respectively. 
4.3.2 Mini-matrix dissolution studies 
The USP XXIII basket method (Copley Dissolution System and Drive Control, 
Copley Instruments, Nottingham, England) was used with a constant temperature 
water bath at 37±0.5"C. The dissolution medium was 0.05 M phosphate buffer (pH 
7.0). The speed of rotation was 100±1 rpm. The dissolution apparatus was connected 
to a flow-through UV spectrophotometer (Ultrospec II, LKB Biochrom Ltd., England) via 
a peristaltic pump. The absorbance was measured automatically at 275 nm in a 10 mm 
cell at 30 minute time intervals over a 12 hour period. 
The effect of rotating speed was also studied by varying the speed of rotation 
from 50 to 100 and 150 rpm. 
The studies were carried out in triplicate. The cumulative percentage of 
diclofenac sodium released was calculated and plotted against time. The release rates 
were calculated from a Higuchi plot (Equation 1.8). The values of nand k were 
calculated from log fraction of drug release against log time plot (Equation 1.1). The 
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Fickian and relaxational contributions were calculated according to Equations 1.2, 1.4 
and 1.5. 
The release profiles of commercially available diclofenac sodium sustained-
release products; Diclomax Retard® (Park-Davis, 100 mg/capsule) and Motifene® 
(Panpharma, 75 mg/capsule), were also studied. In order to study the effect of 
dissolution medium on release characteristics of these products, various dissolution 
media; citrate-phosphate buffer pH 3, 4,5, and 5.5, and 0.05 M phosphate buffer pH 6, 
6.5, 7, 7.4 and 8, were used. The absorbance of the solutions was measured at 
wavelength 271 nm for the dissolution medium pH ~ 4 and at wavelength 275 nm for 
the others. 
4.4 RESULTS AND DISCUSSION 
4.4.1 Effect of gum type on release characteristics 
The four natural hydrophilic gums used showed greatly different in vitro 
dissolution profiles for diclofenac sodium from the encapsulated mini-matrices using a 
buffered dissolution medium (pH 7.0) and at drug: gum ratios of 1:1. The studies were 
carried out using hard gelatin capsules each containing six mini-matrices (4.5 mm 
diameter, 30 mg weight) of each gum formulation (Formulations 1-4 of Table 4.1). As 
seen in Figure 4.1, the times for 50% release (t50% values) are 30, 165, 280 and 630 
minutes for carrageenan, locust bean, xanthan and karaya gums respectively. The 
Type 1 carrageenan gum used, which contains predominantly kappa- and lesser 
amounts of lambda-carrageenan, does not produce sufficient sustained release of 
diclofenac sodium in spite of the fact that kappa-carrageenan is reported (suppliers' 
literature) to form rather rigid gels. On the other hand locust bean, xanthan and karaya 
gums do show variable degrees of sustained release. 
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Figure 4.1. Percentage of diclofenac sodium released against time from 6 mini-
matrices (4.5 mm diameter) containing diclofenac sodium (0) and various hydrophilic 
gums; xanthan (X), karaya (K), locust bean (LB) and carrageenan (C), or HPMC 
enclosed in a hard gelatin capsule (mean values±SO, n=3). 
The maximum amount of accumulated drug released is about 75% for 
carrageenan and locust bean gums whereas for xanthan and karaya gums the 
maximum amount released after 12 hours was 66% and 54% respectively. However in 
the case of the latter two gums the drug was still being released slowly from the 
hydrated matrices after 12 hours. After 24 hours this amount had risen to 77 and 71 % 
respectively. 
HPMC can sustain the release of diclofenac sodium but has a lesser sustaining 
effect when compared with locust bean gum, xanthan gum and karaya gum (see 
88 
Figure 4.1). The maximum amount of accumulated drug released at 12 hour is 86% 
and t50% is 150 min. This result is not totally unexpected because there is a study 
which showed that diclofenac sodium causes failure of HPMC matrices because it 
substantially depresses the thermal gelation temperature of HPMC (Rajabi-Siahboomi 
et al. 1993). 
The values for release exponent (n), kinetic constant (k), t50% value, mean 
dissolution time and release rate together with the correlation coefficient (r) for mini-
matrices containing diclofenac sodium and each gum are given in Table 4.3. A value of 
n = 0.45 indicates Case I or Fickian diffusion, n = 0.89 indicates Case II transport, 0.45 
< n < 0.89 indicates anomalous (non-Fickian) diffusion and n > 0.89 for Super Case II 
transport (Ritger and Peppas 1987). The release behaviour of each of the three gums 
displaying sustained release was clearly anomalous (non-Fickian) with values of n = 
0.703, 0.731 and 0.777 for xanthan, karaya and locust bean gums respectively. This 
suggests that these gums (particularly locust bean) are in moving boundary conditions, 
since the swelling and dissolution of the gum continuously modify the effective 
diffusivity of the drug. The release behaviour of HPMC was Super Case II transport 
with a n value of 0.913. This implies that the release of HPMC is nearly time 
independent and erosion is more dominant than diffusion. 
It is commonly known that locust bean gum can react strongly in solution with 
xanthan gum (Kovac 1973), so mini-matrices containing diclofenac sodium: xanthan 
gum: locust bean gum in the ratio of 1 :0.5:0.5 (Formulation 6, Table 4.1) were also 
produced in order to investigate whether such a combination would produce any 
significant effect on drug release from the solid mini-matrices. The release profile of 
diclofenac sodium: xanthan gum: locust bean gum in the ratio of 1 :0.5:0.5 resembles 
the profile of diclofenac sodium: locust bean gum in the ratio of 1: 1 (Figure 4.1). The 
time for 50% release (t50%) was 160 min. The dissolution results did not therefore 
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provide any clear evidence for a synergistic effect between xanthan gum and locust 
bean gum on the rate of diclofenac sodium release from solid mini-matrices. 
The percentage contributions of Fickian diffusion (F) and Relaxation (R) over the 
first 60% of drug release for each of the three gums and HPMC are shown graphically in 
Figures 4.2a, b, c and d. In the case of xanthan gum and karaya gum, Fickian diffusion 
predominates for the first half of the dissolution period, gradually decreasing until polymer 
relaxation becomes predominant in the second half. During the dominant Fickian 
diffusion period, the thickness of the viscous gel layer around the matrix will increase with 
time creating a longer path length for the drug to diffuse into the external dissolution 
medium. Thereafterthe polymer chains increasingly relax, disentangle and dissolve. It is 
noted that drug release due to relaxation takes over from the declining diffusional release 
mechanism about half way through the dissolution time period, thus faCilitating an 
approach toward zero-order release. On the other hand, with locust bean gum and 
HPMC the contribution of Fickian diffusion (F) is relatively small whilst release due to 
Relaxation (R) is dominant for the entire dissolution time period. These findings are 
consistent with the calculated n values (Table 4.3) and with the erosion and swelling 
studies reported in Chapter 5. 
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Table 4.3. Release parameters from the encapsulated mini-matrices using Equation 1.1 to derive the release exponent (n) and the kinetic 
constant (k). Mean dissolution time (min) was calculated from Equation 1.6. The release rate (% min-112) was calculated from the slopes of the 
plots of fraction of drug released versus square root of time (Equation 1.8) (mean values±SD, n=3). 
Mini-matrices Release exponent Kinetic constant Correlation t50% value Mean dissolution Release rate Correlation 
Composition • (n) (k) (min-n)x10-3 coefficient (r) (min) time (min) (%min-1I2) coefficient (r) 
D:X 1:1 0.703±O.017 9.27±1.63 0.988 280 329±60 3.53±0.34 0.994 
O:LB 1:1 0.777±O.092 10.21±4.44 0.994 165 180±36 5.10±0.52 0.997 
O:K 1:1 0.731±O.009 4.70±0.62 0.991 630 655±120 2.46±0.30 0.997 
O:HPMC 1:1 0.913±O.093 S.78±2.35 0.995 137 147±20 6.02±0.43 1.000 
0:X2:1 0.906±0.030 4.30±0.76 0.999 189 196±4 5.55±0.06 0.999 
O:X 1:1 0.703±O.017 9.27±1.63 0.988 280 329±60 3.53±O.34 0.994 
0:X2:3 0.705±O.021 6.92±O.67 0.988 423 483±36 2.87±O.14 0.995 
O:X 1:2 0.671±O.035 7.91±1.57 0.990 480 558±20 2.63±O.09 0.993 
·0, Diclofenac sodium; X, Xanthan gum; LB, Locust bean gum; K, Karaya gum; HPMC, Hydroxypropyl methylcellulose. 
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Figure 4.2a. The percentage contributions of Fickian diffusion and the polymer relaxation 
mechanisms valid over the first 60% of drug release from mini-matrices containing 
diclofenacsodium and xanthan gum (mean values±SD, n=3) . 
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Figure 4.2b. The percentage contributions of Fickian diffusion and the polymer relaxation 
mechanisms valid over the first 60% of drug release from mini-matrices containing 
diclofenac sodium and karaya gum (mean values±SD, n=3) . 
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Figure 4.2c. The percentage contributions of Fickian diffusion and the polymer relaxation 
mechanisms valid over the first 60% of drug release from mini-matrices containing 
diclofenac sodium and locust bean gum (mean values±SD, n=3) . 
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Figure 4.2d. The percentage contributions of Fickian diffusion and the polymer relaxation 
mechanisms valid over the first 60% of drug release from mini-matrices containing 
diclofenac sodium and HPMC (mean values±SD, n=3). 
4.4.2 Effect of quantity of gum on release characteristics 
Xanthan gum was selected for this study because approximately 50% of the 
drug was released after almost half of the dissolution time period. Drug: xanthan gum 
ratios of 2: 1, 1: 1, 2:3 and 1:2 were used with compositions as shown in Table 4.1 
(Formulations 7,1,8 and 9 respectively) . Figure 4.3 clearly shows that the drug release 
rate is greatly influenced by the diclofenac sodium: xanthan gum ratio of the matrix. As 
the proportion of xanthan gum increases, there is a progressive decline in the release 
rate. This can also be shown by plotting the release rates (% min-'h) for diclofenac 
sodium against the percentage of xanthan gum in each capsule (Figure 4.4). This 
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curve could be used to allow predictions of the release rate to be made for diclofenac 
sodium: xanthan gum ratios not experimentally determined provided that no drug/gum 
interactions are encountered which will complicate the calculations. Values for nand k 
(±SD; n=3) are shown in Table 4.3 and these also show anomalous (non-Fickian) 
release behaviour for drug: xanthan gum ratios of 1: 1, 2:3 and 1 :2. Although the drug 
release rate decreased with increasing gum content, the mechanism of release 
nevertheless remained the same. However, for drug: gum ratio of 2:1, the n value is 
0.906 (Super Case II transport). This would be due to the greater drug concentration 
which would enhance the dissolution mechanism and compensate for the decrease in 
release due to gum swelling. 
96 
100 
90 -
80 t 
1:1 70 -
CI) 
en 
III 
CI) 60 -e I 
CI) 
> 50 -.. 
.!! 
:l 
E 40 -
:l 
(,) 
~ 0 30 ~ 
20 -
o -t-+-
o 60 120 180 240 300 360 420 480 540 600 660 720 
Time (min) 
[ -+-D:X2:1 -ll- D:X 1:1 -.- D:X2:3 -*- D:X 1:2 
Figure 4.3. Percentage of diclofenac sodium released against time from 6 mini-
matrices (4.5 mm diameter) containing diclofenac sodium (0) and xanthan gum (X) in 
various proportions enclosed in a hard gelatin capsule (mean values±SD, n=3). 
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The percentage contributions of Fickian diffusion and Relaxation over the first 
60% of drug release for diclofenac sodium and xanthan gum in the ratios of 2: 1, 2:3 and 
1.2 are shown graphically in Figures 4.5a, band c. The Fickian diffusion contribution to 
the release process decreases as the proportion of xanthan gum decreases, with a 
corresponding increase in the Relaxation contribution as the drug content increases. This 
relationship is especially dramatic between the diclofenac sodium: xanthan gum 1:1 and 
2: 1 ratios . It can be concluded therefore that the xanthan gum is mainly responsible for 
the Fickian diffusion mechanism, whereas the drug contributes mainly to the dissolution 
or eroSion mechanism. 
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Figure 4.5a. The percentage contributions of the Fickian diffusion and the polymer 
relaxation mechanisms valid over the first 60% of drug release from mini-matrices 
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Figure 4.5c. The percentage contributions of the Fickian diffusion and the polymer 
relaxation mechanisms valid over the first 60% of drug release from mini-matrices 
containing diclofenac sodium and xanthan gum in the ratio of 1:2 (mean valuest SD, 
n=3). 
4.4.3 Effect of excipients on release characteristics 
4.4.3.1 Rational for selection of excipients 
Lactose (freely water-soluble), dicalcium phosphate (Encompress®, water-
insoluble), cellulose acetate phthalate (CAP; soluble in USP buffer solutions pH ~ 6.2) 
and magnesium aluminium silicate (Veegum F®; practically insoluble in water, but 
swells to form a colloidal dispersion) were used as excipients in various proportions. 
Lactose and Encompress® are commonly used as diluents in tablet formulations. 
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Having opposite solubility characteristics, it is reasonable to expect that lactose and 
Encompress® would exhibit significant differences in drug release from hydrated gum 
matrices. It has been reported that lactose produced increased release rates of various 
drugs from polymeric matrices (Marin Bosca et al. 1995; Talukdar and Kinget 1995). 
Lactose diffuses outwards through the gel layer, increasing the porosity and 
decreasing the tortuosity of the diffusion path of drug. On the other hand, 
Encompress® forms a porous, insoluble and nonswellable matrix which has been used 
to control the release of some water-soluble drugs (Mulye and Turco 1994). Cellulose 
acetate phthalate was blended with gum in order to maintain the integrity of the mini-
matrix in the acid contents of the stomach. On reaching the intestine (pH>6), the 
cellulose acetate phthalate would dissolve and then possibly act in a similar manner to 
lactose in regulating the drug release rate. Furthermore, it has been reported that the 
viscosity of aqueous xanthan gum solutions is greatly increased, or gelation occurs, by 
combination with Veegum ~ due to synergistic effects (Kovacs 1973). Veegum ~ 
was therefore combined with xanthan gum to investigate whether such synergism 
would produce any Significant effect on drug release from the solid mini-matrices. 
The dissolution studies were carried out on Formulations 10A-O - 14A-O (Table 
4.2) and consisted of six mini-matrices (4.5 mm diameter, 30.2±1.1 mg weight) 
enclosed in a hard gelatin capsule. 
4.4.3.2 Effect of exclplents on release characteristics 
In spite of the widely varying physico-chemical characteristics of the excipients, 
the drug dissolution profiles displayed similar tendencies. The drug release rate 
increased with increasing proportions of excipient (corresponding decrease in xanthan 
gum content) irrespective of the solubility characteristics of the excipient. The release 
profiles of diclofenac sodium, xanthan gum and various excipients; lactose, 
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Encompress®, CAP and Veegum®, at different ratios are shown in Figures 4.6-4.9 
respectively. The values for release exponent (n), kinetic constant (k), t5O% and release 
rate together with the correlation coefficient (r) of these mini-matrices are shown in 
Tables 4.4 - 4.7. The release exponent for some formulations containing drug, xanthan 
gum and excipients in the ratio of 3:1:2 and 3:0.5:2.5 are not shown because there 
were insufficient data points on the release profiles between 10 and 60% release to 
provide accurate values. The tabulated data show that the release mechanism 
changes from anomalous (non-Fickian) transport (0.45<n<0.89) to Case" transport 
(n=0.89) and Super Case" transport (n>0.89) when xanthan gum was increasingly 
substituted with excipients. It is evident that dissolution or erosion of the excipient 
would account for the increasing values of n as the excipient content increased. The 
t50% values for mini-matrices containing Veegum ~/xanthan gum and cellulose acetate 
phthalate/xanthan gum mixtures were on average 10-15% longer than those 
containing lactose and Encompress® as excipients (Tables 4.4-4.7). These relatively 
small differences in t50% values suggest that the nature of the excipient used appeared 
to play a minor role in regulating release, while the xanthan gum content was the 
dominating factor. A lower gum content would result in reduced swelling with 
corresponding decrease in diffusional path length. Moreover the excipients would 
enhance either the dissolution or erosion mechanism, depending on the solubility of 
the excipient, which compensates for the slowing diffusion rate through the gradually 
increasing gel layer by creating greater porosity for the drug pathway. 
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Table 4.4. Release parameters from the encapsulated mini-matrices (4.5 mm diameter) containing diclofenac sodium (D), xanthan gum (X) 
and lactose (L) using Equation 1.1 to derive the release exponent (n) and the kinetic constant (k). The release rate (% min-112) was calculated 
from the slopes of the plots of fraction of drug released versus square root of time (Equation 1.8) (mean values±SD, n=3). 
Mini-matrices Release exponent Kinetic constant (k) Correlation t50% value Release rate Correlation 
composition (n) (min-n) x10-3 coefficient (r) (min) (%min-112) coefficient (r) 
D:X:L3:3:0 0.703±O.017 9.27±1.63 0.988 280 3.53±O.34 0.994 
D:X:L 3:2.5:0.5 0.695±O.048 9.78±2.81 0.983 280 3.44±0.43 0.991 
D:X:L 3:2:1 0.727±O.047 9.66±2.52 0.991 229 4.15±O.18 0.995 
D:X:L 3:1.5:1.5 0.985±O.136 3.83±1.89 0.991 145 6.85±O.78 0.993 
D:X:L3:1:2 1.123±O.216 3.06±3.29 0.989 127 8.74±1.60 0.996 
D:X:L 3:0.5:2.5 57 
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Table 4.5. Release parameters from the encapsulated mini-matrices (4.5 mm diameter) containing diclofenac sodium (D), xanthan gum (X) 
and Emcompress® (E) using Equation 1.1 to derive the release exponent (n) and the kinetic constant (k). The release rate (% min-1/2) was 
calculated from the slopes of the plots of fraction of drug released versus square root of time (Equation 1.8) (mean values±SD, n=3). 
Mini-matrices Release exponent Kinetic constant (k) Correlation t50% value Release rate Correlation 
composition (n) (min-n) x10-3 coefficient (r) (min) (%min-112) coefficient (r) 
D:X:E 3:3:0 0.703±O.017 9.27±1.63 0.988 280 3.53±0.34 0.994 
D:X:E 3:2.5:0.5 O.727±O.044 8.25±O.90 0.980 261 3.67±O.62 0.985 
D:X:E3:2:1 0.795±O.036 7.75±1.66 0.995 190 5.0HO.17 0.998 
D:X:E 3:1.5:1.5 0.887±O.104 5.41±2.57 0.998 174 5.36±O.76 0.998 
D:X:E 3:1:2 1.122±O.180 4. 19±2.91 0.978 72 
D:X:E 3:0.5:2.5 72 
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Table 4.6. Release parameters from the encapsulated mini-matrices (4.5 mm diameter) containing dic/ofenac sodium (D), xanthan gum (X) 
and cellulose acetate phthalate (CAP) using Equation 1.1 to derive the release exponent (n) and the kinetic constant (k). The release rate (% 
min-112) was calculated from the slopes of the plots of fraction of drug released versus square root of time (Equation 1.8) (mean values±SD, 
n=3). 
Mini-matrices Release exponent Kinetic constant (k) Correlation t50% value Release rate Correlation 
composition (n) (min-n) x10-3 coefficient (r) (min) (%min-112) coefficient (r) 
D:X:CAP 3:3:0 0.703±O.017 9.27±1.63 0.988 280 3. 53±0.34 0.994 
D:X:CAP 3:2.5:0.5 0.745±O.099 9.76±4.30 0.976 204 4.14±1.34 0.984 
D:X:CAP 3:2: 1 0.839±O.064 6.35±1.85 0.940 156 5.85±O.91 0.977 
D:X:CAP 3:1.5:1.5 1.199±0.121 1.28±O.94 0.991 160 7.27±0.82 0.975 
D:X:CAP 3:1:2 1.181±O.093 1.04±O.36 0.979 184 6.75±O.71 0.959 
D:X:CAP 3:0.5:2.5 1.240±0.120 0.85±O.34 0.983 167 
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Table 4.7. Release parameters from the encapsulated mini-matrices (4.5 mm diameter) containing diclofenac sodium (D), xanthan gum (X) 
and Veegum F® (V) using Equation 1.1 to derive the release exponent (n) and the kinetic constant (k). The release rate (% min-112) was 
calculated from the slopes of the plots of fraction of drug released versus square root of time (Equation 1.8) (mean values±SD, n=3). 
Mini-matrices Release exponent Kinetic constant (k) Correlation t50% value Release rate Correlation 
composition (n) (min-n) x10-3 coefficient (r) (min) (%min-112) coefficient (r) 
D:X:V 3:3:0 0.703±O.017 9.27±1.63 0.988 280 3. 53±0. 34 0.994 
D:X:V 3:2.5:0.5 0.816±O.041 5.45±0.82 0.989 250 4.22±0.38 0.995 
D:X:V3:2:1 0.861±O.066 4.85±1.90 0.991 219 4.74±0.40 0.997 
D:X:V 3:1.5:1.5 0.930±0.076 3.51±1.04 0.989 208 5.12±0.90 0.997 
D:X:V3:1:2 1.016±O.130 2.59±1.09 0.990 193 5.82±1.20 0.998 
D:X:V 3:0.5:2.5 134 9. 35±O.49 0.999 
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The plots of release rate (% min-%) versus the percentage of excipients; 
lactose, Encompress®, CAP and Veegum F®, contained in the mini-matrices are shown 
in Figure 4.10. It is seen from this graph that there is a linear increase in release rate 
until the percentage of Veegum ~ reaches about 33%. Higher percentages of 
Veegum ~ result in a sudden marked increase in release rate. The percentage of 
lactose in the range of 0-17% only slightly affected the release rate of diclofenac 
sodium from the mini-matrices. Higher concentration of lactose resulted in a greater 
increased release rate until about 33% lactose. At higher concentration than 33%, the 
release of diclofenac sodium from the mini-matrices was very fast, hence the accurate 
release rate cannot be provided as mentioned earlier. Encompress® and CAP also 
showed a linear increase in release rate with percentage increase in Encompress® and 
CAP until the percentage of them were about 25%. The release rate seemed to be 
constant at the percentage of CAP from 25 to 33%. At higher concentration than 25% 
for Encompress®, and 33% for CAP the release rates of the drug from the mini-
matrices were too fast to obtain an accurate release rate. These results indicated that 
the added excipients similarly affected the release rates of diclofenac sodium from 
mini-matrices but to different extents. There is an amount which each excipient must 
not exceed in order to maintain the sustaining performance of the mini-matrices. These 
plots (Figure 4.10) can be used to predict release rates for amounts of excipient not 
experimentally determined. From these results there is no evidence to show that the 
synergistic viscosity effects between Veegum ~ and xanthan gum had any noticeable 
affect on the rate of drug release from solid mini-matrices. 
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Figure 4.10. Relationship between release rate of diclofenac sodium (%mm1l2) and 
the percentage of excipients; lactose, Encompress®, CAP and Veegum F®, contained 
in each capsule (mean values±SD, n=3). 
4.4.4 Effect of dissolution medium on release characteristics 
The dissolution profiles of diclofenac sodium mini-matrices (Formulations 1 and 
2, Table 4.1) encapsulated in hard gelatin capsules were carried out in 0.1 M HCI pH 
1.5; in order to simulate the pH of the stomach. The amount of diclofenac sodium 
released was very little «1 % after 10 hours). Negligible swelling of the mini-matrices 
were observed after 10 hours contact with 0.1 M HCI pH 1.5. Since the swelling is not 
eVident, it was expected that the drug release should be very rapid due to the short 
diffusional path length. However, the pH solubility profile carried out on diclofenac 
sodium showed that diclofenac sodium was practically insoluble in the dissolution 
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medium at pH :5; 2 (3.8 mgtl) and at pH 5 the drug was still practically insoluble (43.8 
mgll). It is reasonable to say that the dissolution medium has an influence on the 
solubility of the drug consequently affecting the release profile of the mini-matrices. 
Since the solubility of the drug in the acid gastric fluid would be so poor it is doubtful 
whether there is a need to enteric coat oral sustained release dosage forms of 
diclofenac sodium (which are based on the matrix principle) to protect the gastric 
membrane from its irritant effects. 
The release profiles of commercial sustained-release diclofenac sodium 
products; Diclomax® and Motifene®, in citrate-phosphate buffer pH 3, 4,5 and 5.5, and 
0.05 M phosphate buffer pH 6, 6.5, 7, 7.4 and 8 are shown in Figures 4.11a and b 
respectively. The release of diclofenac sodium from these two products depended 
greatly on the dissolution medium pH. The amount of drug released is very small 
«20%) at pH :5; 5.5 for Diclomax® or ~ 5 for Motifene® but greatly increased at pH> 5.5 
or >5 for these two products respectively. The release profiles at pH ~ 7 for Diclomax® 
and ~ 6.5 for Motifene® were very similar. This implied that there was a certain 
solubility of diclofenac sodium in phosphate buffer. These profiles were consistent with 
the pH solubility profile of diclofenac sodium which was practically insoluble at pH<5.2, 
solubility gradually increased from pH 5.2 to 6.5, greatly increased at pH 6.5 to 7.8 
after which the solubility remained the same. 
It is noticeable that, in the dissolution medium pH 7.0, 90% of diclofenac 
sodium released from Diclomax® within 120 minutes and from Motifene® within 90 
minutes. These release rates were much faster than the release rates of mini-matrices 
containing xanthan gum, karaya gum or locust bean gum (Figure 4.1). 
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various dissolution medium. 
4.4.5 Effect of stirring speed on release characteristics 
The release profiles of mini-matrices containing diclofenac sodium and 
xanthan, karaya, locust bean and carrageenan gums in the ratio of 1: 1 were monitored 
in 0.05 M phosphate buffer pH 7.0 at stirring speeds of 50, 100 and 150 rpm. The 
release profiles showed that the release of diclofenac sodium was only slightly 
increased «10%) when the stirring speed increased from 50 to 150 rpm (Figures 
4.12a-d). When the stirring speed increased, the increased hydrodynamic flow would 
have the potential to increase the erosion or dissolution of the mini-matrix material and 
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consequently produce faster drug release. If erosion is the sole factor controlling the 
release of the drug, increasing the stirring speed of the basket should have a great 
effect on the release rate . The result implied that erosion is not the only factor 
controlling the release of the drug from mini-matrices. This lends support to the 
previous findings which demonstrated that both diffusion and erosion play a part in 
drug release (n values indicate anomalous mechanisms) . 
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Figure 4.12a. Percentage of diclofenac sodium release against time from six mini-
matrices containing diclofenac sodium (D) and xanthan gum (X) in the ratio of 1: 1 at 
various stirring speed of basket (mean values ± SD, n=3). 
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Figure 4.12b. Percentage of diclofenac sodium release against time from six mini-
matrices containing diclofenac sodium (0) and karaya gum (K) in the ratio of 1: 1 at 
various stirring speed of basket (mean values ± SO, n=3) . 
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Figure 4.12c. Percentage of diclofenac sodium release against time from six mini-
matrices containing diclofenac sodium (0) and locust bean gum (LB) in the ratio of 1: 1 
at various stirring speed of basket (mean values ± SO. n=3) . 
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4.4.6 Effect of tablet volume on release characteristics 
In order to establish the effect of matrix volume on drug release rate , mini-
matrices of diameters 3, 4.5, and 5.5 mm were produced with the same composition 
(drug: xanthan gum ratio 1: 1). The calculated volumes of the 3, 4.5 and 5.5 mm mini-
matrices were 15.1, 22.35 and 31.12 mm3 respectively. Dissolution studies were 
carried out on a single mini-matrix of each volume and the profiles show that more 
than 90% of drug was released (Figure 4.13). There was < 10% difference in the 
average cumulative release between the smallest and largest volume matrices after 10 
hours. Compared with the sUbstantial differences in volume, the differences in 
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cumulative release are relatively small and provide evidence that gum concentration is 
the main retarding factor. 
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Figure 4.13. Percentage of diclofenac sodium released against time from single mini-
matrices of varying diameter containing diclofenac sodium (0) and xanthan gum (X) in 
the ratio of 1:1 (mean values±SO, n=3) . 
The release exponents (n values) calculated from the first 60% of drug 
released from the individual mini-matrices were 0.910, 0.870 and 0.825 for the 3, 4.5 
and 5.5 mm diameters respectively (Table 4.8). Phenomenologically therefore the 
single mini-matrices behave as near Case \I and Super Case II transport regardless of 
the specific molecular mechanisms of drug transport. The larger surface area to 
volume ratio of the individual mini-matrices provides a suitable balance between 
swelling and dissolution of the matrix to achieve Case II transport. As noted earlier, the 
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maximum release after 12 hours from six encapsulated mini-matrices contained in the 
dissolution basket was lower (71 %) than that from individual mini-matrices (>90%). 
This is probably due to the fact that in the former case the mini-matrices are confined 
to the area of the base of the basket (±3.14 cm2). These matrices tend to aggregate 
forming a gel-like mass which is much larger in volume than an individual mini-matrix. 
Therefore complete release of the drug from the centre of the collective gel is very 
slow. The surface area to volume ratio is smaller and dissolution is suppressed. The 
main release mechanism through this larger swollen gel is diffusion, while dissolution is 
reduced. Hence the release mechanism tends towards Case I (Fickian) transport. 
Table 4.8. Release parameters from the encapsulated mini-matrices using Equation 
1.1 to derive the release exponent (n) and the kinetic constant (k) (mean valuestSD, 
n=3). 
Mini-matrices Diameter Release exponent Kinetic constant Correlation 
Composition. (mm) (n) (k) (min'")x10'3 coefficient (r) 
D:X 1:1 3.0 0.910±0.068 5.755±2.375 0.997 
D:X 1:1 4.5 0.870±0.053 5.917±1.133 0.996 
D:X 1:1 5.5 0.825±0.022 7.344±1.066 0.998 
i'D, Oiclofenac sodium; X, Xanthan gum. 
4.5 CONCLUSION 
Oiclofenac sodium sustained-release mini-matrices can be produced from 
xanthan gum, karaya gum, locust bean gum and HPMC while carrageenan gum does 
not produce sufficient sustained release. The degree of sustaining the release of 
diclofenac sodium is much different for each gum. Karaya gum can sustain the release 
of diclofenac sodium to a greater degree than xanthan gum, locust bean gum and 
HPMC, with the maximum amount of accumulated drug released 54%, 66%, 75% and 
86% at 12 hours, respectively. The mechanisms of diclofenac sodium release from 
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three natural gums were anomalous diffusion with n values of 0.703,0.731,0.777 for 
xanthan gum, karaya gum and locust bean gum, respectively, while HPMC exhibits 
Super Case II transport with a n value of 0.913. There is no synergistic effect between 
xanthan gum and locust bean gum on the release of diclofenac sodium from solid mini-
matrices. 
The effect of quantity of gum on release characteristics was carried out using 
xanthan gum. The drug release rate declined linearly with a progressive increase in 
gum content. The mechanisms of drug release are still anomalous diffusion for 
diclofenac sodium and xanthan gum in the ratios of 1: 1, 2:3 and 1:2 while at the ratio of 
2: 1, the mechanism is changed to Super Case II transport as a result of dissolution of 
the drug. From the contribution of Fickian diffusion and Relaxation, xanthan gum is 
mainly responsible for the Fickian diffusion mechanism and diclofenac sodium 
contributes mainly to the dissolution or erosion mechanism. 
In spite of the widely varying physico-chemical characteristics of the excipients, 
the drug dissolution profiles display similar tendencies. The drug release rate 
increased with increasing proportions of excipient and corresponding decrease in 
xanthan gum content. The mechanisms of drug release were anomalous (non -
Fickian) diffusion at low proportion of excipient which gradually changed to Case II and 
Super Case II transport at higher proportion of excipient. 
The pH of the dissolution medium greatly affected the release of diclofenac 
sodium. The higher the pH of the dissolution medium, the faster the release rate. 
These results are consistent with the pH solubility profile of diclofenac sodium. 
The stirring speed (from 50 to 150 rpm) and the tablet volume have a relatively 
small effect on drug release. 
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It can be concluded that the release profile of diclofenac sodium is greatly 
dependent on the proportion of xanthan gum in the formulation, and the pH of the 
dissolution medium. 
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CHAPTERS 
HYDROPHILIC MINI-MATRICES CONTAINING DICLOFENAC 
SODIUM AND NATURAL GUMS: INVESTIGATION OF THE 
SWELLING, SOLVENT PENETRATION AND EROSION 
PROPERTIES 
5.1 INTRODUCTION 
The mechanism of drug release from hydrophilic matrices is controlled by two 
factors; drug diffusion and polymer relaxation (Calanchi et al. 1987) (see also Chapter 
1). The diffusion of the drug throughout the gel layer into the dissolution medium is 
directly influenced by the swelling behaviour of the system. Hence, the swelling 
behaviour, the solvent penetration profile (a factor that would affect the swelling 
behaviour) and the erosion profile of the mini-matrices are the important factors in the 
release characteristics of hydrophilic matrices. The swelling behaviours, both axial and 
radial, and the solvent penetration profiles were studied using photographic 
techniques. The erosion profiles were studied using the method applied from the 
dissolution study. The compatibility between model drug and excipients (from the most 
satisfactory formulation) was also studied using differential scanning calorimetry 
(DSC). 
5.2 MATERIALS 
Oiclofenac sodium mini-matrices (formulations 1-3, Table 4.1 and formulations 
10-140, Table 4.2). 
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Buffers, liquids and solutions: sodium hydroxide and potassium dihydrogen 
orthophosphate were used to prepare phosphate buffer solution pH 7.0 (USP XXIII 
1994). 
5.3 METHODS 
5.3.1 Swelling properties of mini-matrices 
5.3.1.1 Axial swelling test 
A Single mini-matrix tablet was placed on a glass slide in a petri dish (6 cm in 
diameter) containing 30 ml of 0.0001 % w/v methylene blue solution in 0.05 M 
phosphate buffer pH 7.0 (USP XXIII 1994). Methylene blue was added in the buffer 
solution in order to ensure that the swelling was easily observed. The temperature was 
controlled at 37±0.S'C in a thermostatic water bath. The lateral edge of the mini-matrix 
was photographed (Olympus OM-2n camera with Zuiko MC Auto-S lens, focal length 
50 mm, maximum aperture 1.4, fitted with multiple extension tubes up to 65 mm) at 
regular time intervals for 360 minutes. The axial swelling distances were measured 
directly from the photographs using the thickness of the glass slide as a reference. All 
determinations were performed in triplicate and the mean axial swelling index (%; ±SD) 
was plotted against time. 
5.3.1.2 Radial swelling test 
A mini-matrix tablet was placed in identical conditions as described under axial 
swelling, but with a standard scale (in mm) placed underneath the petri dish. Visual 
measurements of the diameter were taken at regular time intervals for 360 minutes. All 
determinations were performed in triplicate and the mean radial swelling index (%; 
±SD) was plotted against time. 
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5.3.2 Solvent penetration study 
The penetration of the solvent front was monitored as a function of time using a 
simple method to allow solvent to penetrate only from the lateral edge of the mini-
matrices. Both flat surfaces of the matrices were coated with a silicone high vacuum 
grease to prevent solvent penetration from these surfaces. Each mini-matrix was then 
sandwiched between two glass cover slips and then placed in a petri dish (6 cm in 
diameter). To ensure that the penetration front was easily distinguishable, a 0.0001 % 
w/v solution of methylene blue in 0.05 M phosphate buffer (pH 7.0) was poured into the 
petri dish just sufficient to reach the level of the top cover slip. The penetration of the 
solvent was easily visible as a sharp front and this solvent front was photographed 
(Olympus OM-2n camera with Zuiko Me Auto-S lens, focal length 50 mm, maximum 
aperture 1.4, fitted with multiple extension tubes up to 65 mm) at regular time intervals 
for 360 minutes. From the photographs the penetration distance of the solvent (in mm) 
was measured using the scale on micrometer disc as a reference. All determinations 
were performed in triplicate and the mean solvent front penetration distance (in mm; 
±SD) was plotted against time. 
5.3.3 Data analYSis 
The axial and radial swelling indices (SI) were calculated according to Equation 
5.1: 
s-a SI = (-) x 100 ........................................... (5.1) 
a 
For axial swelling; a is the original thickness, while for radial swelling a is the 
original diameter of the dry mini-matrix. In the case of the swollen mini-matrix, s is the 
thickness and diameter for axial and radial swelling respectively. Swelling profiles were 
obtained by plotting the swelling index against time (t). The kinetics of the swelling and 
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the solvent front penetration processes were calculated according to Equations 5.2a and 
b respectively: 
Os = Cstn, ..................................................... (5.2a) 
o p = Cptnp .................................................... (5.2b) 
where Os is the swelling index, op is the solvent front penetration distance, ns is 
the exponent describing the swelling mechanism, np is the exponent describing the 
solvent front penetration mechanism, and Cs and Cp are constants for swelling and 
penetration fronts respectively. The values for ns and np = 0.45 for Case I or Fickian 
diffusion, 0.45 < ns and np < 0.89 for anomalous (non-Fickian) diffusion, ns and np = 0.89 
for Case II transport and ns and np > 0.89 for Super Case II transport. 
5.3.4 Erosion study 
The method used was similar to the method of determining the in vitro 
dissolution profile as described in Chapter 4. However, single mini-matrices were 
placed in thoroughly clean wire mesh baskets and then weighed accurately. During the 
dissolution process at 60 minute time intervals a basket containing the remnants of a 
mini-matrix was removed and dried at 60' C for 24 hours. After cooling in a desiccator 
to room temperature these were weighed accurately and the percentage weight loss 
(% erOSion) was calculated and plotted against time. 
5.3.5 Compatibility of model drug and exclplents 
Only the diclofenac sodium mini-matrices that produced satisfactory release 
profiles were considered for this test. Physical mixtures of binary systems containing 
either diclofenac sodium, natural hydrophilic gums and/or excipients in a ratio of 1: 1 
were prepared with a mortar and pestle. The individual substances and phYSical 
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mixtures were thermally characterised by using a differential scanning calorimeter 
(Pyris1, Perkin Elmer, USA). The samples (1.5-5 mg) were weighed directly into flat 
bottomed aluminium sample pans. The pans were crimped with the lid on top of the 
sample. These samples were heated in a nitrogen atmosphere. The heat flow rate of 
20·C/min was monitored as a function of temperature from 30 to 400·C. The 
thermograms were recorded. 
5.4 RESULTS AND DISCUSSION 
5.4.1 Swelling study of mini-matrices 
5.4.1.1 Effect of gum type 
When the mini-matrix was placed in the 0.0001 % methylene blue solution in 
0.05 M phosphate buffer, liquid penetrates into the matrix and a gel is formed due to 
uncoiling of the structure of the gum molecules and the formation of hydrogen bonds 
with water molecules. As a result, the thickness and diameter of the matrix increase 
progressively and a distinct gel-sol boundary develops. 
The photographs of the lateral edge of a mini-matrix containing diclofenac 
sodium and hydrophilic gums; xanthan gum, karaya gum or locust bean gum, in a ratio 
of 1:1 at 0, 60 and 360 minutes after contact with 0.0001% methylene blue solution in 
0.05 M phosphate buffer pH 7.0 are shown in Figures 5.1a-c, 5.2a-c and 5.3a-c 
respectively. 
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(a) 
(b) 
(c) 
Figure 5.1 a-c. The photographs of the lateral edge of a mini-matrix containing 
diclofenac sodium and xanthan gum in a ratio of 1: 1, at time zero (a), 60 (b) and 360 
minutes (c) after contact with 0.0001 % methylene blue solution in 0.05 M phosphate 
buffer pH 7.0. 
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(a) 
(b) 
(c) 
Figure 5.2a-c. The photograph of the lateral edge of a mini-matrix containing 
diclofenac sodium and karaya gum in a ratio of 1: 1, at time zero (a), 60 (b) and 360 
minutes (c) after contact with 0.0001% methylene blue solution in 0.05 M phosphate 
buffer pH 7.0. 
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(a) 
(b) 
(c) 
Figure 5.3a-c. The photograph of the lateral edge of a mini-matrix containing 
diclofenac sodium and locust bean gum in a ratio of 1: 1, at time zero (a) , 60 (b) and 
360 minutes (c) after contact with 0.0001% methylene blue solution in 0.05 M 
phosphate buffer pH 7.0. 
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The axial and radial swelling profiles (81 against time) of mini-matrix formulations 
of each gum (xanthan gum, karaya gum and locust bean gum) combined with diclofenac 
sodium in a ratio of 1: 1 are shown respectively in Figures 5.4a and b. Diclofenac sodium 
and carrageenan gum in a ratio of 1: 1 disintegrated within 10 minutes after contact with 
the medium, so the experiment with carrageenan gum was discontinued. The xanthan 
gum mini-matrices showed the greatest swelling indices in both the axial and radial 
dimensions when in contact with the phosphate buffer (0.05 M) at pH 7.0, being 
254.7±10.5% and 178.3±4.1% respectively after 360 minutes. Karaya gum displayed an 
intermediate swelling index (153.7±6.9% and 166.9±2.8% respectively), while the lowest 
indices were for locust bean gum (69.6±7.2% and 91.3±1.4% respectively) after 360 
minutes. The swelling rates, calculated from the slopes of the plots of swelling index 
versus square root of time (Figures 5.5a and b), for xanthan gum, karaya gum and locust 
bean gum were 12.44, 7.30 and 2.68 % min-112 for axial dimension and 9.73.9.44 and 
4.29 % min-112 for radial dimension respectively (Tables 5.1 and 5.2). This order would 
indicate the rates at which the gums are able to absorb water and swell. Thus xanthan 
gum has the ability to hydrate more rapidly than the other two gums used. The resulting 
drug diffusional path length for xanthan gum was therefore the longest. Provided the 
gums have nearly similar diffusion coefficients, it would follow that the drug release rate 
from the xanthan gum matrices would be the slowest. However. the drug dissolution 
profiles (see Figure 4.1) actually show that the order of decreasing drug release was 
locust bean gum>xanthan gum>karaya gum, with mean dissolution times (MDT) of 
180±36, 329±60 and 655±120 minutes respectively. It is obvious therefore that Fickian 
drug diffusion through the gradually expanding hydrated matrix with increasing diffusional 
path length was not the only mechanism accounting for drug release. The release 
behaviour of each of the three gums was anomalous (non-Fickian) having release 
exponent (n) values of 0.703±0.014. 0.731%0.008 and 0.777±0.080 for xanthan, karaya 
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and locust bean gums respectively. On the other hand, when the results of the swelling 
index studies are processed in accordance with Equation 5.2a, the resulting swelling 
exponents (ns) in both dimensions (Tables 5.1 and 5.2) represent almost Fickian swelling 
behaviour. This swelling mechanism can be explained as a result of the rapid hydration 
of gum molecules on the surface of the mini-matrices, which results in a gel or a highly 
viscous solution surrounding the mini-matrices that restricts water penetration into the 
centre. Swelling occurs rapidly both axially and radially in the first 30 minutes and 
thereafter the swelling rate gradually declines with time. The diclofenac sodium: locust 
bean gum 1:1 formulation showed little axial swelling behaviour (ns= 0.299±0.054). 
This could be due in part to the poor swellability of the locust bean gum. Figure 5.5a 
shows plots of axial swelling index versus square root of time which are linear (r = 0.994, 
0.993 and 0.982 for diclofenacsodium: xanthan gum 1 :1, diclofenacsodium: karaya gum 
1: 1 and diclofenac sodium: locust bean gum 1: 1 respectively). Figure 5.5b also shows 
the similar results for radial swelling (r = 0.990, 0.980 and 0.984 respectively). The 
swelling rates in both dimensions are calculated from the slope of these plots and shown 
in Tables 5.1 and 5.2. 
134 
~ ~ 
>< Q) 
" .= 
Cl 
.= 
Qj 
~ 
II) 
'jij 
'X 
< 
300 T 
250 t 
I 
200 r 
150 T 
I 
I 
100 
50 
o __ ------~--------~-----
o 60 120 180 
Time (min) 
240 
i -+-O:X 1~--=O:K 1:1 -,- O:LB 1:1 1 
300 360 
Figure 5.4a. Axial swelling profiles showing the swelling indices (%) against time (min) of 
single mini-matrices containing 1: 1 mixtures of various hydrophilic gums; xanthan gum 
(X), karaya gum (K) and locust bean gum (LB), and diclofenac sodium (0) in 0.0001 % 
methylene blue solution in 0.05 M phosphate buffer pH 7.0 (mean value SO, n=3) . 
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Figure 5.4b. Radial swelling profiles showing the swelling indices (%) against time (min) 
of single mini-matrices containing 1: 1 mixtures of various hydrophilic gums; xanthan gum 
(X), karaya gum (K) and locust bean gum (LB), and diclofenac sodium (0) in 0.05 M 
phosphate buffer pH 7.0 (mean values±SO, n=3). 
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Figure 5.5a. Plot of mean axial swelling index (%) against the square root of time (min1 /2) 
of single mini-matrices containing 1: 1 mixtures of various hydrophilic gums; xanthan gum 
(X), karaya gum (K) and locust bean gum (LB), and diclofenac sodium (0) in 0.0001 % 
methylene blue solution in 0.05 M phosphate buffer pH 7.0 (mean value SO, n=3). [If 
straight lines were drawn the correlation coefficients (r) would be 0.994 (xanthan gum) , 
0.993 (karaya gum) and 0.982 (locust bean gum)]. 
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Figure 5.5b. Plot of mean radial swelling index (%) against the square root of time 
(min 1/2) of single mini-matrices containing 1: 1 mixtures of various hydrophilic gums; 
xanthan gum (X), karaya gum (K) and locust bean gum (LB), and diclofenac sodium (0) 
in 0.05 M phosphate buffer pH 7.0 (mean values±SO, n=3). [If straight lines were drawn 
the correlation coefficients (r) would be 0.990 (xanthan gum), 0.980 (karaya gum) and 
0.984 (locust bean gum)]. 
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Table 5.1. Axial swelling parameters and correlation coefficients from single mini-matrices using Equation S.2a to derive the swelling 
exponent (ns) and the kinetic constant (Cs). The swelling rate (% min-112) was calculated from the slopes of the plots of axial swelling index 
versus square root of time (mean values±SO; n=3). 
Mini-matrices Swelling exponent Kinetic constant (Cs) Correlation Swelling rate Correlation 
composition • (ns) (min-") coefficient (r) (% min-112) coefficient (r) 
O:X 1:1 0.460±0.056 17.46±4.83 0.993 12.44±1.S2 0.994 
O:K 1:1 0.414±O.029 13.63±1.79 0.996 7.30±0.61 0.993 
O:LB 1:1 0.299±O.054 12.16±3.00 0.987 2.68±0.54 0.982 
0:X2:1 0.462-.+0.029 22.43±1.7S 0.992 17.6S±1.29 0.991 
0:X2:3 0.423±O.02S 18.16±3.67 0.990 11.80±1.51 0.994 
O:X 1:2 0.441±O.069 1S.S2±4.0S 0.987 11.67±2.32 0.983 
*0, Oiclofenac sodium; X, Xanthan gum; K, Karaya gum; LB, Locust bean gum. 
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Table 5.2. Radial swelling parameters and correlation coefficients from single mini-matrices using Equation 5.2a to derive the swelling 
exponent (ns) and the kinetic constant (Cs). The swelling rate (% min-1I2) was calculated from the slopes of the plots of radial swelling index 
versus square root of time (mean values±SD; n=3). 
Mini-matrices Swelling exponent Kinetic constant (Cs) Correlation Swelling rate Correlation 
composition • (ns) (min-n) coefficient (r) (% min-1/2) coefficient (r) 
D:X 1:1 0.460±0.019 13.24±1.18 0.990 9. 73±0.43 0.990 
D:K 1:1 0.432±O.020 15.91±1.67 0.988 9.44±0.79 0.980 
D:LB 1:1 O. 384±O. 052 10.17±2.70 0.986 4.29±0.53 0.984 
D:X2:1 0.706±O.023 3. 96±0.40 0.998 13.88±O.31 0.995 
D:X2:3 0.421±O.010 13.63±O.52 0.994 7.65±0.81 0.989 
D:X 1:2 0.395±O.OO3 16.52±O.27 0.995 7.61±O.09 0.991 
'D. DicIofenac sodium; X. Xanthan gum; K. Karaya gum; LB. Locust bean gum. 
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5.4.1.2 Effect of drug: xanthan gum ratio 
The axial and radial swelling profiles for various mixtures of diclofenac sodium 
with xanthan gum are shown in Figure 5.6a and b respectively, while the respective 
swelling exponents (ns) and swelling rates are shown in Tables 5.1 and 5.2. The mini-
matrix containing the lowest proportion of xanthan gum (drug: gum 2: 1) produced profiles 
with the highest rate of axial and radial swelling over the 6 hour period. The axial swelling 
index decreased in the order of drug: gum ratios of 2:1, 1: 1, 2:3 and 1 :2. A similar, but 
less pronounced, trend was observed for the radial swelling index. Initially this order of 
decreasing swelling index profiles was not expected since, as pointed out in Chapter 4, 
the drug release rate decreased in the order of increasing proportion of xanthan gum. It 
was reasoned that as the amount of xanthan gum in the matrix increased there would be 
a greater degree of gum hydration with simultaneous swelling. This would result in a 
corresponding lengthening of the drug diffusion pathway and reduction in drug release 
rate. The increased drug release that occurred with increased swelling rate could, 
however, be explained on the basis of a change in the integrity of the matrix. Mini-
matrices with a drug: gum ratio of 2: 1 actually showed a disintegration of the matrix 
structure as seen in Figure 5.6a which shows a sudden surge in the axial swelling index 
after 3 hours. The phosphate buffer medium will permeate through the gum matrix 
dissolving the drug which passes by diffusion outwards into the medium and the volume 
occupied by the drug molecules will be replaced with water molecules. If drug diffusion 
outwards through the hydrated gel is slower than the permeation of water inwards, then 
the swelling effect would be more pronounced. 
Swelling stUdies carried out concurrently using mini-matrices of xanthan gum only 
(no drug present) showed that the mini-matrices maintained their integrity and reached a 
radial swelling index of 233% after 24 hours {compared to a maximum radial swelling 
index at 6 hours of 178% for a 1:1 drug: gum ratio as seen in Figure 5.6b}. Hydration and 
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swelling of matrices with a high gum content may be slower, but eventually they swell to 
greater maximum values compared to matrices with a low gum content, which would 
swell more rapidly but reach a lower maximum swelling index, or disintegrate, in a 
relatively shorter time period. 
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Figure 5.6a. Axial swelling profiles showing the swelling indices (%) against time (min) of 
single mini-matrices containing various mixtures of xanthan gum (X) with diclofenac 
sodium (0) in 0.0001% methylene blue solution in 0.05 M phosphate buffer pH 7.0 
(mean values±SD, n=3) . 
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Figure 5.6b. Radial swelling profiles showing the swelling indices (%) against time (min) 
of single mini-matrices containing various mixtures of xanthan gum (X) with diclofenac 
sodium (0) in 0.05 M phosphate buffer pH 7.0 (mean value SO, n=3). 
5.4.1.3 Effect of excipient concentration 
The mini-matrices containing diclofenac sodium, xanthan gum and Veegum® at 
various ratios were carried through the swelling study because they showed the most 
discriminating drug release profiles between each ratio (see Figure 4.9) . The axial and 
radial swelling profiles of these mini-matrices are shown in Figures 5.7a and b 
respectively. The swelling exponents (ns) and swelling rates for both dimensions are also 
shown in Tables 5.3 and 5.4. The axial swelling profiles tend to decline when the amount 
of Veegum® increases, corresponding to a decrease in the amount of xanthan gum 
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(Figure 5.7a). This decline is very little at the low proportion of Veegum® (drug: xanthan 
gum: Veegum® 3:3:0 to 3: 1.5: 1.5), until the ratio of drug: xanthan gum: Veegum® was 
3: 1 :2, the profile is greatly declined. When the mini-matrices contacted with 0.05 M 
phosphate buffer pH 7.0, xanthan gum and Veegum® absorbed water, they swelled and 
formed a viscous gel layer around the mini-matrices. The profiles from Figure 5.7a 
indicated that Veegum® swells to a smaller extent than xanthan gum at equal time, 
resulting in less swelling of the mini-matrices at low proportions of Veegum®. In addition, 
Veegum® also has a disintegration property, therefore the mini-matrices containing a 
high proportion of Veegum®, drug: xanthan gum: Veegum® in a ratio of 3:0.5:2.5, 
exhibited initial high swelling and disintegrated within 60-120 minutes after contact with 
phosphate buffer solution. The swelling rate and swelling exponent of this ratio 
(3:0.5:2.5) were unobtainable because there were not sufficient data points to provide 
accurate values. The swelling exhibited Fickian and anomalous mechanisms with a n. 
value range of 0.333-0.470 (Table 5.3). 
The radial swelling profiles exhibited similar but less pronounced trends (Figure 
5.7b). The swelling exhibited an anomalous mechanism with a n. value range of 0.452-
0.564 and swelling rate range between 7.51-10.33 O-'min"112 (Table 5.4). 
It can be concluded that Veegum® did not affect the swelling of the mini-matrices 
consisting of diclofenac sodium and xanthan gum. The decline in swelling at high 
proportions of Veegum® should be due to the lowering of xanthan gum proportion. As the 
xanthan gum proportion decreases there would be a lesser degree of gum hydration with 
simultaneous swelling. This would result in a corresponding shortening of the drug 
diffusional path length and an increase in drug release rate. This result is consistent with 
the release profiles of the mini-matrices which exhibited the higher drug release rate at 
lower xanthan gum proportion (see also Figure 4.9). 
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Figure 5.7a. Axial swelling profiles showing the swelling indices (%) against time (min) of 
Single mini-matrices containing diclofenac sodium (0), xanthan gum (X) and Veegum® 
(V) at various ratios in 0.0001 % methylene blue solution in 0.05 M phosphate buffer pH 
7.0 (mean values±SO, n=3). 
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Table 5.3. Axial swelling parameters and correlation coefficients from single mini-matrices using Equation 5.2a to derive the swelling 
exponent (ns) and the kinetic constant (Cs). The swelling rate (% min·112) was calculated from the slopes of the plots of axial swelling index 
versus square root of time (mean values±SD; n=3). 
Mini-matrices Swelling exponent Kinetic constant (Cs) Correlation Swelling rate Correlation 
composition • ens) (min"") coefficient (r) (% min-1/2) coefficient (r) 
D:X:V3:3:0 0.460±0.056 17.46±4.83 0.993 12.44±1.52 0.994 
D:X:V 3:2.5:0.5 0.470±0.058 14.47±5.20 0.987 11.36±1.83 0.988 
D:X:V3:2:1 0.467±O.116 14.70±9.23 0.976 10.16±1.78 0.973 
D:X:V 3: 1.5: 1.5 0.333±O.042 32.92±11.27 0.976 10.41±O.73 0.980 
D:X:V3:1:2 0.436±O.039 12.55±4.42 0.970 8.40±1.56 0.970 
D:X:V 3:0.5:2.5 
-0, Diclofenac sodium; X, xanthan gum; V, VeegumIB. 
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Figure 5.7b. Radial swelling profiles showing the swelling indices (%) against time (min) 
of single mini-matrices containing diclofenac sodium (0), xanthan gum (X) and Veegum® 
(V) at various ratios in 0.05 M phosphate buffer pH 7.0 (mean value SO, n=3) . 
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Table 5.4. Radial swelling parameters and correlation coefficients from single mini-matrices using Equation 5.2a to derive the swelling 
exponent (ns) and the kinetic constant (Cs). The swelling rate (% min-112) was calculated from the slopes of the plots of radial swelling index 
versus square root of time (mean values±SO; n=3). 
Mini-matrices Swelling exponent Kinetic constant (Cs) Correlation Swelling rate Correlation 
composition • (ns) (min-n) coefficient (r) (%min-112) coefficient (r) 
D:X:V3:3:0 0.460±0.019 13.24±1.18 0.990 9.73±0.43 0.990 
D:X:V 3:2.5:0.5 0.564±O.039 6.85±1.32 0.992 9.84±0.44 0.994 
D:X:V3:2:1 0.562-+0.017 6.91±O.71 0.994 10.33±0.32 0.996 
D:X:V 3:1.5:1.5 0.555±O.OO8 6.69±0.28 0.994 9.38±O.22 0.992 
O:X:V3:1:2 0.452±O.054 10.87±2.72 0.990 7.51±O.77 0.984 
O:X:V 3:0.5:2.5 
-0, Oiclofenac sodium; X, xanthan gum;-V~\leegumQ!J. 
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5.4.2 Solvent penetration study 
5.4.2.1 Effect of gum type 
The photographs of solvent front penetration of mini-matrices containing 
diclofenac sodium and hydrophilic gums; xanthan gum, karaya gum and locust bean 
gum, in a ratio of 1:1 at 0,60 and 360 minutes after contact with 0.0001% methylene 
blue solution in 0.05 M phosphate buffer pH 7.0 are shown in Figures S.Ba-c, S.9a-c 
and S.10a-c respectively. 
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(a) 
(b) 
(c) 
Figure 5.8a-c. The photograph of solvent front penetration of mini-matrix containing 
diclofenac sodium: xanthan gum in the ratio of 1: 1, at time zero (a) , 60 (b) and 360 
minutes (c) after contact with 0.0001 % methylene blue solution in 0.05 M phosphate 
buffer pH 7.0. 
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(a) 
(b) 
(c) 
Figure 5.9a-c. The photograph of solvent front penetration of mini-matrix conta nlng 
diclofenac sodium: karaya gum in the ratio of 1: 1, at time zero (a), 60 (b) and 360 
minutes (c) after contact with 0.0001% methylene blue solution in 0.05 M phosphate 
bUffer pH 7.0. 
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(a) 
(b) 
(c) 
Figure 5. 1 Oa-c. The photograph of solvent front penetration of mini-matrix containing 
diclofenac sodium: locust bean gum in the ratio of 1:1, at time zero (a) , 60 (b) and 360 
minutes (c) after contact with 0.0001 % methylene blue solution in 0.05 M phosphate 
buffer pH 7.0. 
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The solvent front penetration profiles of mini-matrices containing diclofenac 
sodium and hydrophilic gums; xanthan gum, karaya gum or locust bean gum, in a ratio of 
1: 1 are shown in Figure 5.11 and the solvent front penetration rates and exponents are 
presented in Table 5.5. The medium penetrates the xanthan gum at a faster rate 
compared with the other two gums. This is consistent with the axial and radial swelling 
studies which showed that xanthan gum also had the fastest swelling rate . The solvent 
front penetration exponents (np) follow almost Fickian kinetics in common with the 
swelling exponents. 
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Figure 5.11. Solvent front penetration profiles showing the degree of solvent front 
penetration (mm) against time (min) in single mini-matrices containing 1: 1 mixture of 
various hydrophilic gums; xanthan gum (X), karaya gum (K) and locust bean gum (LB), 
and diclofenac sodium (0) in 0.0001 % methylene blue solution in 0.05 M phosphate 
bUffer pH 7.0 (mean values±SD, n=3). 
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Table 5.5. Solvent front penetration parameters using Equation 5.2b to calculate the solvent front penetration exponent (np) and the kinetic 
constant (Cp). The solvent front penetration rate was calculated from the slopes of the linear portion of the plot of penetration front versus 
square root of time (mean values±SD; n=3). 
Mini-matrices Solvent penetration Kinetic constant (Cp) Correlation Solvent front penetration Correlation 
composition • exponent (np) (min-n) coefficient (r) rate (mm sec-112)x10-3 coefficient (r) 
D:X 1:1 0.396±O.051 0.155±O.041 0.989 9. 02±2. 02 0.992 
D:K 1:1 0.430±0.052 0.087±O.011 0.995 7.70±1.40 0.985 
D:LB 1:1 0.592-+0.119 O. 045±O. 029 0.989 6.71±1.32 0.992 
0:X2:1 0.361±O.048 0.172±O.045 0.982 8.39±O.75 0.987 
0:X2:3 0.366±O.010 0.208±O.021 0.990 10.64±0.98 0.994 
O:X 1:2 0.426±O.035 0.188±O.029 0.993 15.04±2.06 0.994 
'0, DicIofenac sodium; X, Xanthan gum; K, Karaya gum; LB, locust bean gum. 
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5.4.2.2 Effect of drug: xanthan gum ratio 
The solvent front penetration profiles of diclofenac sodium: xanthan gum at 
various ratios (Figure 5.12) show that medium penetration is impeded in the matrices 
with the highest drug content (drug: gum 2:1). The solvent front penetration rates of the 
mini-matrices containing various proportions of drug and xanthan gum are shown in 
Table 5.5. The penetration rate is lowest in the matrices containing the highest drug 
content. Other workers (Mitchell et al. 1991; Vandelli and Cameroni 1993; Panomsuk et 
al. 1995a) have reported similar findings using other polymers and drugs. The solvent 
molecules bombard the polymer chains in a random fashion, therefore the presence of 
solid particles of drug embedded in the polymer network will further impede the 
movement of water molecules through the hydrated material. Although water penetration 
into highly drug-loaded matrices is relatively slow, these hydrated regions would be much 
more porous as a result of dissolution of the drug. The degree of porosity and swelling 
would be directly related to the drug content of the matrix. The dissolved drug does not 
inhibit the swelling process, but rather bonding between the polymer network chains is 
reduced as they become separated with consequent loss of matrix integrity. 
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Figure 5.12. Solvent front penetration profiles showing the degree of solvent front 
penetration (mm) against time (min) in single mini-matrices containing various mixtures 
of xanthan gum (X) with diclofenac sodium (0) in 0.0001 % methylene blue solution in 
0.05 M phosphate buffer pH 7.0 (mean values±SO, n=3). 
5.4.2.3 Effect of excipient concentration 
The solvent front penetration profiles of diclofenac sodium, xanthan gum and 
Veegum® at various ratios are shown in Figure 5.13. The solvent front penetration 
profiles were insignificantly different; ~ 0.3 mm difference between the maximum and 
minimum front at 360 minutes after contact with the medium. All the profiles exhibited 
Fickian kinetics with the np value range between 0.384-0.447 and the penetration rate 
range between 8.55-11.29x10·3 mm sec·1/2 (Table 5.6) . These results Implied that 
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Table 5.6. Solvent front penetration parameters using Equation 5.2b to calculate the solvent front penetration exponent (np) and the kinetic 
constant (Cp). The solvent front penetration rate was calculated from the slopes of the linear portion of the plot of penetration front versus 
square root of time (mean values±SD; n=3). 
Mini-matrices Solvent penetration Kinetic constant (Cp) Correlation Solvent front penetration Correlation 
composition • exponent (np) (min-n) coefficient (r) rate (mm sec-112) x 1 0-3 coefficient (r) 
D:X:V3:3:0 0.396±O.051 0.16±O.04 0.989 9.02±2.02 0.992 
D:X:V 3:2.5:0.5 0.447±O.084 0.14±O.05 0.989 11.29±2.07 0.989 
D:X:V3:2:1 O.384±O.O36 0.18±O.03 0.983 10.04±0.99 0.983 
D:X:V 3:1.5:1.5 0.393±O.017 0.16±O.02 0.988 10.12±O.70 0.990 
D:X:V3:1:2 0.394±O.017 0.14±O.02 0.980 8.55±O.40 0.986 
D:X:V 3:0.5:2.5 
-0, Oiclofenac sodium; X, Xanthan gum; V.-Veegumw. 
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5.4.3 Erosion study 
Results of the erosion studies on diclofenac sodium: gum ratios of 1: 1 are 
provided in Figure 5.14. These studies reflect both the amounts of drug dissolved and the 
relaxation of the gum from the mini-matrices during the dissolution study. The matrix 
consisting of diclofenac sodium: locust bean gum 1: 1 showed the greatest degree of 
erosion after 6 hours (63%), followed by diclofenac sodium: xanthan gum (43%) and 
diclofenacsodium: karaya gum (24%). 
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Figure 5.14. The percentage of erosion against time (min) from single mini-matrices 
containing 1: 1 mixtures of various hydrophilic gums; xanthan gum (X), karaya gum (K) 
and locust bean gum (LB), and diclofenac sodium (0) in 0.05 M phosphate buffer pH 7.0 
(mean values±SD, n=3). 
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The fact that xanthan gum does not yield the slowest drug dissolution rate can be 
explained by its moderate erosion rate. There are two competing mechanisms of drug 
release. Swelling and erosion of the material are occurring simultaneously resulting in 
moving boundary conditions which continuously modify the effective diffusivity of the 
drug. Erosion increases the drug dissolution rate thus compensating to some extent for 
the high swelling index and the consequent slowing of drug diffusion by the increasing 
diffusional path length. 
With locust bean, on the other hand, the high erosion rate coupled with the low 
axial and radial swelling index and consequent shorter diffusional path length. account for 
the high drug release rate. As would be expected, the penetration rate of the dissolution 
medium was also low, which is characteristic of a material with a low swelling index. 
Karaya gum shows moderate swelling and solvent penetration rates, but has a 
very slow rate of erosion. These factors combine to result in a low rate of drug release. 
Karaya gum did not demonstrate an initial "burst" release, but in fact there was a brief lag 
time before any measurable amount was detected (see Figure 4.1). This lag period could 
also be explained on the basis of moderate swelling and low erosion rate. 
5.4.4 Compatibility of model drug and exclplenta 
Differential scanning calorimetry (DSC) was used as a quick screening 
technique for assessing the possible interaction between the model drug, diclofenac 
sodium, and the substances used in the formulation. Interaction In the samples are 
derived or deduced from DSC by changes in the thermal events such as elimination of 
an endotherm or exotherm peak or appearance of a new endotherm or exotherm peak. 
Changes in peak shape, peak onset or peak maximum temperature and relative peak 
heights are changes which might also be considered. However, it should be cautioned 
that some broadening of peaks leading to changes in area, onset or peak 
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temperatures are simply due to mixing the components without indicating an 
interaction. Provided that all thermal features more or less remain in the sample, 
compatibility can be accepted. The thermal characteristics of all the substances and 
mixtures studied were tabulated in Table 5.6. 
The thermogram of diclofenac sodium showed an endotherm with an onset 
temperature of 280.4·C followed by the broad exotherm in the range of 310-335·C. 
This result indicated melting and decomposition of diclofenac sodium respectively. The 
thermogram of xanthan gum showed a broad exotherm at the range of 254-316·C. It 
indicated decomposition of the gum. The physical mixture of diclofenac sodium and 
xanthan gum 1: 1 showed the endotherm of diclofenac sodium and the combination of 
exotherm of diclofenac sodium and xanthan gum with the endotherm onset of 281.4·C 
and the exotherm range of 288-310·C. The transitions of diclofenac sodium and 
xanthan gum might overlap each other resulting in slightly changed transition 
temperatures. 
The thermogram of lactose exhibited two endotherms with onset temperatures 
of 146.7 and 212.3·C. Lactose exists in several forms which vary in their response to 
water. a-Lactose is an unstable anhydrate which absorbs one water molecule to form 
a-lactose monohydrate. Therefore, the first endotherm referred to 1088 of water of 
crystallisation and the second shows the melting of a-lactose. A phYSical mixture of 
xanthan gum and lactose 1 : 1 exhibited two endotherms of lact08e with onset 
temperature of 145.8 and 210.5°C and one exotherm of xanthan gum at the range of 
281-303·C (Table 5.6). The physical mixture of diclofenac sodium and lactose 1:1 
exhibited the two endotherms of lactose and an irregular exotherm at the range of 240 
to 300·C (Table 5.6). Diclofenac sodium and lactose might be dissolving in each other 
reSulting in lowering of the second endotherm onset (lower melting point) and no 
endotherm of diclofenac sodium. However, the broad irregular exotherm resulting from 
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decomposition of diclofenac sodium still remained. There was no evidence of any new 
thermal events. In addition, this test was performed at elevated temperature but the 
production and administration of this product would be at room temperature. Hence 
lactose was unlikely to cause any interaction in the preparation of diclofenac sodium, 
xanthan gum and lactose mini-matrices. 
The thermogram of Encompress® exhibited no transition over the temperature 
range of 30-400°C. The physical mixture of diclofenac sodium and Encompress® 1:1 
exhibited the endotherm of diclofenac sodium at an onset temperature of 258.3·C. The 
phYSical mixture of xanthan gum and Encompress® 1:1 exhibited the exotherm of 
xanthan gum at the range of 254-316°C. Encompress® is reported to decompose 
below 100°C (Parikh 1994) but from this experiment there was no exotherm of 
decomposition of Encompress®. However, the thermal characteristics of diclofenac 
sodium and xanthan gum still remained in the mixtures of these substances and 
Encompress®. These results indicated no interaction between diclofenac sodium, 
xanthan gum and Encompress®. 
The thermogram of cellulose acetate phthalate (CAP) and physical mixture of 
either diclofenac sodium or xanthan gum and CAP 1: 1 exhibited no transition over the 
temperature range of 30-400·C. The melting point of CAP was reported to be 192·C 
(Sakellariou et al. 1985). The thermal characteristics of diclofenac sodium and xanthan 
gum were eliminated from the mixture of these substances and CAP. This might 
indicate some interaction between diclofenac sodium and xanthan gum with CAP. 
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Table 5.6. The onset and range of transition (C) of diclofenac sodium, xanthan gum, 
excipients and 1 : 1 physical mixtures of each of these substances from OSC 
thermograms. 
Substance* Endotherm 
onset (C) 
D 280.4 
X 
L 
D:X 
D:L 
X:L 
E 
D:E 
X:E 
CAP 
D:CAP 
X:CAP 
V 
D:V 
X:V 
MgSt 
D:MgSt 
281.4 
258.3 
287.9 
Exotherm 
range (C) 
310-335 
240-300 
295-315 
Endotherm 
onset (C) 
146.7 
147.0 
145.8 
Endotherm 
onset (C) 
212.3 
176. 7 
210.5 
106.3 
104.6 
Exotherm 
range (C) 
254-316 
288-310 
281-303 
254-316 
289-317 
*0; Oiclofenac sodium, X; Xanthan gum, L; Lactose, E; Encompress®, CAP; Cellulose 
acetate phthalate, V; Veegum F® and MgSt; Magnesium Stearate. 
The thermogram of Veegum® also exhibited no transition over the temperature 
range of 30-400·C. The physical mixture of diclofenac sodium and Veegum® 1: 1 
exhibited the endotherm of diclofenac sodium at the onset temperature of 287.9°C 
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followed by the exotherm in the range of 295-315°C. The physical mixture of xanthan 
gum and Veegum® 1:1 exhibited the exotherm of xanthan gum in the range of 289-
31tC. The thermal characteristics of diclofenac sodium and xanthan gum in the 
mixtures of these substances with Veegum® indicated no interaction between 
diclofenac sodium, xanthan gum and Veegum®. 
The thermogram of magnesium stearate exhibited one endotherm with an 
onset temperature of 10S.3°C. The physical mixture of diclofenac sodium and 
magnesium stearate 1: 1 exhibited one endotherm of magnesium stearate at an onset 
temperature of 104.SoC. The endotherm of diclofenac sodium was eliminated indicating 
that diclofenac sodium had possibly dissolved in the melted magnesium stearate. 
However, in the real situation this phenomenum was unlikely to happen because of the 
fact that this test was performed at elevated temperature but the production and 
administration of this product would be at room temperature. Furthermore, the amount 
of magnesium stearate used in the formulation was very little, 1 % in the matrix, 
compared with 50% in this experiment. In addition, there are many reports using 
magnesium stearate in diclofenac sodium sustained-release preparation without the 
evidence of any incompatibility problem (Malamataris and Ganderton 1991; Bain et al. 
1991; Naggar et al. 1992; Sarisuta and Mahahpunt 1994; Navarro and Ballesteros 
1994; Conte et al. 1994; Chetty et al. 1994; Lin et al. 1995; Chattaraj and Das 1996). 
5.5 CONCLUSION 
The xanthan gum mini-matrices showed the greatest swelling In both the axial 
and radial dimensions. The medium penetration profiles presented the same order; 
xanthan gum> karaya gum> locust bean gum but the degree of erosion was somewhat 
different; locust bean gum> xanthan gum> karaya gum. The drug release from these 
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mini-matrices depended on both swelling and erosion of the gum. These results 
supported the findings on the Fickian diffusion and relaxation contributions shown in 
Chapter 4. 
For diclofenac sodium and xanthan gum at various ratios, the higher the 
xanthan gum content the slower the swelling rate. However, high xanthan gum content 
mini-matrices eventually swell to a greater maximum extent compared to low xanthan 
gum content mini-matrices. The solvent penetration profiles of diclofenac sodium and 
xanthan gum mini-matrices in the ratio of 1:2 is higher than 2:3, 1: 1 and 2: 1 
respectively. The presence of solid particles of drug embedded in the polymer network 
impede the movement of water molecules through the hydrated material. Although 
water penetration into highly drug loaded matrices is relatively slow, these hydrated 
regions would be much more porous as a result of dissolution of the drug. 
Veegum® has inSignificant effect on the swelling and solvent penetration of 
mini-matrices consisting of diclofenac sodium and xanthan gum. The slight lowering of 
the swelling rate at high proportion of Veegum® was due to the corresponding lowering 
of the xanthan gum proportion. 
Diclofenac sodium, xanthan gum and excipients used in this formulation 
(lactose, Encompress® and Veegum®), except for CAP, were unlikely to have any 
interaction with each other due to the screening by esc. 
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CHAPTER 6 
APPLICATION OF THE HYDROPHILIC MINI-MATRIX PRINCIPLE 
TO THE DEVELOPMENT AND EVALUATION OF A MULTIPLE· 
UNIT ORAL SUSTAINED RELEASE DOSAGE FORM FOR 
S(+)IBUPROFEN 
6.1 INTRODUCTION 
Ibuprofen (2-(4-isobutylphenyl) propionic acid) is a non-steroidal anti-
inflammatory drug (NSAID) widely used in rheumatoid arthritis, osteoarthritis and a 
number of other painful conditions. It has a chiral carbon atom on the propionic side-
chain and therefore exists in two enantiomeric forms. S(+) ibuprofen is the 
pharmacologically active form and 160 times more potent than R(-) ibuprofen (Adams 
et al. 1976). R(-) ibuprofen is inverted to S(+) ibuprofen (Hutt and Caldwell 1983) to the 
extent of 57-69% for oral doses (Cheng et al. 1994; Lee at al. 1985) and 69°Al for 
intravenous doses (Cheng et al. 1994). A large inter-individual variability in the ratio of 
S( +) to R( -) ibuprofen average concentration at steady-state was observed and 
probably accounts for the known lack of correlation between racemic ibuprofen 
concentration and therapeutic efficacy (Oliary et al. 1992; Evans et al. 1990). In 
addition, previous studies in the rat revealed that R(-) ibuprofen formed potentially toxic 
hybrid triglycerides that slowly eliminated from adipose tissue (Williams et al. 1986). 
S(+) ibuprofen is therefore a better choice of drug than racemic ibuprofen. Not only the 
dose of drug but also the metabolic inversion in the body will be reduced. The toxicity 
resulting from R(-) ibuprofen administration will consequently be eliminated. 
The purpose of this study is to prepare S(+) ibuprofen mini-matrix MUDFs. The 
knowledge gained from the preparation of diclofenac sodium mini-matrix MUDFs will 
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be applied to S(+) ibuprofen. Xanthan gum and karaya gum will be the principle 
materials used to form the matrix because they produced satisfactory release profiles 
of diclofenac sodium from mini-matrix MUDFs (see also Chapter 4). HPMC will also be 
used for comparative purposes. The most satisfactory formulation will be subjected to 
stability studies at elevated temperatures and relative humidities. 
6.2 MATERIALS 
Natural hydrophilic gums: xanthan gum (X) and karaya gum (K). 
Synthetic hydrophilic polymer: HPMC. 
Model drug: S(+) ibuprofen (I). 
Excipients: lactose (L), dicalcium phosphate (Encompress®, E) and 
microcrystalline cellulose (Avicel® PH101, A). 
lubricant: talc and hydrogenated cottonseed oil (Lubritab®). 
Buffers, liquids and solutions: sodium hydroxide and potassium dihydrogen 
orthophosphate were used to prepare phosphate buffer solutions pH 6.5, 7.0 and 7.2 
(USP XX"I 1994), hydrochloric acid and potassium chloride were used to prepare 
hydrochloric acid buffer solution pH 1.5 (USP XX"I 1994), sodium phosphate and citric 
acid were used to prepare citrate-phosphate buffer solution pH 5.0 (Wade 1980), and 
potaSSium hydroxide, magnesium chloride and sodium chloride were used to prepare 
saturated solutions for use in the humidity chamber (Wade 1980). 
6.3 METHODS 
6.3.1 Preparation of mlnl.matrlces 
All materials were passed through a mesh sieve with an aperture of 250 fA,m 
before use. Matrix tablets were prepared by the wet granulation method. The 
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composition of the formulations are given in Table 6.1. All materials, with the exception 
of lubricants (talc or Lubritab®), were thoroughly mixed in a tumbling mixer for S 
minutes and then wetted in a mortar with SO% v/v ethanol. The wet mass was then 
passed through a SOO J.lm mesh sieve and dried at a temperature not greater than 
40·C (well below the melting point of S(+) ibuprofen) for 18 hours. The dried granules 
were then rescreened through a 300 J.lm mesh sieve, lubricated with talc 2% wlw or 
Lubritab® 1 % w/w and compressed into flat-faced mini-matrices of diameters 4.S mm 
each weighing 30.61±1.0 mg and containing 10±O.33 mg of S(+)ibuprofen. An 
instrumented Manesty F3 single punch tablet machine (Manesty Machines Ltd., 
Liverpool, England) was used to compress the mini-matrices. The crushing strength of 
10 matrices was individually measured using an Erweka hardness tester (Erweka TBH 
28, Germany). The mean crushing strength and standard deviation were calculated. 
Eight mini-matrices were encapsulated in size 1 hard gelatin capsules to produce a 
multiple unit dosage form (MUDF), with a total dose of 80 mg of S(+) ibuprofen. 
Table 6.1. Composition (%) of the mini-matrices containing S(+)ibuprofen, hydrophilic 
gums (xanthan gum, karaya gum) or HPMC, and various excipients. 
Formulations 
1SA-C* 16A-C* 17A* 18A* 
S( +} ibuprofen 32.67 32.67 32.67 33 
Xanthan gum 32.67 33 
Karaya gum 32.67 
HPMC K4M 32.67 
Excipients (lactose, Encompress® 32.67 32.67 32.67 33 
and AVicel® PH101) 
Talc 2 2 2 
Lubritab® 1 
'A, Band C series for each formulation number contain lactose, Encompress"', and 
AVicel® PH101, respectively. 
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6.3.2 Compression study 
They have been reports in the literature that compression force has a negligible 
influence on the drug release rate from compressed hydrophilic matrices (Hogan 1989; 
Huber and Christenson 1968; Lapidus and Lordi 1968; Ford et al. 1985a; Talukdar and 
Plaizier-Vercammen 1993). However, these studies were conducted using active 
ingredients with much higher melting points than S(+) ibuprofen. Due to the low melting 
pOint of S(+) ibuprofen (S3-SS°C) there is a greater tendency for capping to occur. Mini-
matrices containing S(+) ibuprofen, xanthan gum or karaya gum and lactose in a ratio 
of 1: 1: 1 (Formulations 1SA and 16A, Table 6.1) were produced using a compression 
force in the range of 11-26 kN (F3 Compression Cycle Analysis System, BWI Manesty, 
England). The S.S mm diameter punches and die were used for easy observation. The 
weight of the mini-matrices was increased to 54.93±1.12 mg to suit their size. The 
crushing strength of these mini-matrices was investigated by the method mentioned 
earlier. The mean crushing strength and standard deviation were calculated and 
plotted against compression forces (Figure 6.1). 
6.3.3 Mini-matrix dissolution study 
The USP XXIII basket method (Copley Dissolution System and Drive Control, 
Copley Instruments, Nottingham, England) was used with a constant temperature 
water bath at 37±0.SoC. The dissolution medium used was O.OS M phosphate buffer 
(pH 7.0). The speed of rotation was 100±1 rpm. The dissolution apparatus was 
connected to a flow-through UV spectrophotometer (Ultrospec II, LKB Biochrom Ltd., 
England) via a peristaltic pump. The absorbance was measured automatically at 231 
nm in a 10 mm cell at 30 minute intervals over a 12 hour period. 
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In addition to the new formulations produced, the release profile of 
commercially available ibuprofen sustained release products; Brufen Retard® (Boots, 
800 mg/tablet) and Fenbid Spansule® (Goldshield, 300 mg/capsule), were also 
studied. 
The studies were carried out in triplicate. The cumulative percentage of S(+) 
ibuprofen released was calculated and plotted against time. The release rates were 
calculated from a Higuchi plot (Equation 1.8). The values of nand k were calculated 
from a plot of log fraction of drug release against log time (Equation 1.1). The Fickian 
and relaxational contributions were calculated according to Equation 1.2. 
The pH change dissolution method (changing the pH of the dissolution medium 
while running the dissolution test) was also used with mini-matrices formulations 15A 
and 17 A in order to simulate the environment of the gastro-intestinal tract. The 
dissolution media used were 0.05 M hydrochloric acid buffer pH 1.5 for the first hour, 
citrate-phosphate buffer pH 5 for the second hour, 0.05 M phosphate buffer pH 6.5 for 
the next 3 hours and finally 0.05 M phosphate buffer pH 7.2 for 3 hours. Each medium 
was warmed to 37±0.5°C. At defined time intervals, the dissolution medium was 
removed and fresh medium added. The amount of drug released in the dissolution 
medium at pH 1.5 was analysed by the first order derivative spectrophotometric 
method because of the broad absorbance spectrum. For the other media, the simple 
UV absorption at wavelength 231 nm was used. 
6.3.4 Compatibility of model drug and excipient. 
Only the S( +) ibuprofen mini-matrices that produced satisfactory release 
profiles were considered for this test. Physical mixtures of binary systems containing 
either S( +) ibuprofen, natural hydrophilic gums and/or excipients in a ratio of 1: 1 were 
prepared with a mortar and pestle. The individual substances and physical mixtures 
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were thermally characterised using a differential scanning calorimeter (Pyris1, Perkin 
Elmer, USA). The samples (1.5-5 mg) were weighed directly into flat bottomed 
aluminium sample pans. The pans were crimped with the lid on top of the sample. 
These samples were heated in a nitrogen atmosphere. The heat flow rate of 20·C/min 
was monitored as a function of temperature from 30 to 400·C. The thermograms were 
recorded. 
6.3.5 Stability study of S(+) ibuprofen minl-matricea 
Only the S(+) ibuprofen mini-matrices that produced the most satisfactory 
release profiles were considered for this test. They were stored in open amber bottles 
at 10, 33 and 75% relative humidity. The 10 and 75% relative humidity chambers were 
kept at 22 and 37" C and the 33% relative humidity chambers were kept at 5, 22 and 
37·C for 2 months. The mini-matrices were sampled after 2 weeks and then at 2 
months for investigation of the physical characteristics; weight, crushing strength and 
friability, and the release characteristics compared with mini-matrices within 24 hours 
after preparation. In addition, this production batch was also investigated for uniformity 
of content and weight. 
8.3.5.1 Uniformity of weight 
The weight of 20 tablets were individually measured. The average weight and 
standard deviation were calculated. For the tablets that weigh s 80 mg, the 
requirements are met if not more than two of the individual weights deviate from the 
average weight by more than 10% and none deviates by more than 20% (BP 1993). 
For uncoated tablets that are required to comply with the test for uniformity of content 
for all active ingredients, the test for uniformity of weight is not required. 
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6.3.5.2 Uniformity of content 
In general, the tablets that contain more than 2 mg or more than 2% w/w of 
active ingredient are not required to pass the uniformity of content test (BP 1993). But 
in this experiment, both the uniformity of weight and the uniformity of content were 
studied for the new product. 
The requirements for dose uniformity are met if the amount of the active drug in 
each of the 10 dosage units lies within the range of 85.0% to 115.0% of the stated 
amount. If one unit is outside the range of 85.0 to 115.0% of the stated amount and no 
unit is outside the range of 75.0% to 125.0% of the stated amount, test 20 additional 
units. The requirements are met if not more than one unit of the 30 is outside the range 
of 85.0% to 115.0% of the stated amount and no unit is outside the range of 75.0% to 
125.0% of the stated amount (BP 1993). 
For this study, 10 tablets were individually weighed and dissolved in 10 ml of 
0.05 M phosphate buffer pH 7.0. They were left in the mechanical shaker overnight for 
complete dissolution of the active drug. The solutions were filtered using Whatman® 
filter paper number 1 with cotton as a filter aid, diluted and the absorbance measured 
using a UV-spectrophotometer (Shimadzu, UV 160A, Japan) at wavelength 221 nm. 
The percent labelled amount of active ingredient of each tablet was calculated. 
6.3.5.3 Friability measurement 
Twenty tablets were brushed to remove loose dust and weighed. They were 
placed in the drum of the friabilator (Erweka TA, Germany) and tumbled with a speed 
of 25 rpm for 4 minutes. The loose dust was removed and the tablets were weighed 
again. The percentage weight loss was calculated. 
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If the weight loss is greater than 1 %, the test should be repeated twice and the 
mean of the three tests determined. A maximum weight loss of not more than 1 % of 
the weight of the tablets being tested is considered acceptable for most products (USP 
XXIII 1994). 
6.4 RESULTS AND DISCUSSION 
6.4.1 Preparation of mini-matrlces 
Initially, the production of mini-matrices containing S(+) ibuprofen and xanthan 
gum or karaya gum in a ratio of 1: 1 was attempted. Both these matrices produced 
serious capping problems, i.e., the partial or complete separation of the top or bottom 
crowns of the tablet from its main body. Compaction of cooled granules (5°C) or an 
increase in the diameter of punches to 5.5 mm were also tried, unsuccessfully, to solve 
this problem. Therefore the excipients; lactose, Encompress® and Avice~, which are 
commonly used and have good compressibility properties, were added to the 
formulations to improve the compression characteristics. 
The S(+) ibuprofen granules became moist when magnesium stearate was 
added, indicating the incompatibility of magnesium stearate and S(+) ibuprofen. This 
interaction between magnesium stearate and racemic ibuprofen was also reported by 
Gordon and co-worker (1984). The lubricant was then changed to talc. The mini-
matrices containing S(+) ibuprofen, gum and excipient 1:1:1 were well formed and no 
capping problems were experienced. 
6.4.2 Compression study 
Compression forces in the range of 11-26 kN were suitable for the production 
of mini-matrices containing S(+) ibuprofen, xanthan gum or karaya gum and lactose in 
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a ratio of 1:1:1 (Formulations 15A and 16A, Table 6.1). At compression forces ~26 kN , 
the capping problem was amplified for both formulations. For S(+) ibuprofen mini-
matrices containing xanthan gum, a compression force as small as 2.3 kN could be 
used while for karaya gum the smallest compression force acceptable was 11 .3 kN. 
This implied that xanthan gum had better adhesion properties than karaya gum. 
Compression forces in the range 11-26 kN had little effect on crushing strength 
(Figure 6.1). The crushing strengths of mini-matrices containing xanthan gum varied 
from 25.1 to 28.0 N while the one containing karaya gum varied from 23.3 to 27.6 N. 
Hence the crushing strengths of these two formulations were not very different. 
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Figure 6.1. The crushing strength of mini-matrices containing S(+) ibuprofen (I) , 
xanthan gum (X) or karaya gum (K), and lactose (L) in a ratio of 1: 1: 1 against 
compression force (mean values ± SD; n =10) . 
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6.4.3 Mini-matrices dissolution study 
6.4.3.1 Effect of excipients and type of gum on release characteristics 
Xanthan gum and karaya gum were used to sustain the release of S(+) 
ibuprofen from mini-matrices because they presented a satisfactory release profile for 
diclofenac sodium mini-matrices (see Chapter 4). The excipients were included in the 
formulations not only to overcome the capping problem but also to regulate the release 
rate of the drug. Lactose (freely water soluble), dicalcium phosphate (Encompress®, 
water insoluble) and microcrystalline cellulose (Avicel®, water insoluble) were used in a 
ratio of drug: gum: excipient 1: 1: 1. All three excipients are commonly used as diluents 
in tablet formulations. The mini-matrices produced had crushing strengths in the range 
of 13-19 N. 
The release studies of S( +) ibuprofen from mini-matrices containing xanthan 
gum and various excipients; lactose, Encompress® or Avicel® (Formulations 15A-C, 
Table 6.1) encapsulated in hard gelatin capsules were carried out in 0.05 M phosphate 
buffer pH 7.0. The different excipients used produced differences in release profiles 
and the results are shown in Figure 6.2. The release profile of mini-matrices containing 
Avicel® is higher than Encompress® and lactose respectively. Maximum accumulated 
release of S(+) ibuprofen at 12 hours was 98% for Avicel® and 82% for Encompress® 
and lactose. The release mechanisms were anomalous (non-Fickian), but approached 
Case II transport with n values of 0.732, 0.644 and 0.881 and release rates of 3.74, 
3.69 and 5.56 % min-112 for lactose, Encompress® and Avicel® respectively (Table 6.2). 
There was little difference in release from the formulations containing Encompress® 
and lactose. Although Avicel® and Encompress® are water insoluble excipienta, their 
drug release profiles were different. The mini-matrices containing Avicel® exhibited a 
higher drug release rate than those containing Encompress® after the first 2 hours. 
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This could result from the disintegration property of Avicel®. When in contact with the 
dissolution medium, xanthan gum absorbs water, swells and becomes a hydrated gel. 
At the same time AVicel®, having disintegration properties, promoted the disintegration 
of the mini-matrices. The mini-matrices were therefore easier to erode, compared with 
Encompress®, resulting in a higher release profile. A similar result, i.e., a slightly higher 
dissolution rate of acetylsalicylic acid from Eudragit® 5-100 matrix containing Avicel® 
PH101 than that containing Encompress®, was also observed (Jovanovic et al. 1997). 
In addition, stUdies have been carried out showing that tablets produced with 
Encompress® do not disintegrate readily (Rubinstein and Bodey 1976; Koparkar et al. 
1990; Fischer 1992), so mini-matrices containing Encompress® would have less 
tendency to erode, compared with AVicel®, consequently showing a slower release 
profile. 
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Figure 6.2. Percentage of S(+) ibuprofen released against time from 8 mini-matrices 
(4.5 mm diameter) containing S(+) ibuprofen (I), xanthan gum (X) and lactose (L) , 
Encompress® (E) or Avicel® (A) enclosed in a hard gelatin capsule (mean values ± SO; 
n =3). 
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Table 6.2. Release parameters from the encapsulated mini-matrices using Equation 1.1 to derive the release exponent (n) and the kinetic 
constant (k). The release rate (% min-112) was calculated from the slopes of the plots of fraction of drug released versus square root of time 
(Equation 1.8) (mean values ±SD; n=3). 
Mini-matrices Release exponent Kinetic constant (k) Correlation Release rate Correlation 
composition • (n) (min-")x 1 0-3 coefficient (r) (% min-112) coefficient (r) 
I:X:L 1:1:1 0.732±0.043 8.19±2.34 0.996 3. 74±0. 06 1.000 
I:X:E 1:1:1 0.644±O.012 14.S3±1.33 0.997 3.69±O.13 1.000 
I:X:A 1:1:1 0.881±O.144 7.21±B.27 0.997 S.S6±0.77 0.993 
I:K:L 1:1:1 1.143±O.062 1.48±O.39 0.994 6.91±O.69 0.998 
I:K:E 1:1:1 1.248±O.261 2.02±2.21 0.994 7.79±1.71 0.997 
I:K:A 1:1:1 1.620±0.181 0.30±0.28 0.980 10.18±O.68 0.990 
I:HPMC:L 1:1:1 0.763±O.030 8.88±1.81 0.999 4.80±0.22 0.999 
*1, S(+) ibuprofen; X, xanthan gum; L, Lactose; E, Encompress"'; A, Avice!"'; K, Karaya gum; HPMC, Hydroxypropyl methylcellulose. 
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The percentage contributions of Fickian diffusion (F) and Relaxation (R) over 
the first 60% of drug release from mini-matrices containing xanthan gum and lactose or 
Encompress® are shown graphically in Figure 6.3a and 6.3b respectively. For mini-
matrices containing Encompress®, the contribution of Fickian diffusion predominated 
for the first 8.5 hours of the dissolution period, and gradually decreased until polymer 
relaxation become predominant at the end (Figure 6.3b). Whereas with mini-matrices 
containing lactose, the contribution of Fickian diffusion predominated during the first 2 
hours, gradually decreasing until polymer relaxation became predominant (Figure 
6.3a). On the other hand, with Avicel® the contribution of polymer relaxation occurs 
almost exclusively throughout the entire dissolution time period, and therefore the 
graph for this is not shown. This is also apparent from the n value of 0.881 which 
approaches Case II transport. 
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Figure 6.3a. The percentage contributions of Fickian diffusion and the polymer 
relaxation mechanisms valid over the first 60% of drug release from mini-matrices 
containing S(+) ibuprofen, xanthan gum and lactose (mean values ± SD; n = 3). 
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Figure 6.3b. The percentage contributions of Fickian diffusion and the polymer 
relaxation mechanisms valid over the first 60% of drug release from mini-matrices 
containing S(+) ibuprofen, xanthan gum and Encompress® (mean values ± SD; n = 3) . 
The release profiles of S(+) ibuprofen mini-matrices containing karaya gum and 
lactose, Encompress® or Avicel® are shown in Figure 6.4. The rank order of release 
rate is AVicel® > Encompress® > lactose, the same order as mini-matrices containing 
xanthan gum. The maximum accumulated drug release were 99% for lactose and 
Encompress®, and 94% for Avicel®. The release mechanisms are Super Case II 
transport with n values of 1.143,1 .248 and 1.620 and release rates of 6.91,7.79 and 
10.18 % min-1/2 for lactose, Encompress® and Avicel® respectively (Table 6.2). 
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Figure 6.4. Percentage of S(+) ibuprofen released against time from 8 mini-matrices 
(4.5 mm diameter) containing S(+) ibuprofen (I), karaya gum (K) and lactose (L), 
Encompress® (E) or AVicel® (A) enclosed in a hard gelatin capsule (mean values ± SD; 
n =3). 
The percentage contributions of Fickian diffusion (F) and Relaxation (R) over 
the first 60% of drug release from mini-matrices containing karaya gum and lactose, 
Encompress® or Avicel® were calculated according to Equation 1.2. The contribution of 
polymer relaxation occurs almost exclusively throughout the entire dissolution time 
period for all three excipients, and therefore the graph for these are not shown. These 
results correlate with the high release exponents (super Case II transport) . 
The encapsulated S(+) ibuprofen mini-matrices containing HPMC and lactose 
in a ratio of 1:1:1 showed an intermediate release profile between S(+) ibuprofen: 
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xanthan gum: lactose 1:1 :1; which is lower, and S(+) ibuprofen : karaya gum: lactose 
1: 1: 1; which is higher (Figure 6.5). The maximum accumulated drug release was 100% 
at 12 hours. The release mechanism was anomalous (non-Fickian) transport with a n 
value of 0.763 and a release rate of 4.80 % min-1I2. 
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Figure 6.5. Percentage of S(+) ibuprofen released against time from 8 mini-matrices 
(4.5 mm diameter) containing S(+) ibuprofen (I) , various gums; xanthan gum (X), 
karaya gum (K) or HPMC, and lactose (L) enclosed in a hard gelatin capsule (mean 
values ± SD; n=3) . 
The percentage contributions of Fickian diffusion (F) and Relaxation (R) over 
the first 60% of drug release is shown graphically in Figure 6.6. The contribution of 
Fickian diffusion is relatively small whilst release due to Relaxation is dominant for the 
entire dissolution time period. 
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Figure 6.6. The percentage contributions of Fickian diffusion and the polymer 
relaxation mechanisms valid over the first 60% of drug release from mini-matrices 
containing S(+) ibuprofen, HPMC and lactose (mean values ± SD; n = 3). 
It is noticeable that the release rates of S(+) ibuprofen mini-matrices containing 
xanthan gum and various excipients were lower than those containing karaya gum. 
These results are opposite to the results from previous studies (see Chapter 4) in 
which encapsulated mini-matrices containing diclofenac sodium: xanthan gum 1: 1 
release the active drug faster than those containing diclofenac sodium: karaya gum 
1: 1. 
For diclofenac sodium: karaya gum 1: 1 mini-matrices, the Fickian diffusion was 
dominant for the first 7 hours of the dissolution period (see Chapter 4) , but with S(+) 
ibuprofen: karaya gum: excipients 1: 1: 1 mini-matrices, the polymer relaxation was 
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mostly dominant for the entire dissolution time period. This means that the release 
mechanism of karaya gum mini-matrices containing diclofenac sodium (49.5% karaya 
gum) and S(+) ibuprofen (32.67% karaya gum) was different. But for S(+) ibuprofen: 
xanthan gum: excipients (lactose or Encompress®) the release mechanism at the early 
period was Fickian diffusion followed by polymer relaxation, similar to the result from 
diclofenac sodium mini-matrices. The viscosity study from Chapter 3 also showed that 
the flow behaviour of karaya gum changed from pseudoplastic to the Herschel-Bulkley 
model when 50% of it was substituted by S(+) ibuprofen, while the flow behaviour of 
xanthan gum remained pseudoplastic on substitution. These results imply that xanthan 
gum can tolerate higher concentrations of added substances than karaya gum. In 
addition, previous reports showed that 5.83% xanthan gum can sustain the release of 
caffeine (Talukdar and Plaizier-Vercammen 1993) and 5% xanthan gum exhibits a 
release profile similar to a 15% HPMC tablet (Dhopeshwarkar and Zatz 1993). 
6.4.3.2 Effect of dissolution m.dlum on rei .... ch.racteristlcs 
The release profiles of encapsulated mini-matrices comprised of S(+) 
ibuprofen, xanthan gum or HPMC, and lactose in a ratio of 1:1:1 using the pH change 
dissolution method are shown in Figure 6.7. The release rate of S(+) ibuprofen from 
these two formulations depends on the pH of the medium. For the first hour, in 
hydrochloric acid medium pH 1.5, the accumulated release was <1% which slightly 
increased in citrate phosphate buffer pH 5 (second hour) but was stili negligible 
«10%). The release was greatly increased in phosphate buffer pH 8.5 (the next 3 
hours). The difference in release rate from these two formulations was clearly noticed 
in phosphate buffer pH 6.5 and 7.2. The release pattems were similar but the mini-
matrices containing HPMC showed the higher degree of release. The pH solubility 
profile carried out with S(+) ibuprofen (see Chapter 3) showed that S(+) ibuprofen was 
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practically insoluble in acid medium pH 2 (0.1 mg/ml). The solubility increased slightly 
in the pH range 2 to 5.7 and rapidly increased at pH >5.7. The release profiles from the 
pH change dissolution method are consistent with the pH solubility profile. This implied 
that the release of S(+) ibuprofen from the mini-matrices depended on the solubility of 
S(+) ibuprofen in the dissolution medium, the pH of this medium being the main 
determining factor. Both polymers used achieved a sustaining effect on drug release. 
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6.4.3.3 Dissolution profile of commercially available ibuprofen sustained release 
products 
The release profile of Brufen Retard® and Fenbid Spansule® in 0.05 M 
phosphate buffer pH 7.0 are shown in Figure 6.8. The maximum accumulated release 
of ibuprofen was 11.77% at 12 hours for Brufen Retard®. The release of ibuprofen from 
Fenbid Spansule® reached 100% within 90 minutes. Under these in vitro dissolution 
conditions, Fenbid Spansule® did not display sustained release of the drug, whereas 
with Brufen Retard® the major portion of the drug was retained in the dosage form. 
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Figure 6.8. Percentage of ibuprofen release against time from Bruf n R rd nd 
Fenbid Spansule® in 0.05 M phosphate buffer pH 7.0 (mean v lue SD; n=3). 
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6.4.4 Compatibility of model drug and excipient. 
The components of formulations 15A-C and 18A (Table 6.1) were studied in 
this experiment. The thermal characteristics of each component and mixtures of them 
were tabulated in Table 6.3. The compatibility between S(+) ibuprofen and lubricants; 
talc and Lubritab®, were also studied. 
Table 6.3. The onset temperature and range of transition (C) of S(+) ibuprofen, 
xanthan gum, excipients and 1:1 physical mixtures of each of these substances from 
DSC thermograms. 
Substance* Endotherm Endotherm Endotherm Exotherm 
onset (C) onset (C) onset (C) range (C) 
50.4 
X 254-318 
L 146.7 212.3 
I:X 49.2 253-311 
I:L 50.8 134.7 213.0 
X:L 145.8 210.5 281-303 
E 
I:E 50.7 
X:E 254-318 
A 331.0 
I:A 50.3 341.8 
X:A 263-319 
I:Talc 50.6 
I: Lubritab® 48.5 
*1; S(+} ibuprofen, X; Xanthan gum, L; Lactose. E; Encompre .. •• A; AVicel-. 
and K; Karaya gum. 
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The thermogram of S(+) ibuprofen exhibited one endotherm at an onset 
temperature of 50.4°C. The physical mixture of S(+) ibuprofen and xanthan gum or 
lactose 1: 1 combined the characteristics of the thermograms of each component with 
the onset temperatures and transition ranges as shown in Table 6.3. 
The thermogram of Encompress~ exhibited no transition over the temperature 
range of 30-400°C. The 1:1 physical mixture of S(+) ibuprofen and Encompress~ 
exhibited the endotherm of S(+) ibuprofen at the onset temperature of so.te. The 
physical mixture of xanthan gum and Encompress® 1:1 exhibited the exotherm of 
xanthan gum at the range of 254-316°C. Encompress~ is reported to decompose 
below 100°C (Perikh 1994) but from this experiment there was no exotherm of 
decomposition of Encompress~. However, the thermal characteristics of S(+) Ibuprofen 
and xanthan gum still remained in the mixture of these substances and Encompress~. 
These results indicated no interaction between S(+) ibuprofen, xanthan gum and 
Encompress®. 
The thermogram of Avicel® exhibited one endotherm at the onset temperature 
of 331.0°C. The physical mixture of S(+) ibuprofen and Avlcel- 1:1 combined the 
characteristics of the thermograms of each component with onset temperatures of 50.3 
and 341.6°C respectively (Table 6.3). The physical mixture of xanthan gum and Avlcel· 
1:1 exhibited a broad exotherm of xanthan gum over the range of 263-31 S·C. The 
tranSition range of pure AVicel® was 32Q-36fc, very clos. to the trIInsltlon range of 
xanthan gum. Therefore, it was possible that the transitions of xanthan gum and 
AVicel® overlapped resulting in only one exotherm. 
The phYSical mixtures of S(+) ibuprofen and talc or Lubritab- 1:1 .xhlblted an 
endotherm of S(+) ibuprofen at the onset temperatures of SO.6 and 48.S·C, 
reSpectively. 
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The thermograms of these physical mixtures exhibited the combination of 
transitions for each component. Some transitions may have shifted slightly to lower or 
higher temperatures but there was no evidence of any new endotherms or exotherms. 
These results implied that all the substances studied in this experiment were unlikely to 
produce interactions in the final product in the solid state. 
6.4.5 Stability study of S(+) ibuprofen mlnl-matrlc •• 
The force ratio (R), i.e., the ratio between lower punch maximum force and 
upper punch maximum force, is one of the indicators for efficiency of lubricant action. 
The maximum value of the force ratio is unity. In order to improve the lubricant action, 
by redUCing the force loss at the die wall and interparticulate friction, Lubritabe 1 % was 
used in this production run (Formulation 18A, Table 6.1) instead of 2% talc 
(Formulation 15A, Table 6.1). The force ratio increased from 0.686 when using 2% talc 
to 0.935 when using 1% Lubritab®; compared at 15 kN maximum upper force. The 
force ratio slightly decreased at higher compression forces. 
It is noticeable that the release rate of S(+) ibuprofen slightly decreased when 
the lubricant was changed from 2% talc to 1% Lubritab- (3.74 and 2.98 %mln·112, 
respectively). The release mechanism was still anomalous with n values of 0.732 for 
2% talc and 0.588 for 1 % Lubritab-. The lower release rate of mini-matrices containing 
Lubritab- might be due to higher hydrophobicity of Lubrltab-. However, the difference 
in the two release rates was very little. 
8.4.5.1 Uniformity of weight 
The weights of 20 mini-matrices were individually measured. The average 
weight was 30.23±O.64 mg. None of the weights deviated from the average weight by 
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more than 10%; the maximum weight was 31.16 mg and the minimum weight was 
29.20 mg. This batch of mini-matrices met the requirement for uniformity of weight (BP 
1993). 
6.4.5.2 Uniformity of content 
The amount of S(+) ibuprofen in each of 10 mini-matrices was determined. The 
average percentage was 10S.22±S.22. None of the amounts are outside the range of 
8S.0 to 11S.0% of the stated amounts; the maximum percentage was 114.41 and the 
minimum percentage was 98.S6. This batch of mini-matrices also met the requirement 
of content uniformity (BP 1993). 
6.4.5.3 Friability 
The friability (weight loss) of 20 mini-matrices was 1.22%. It is slightly higher 
than 1%, the acceptable value for most products (USP XXIII 1994). However, the 
tablets produced for this study were very small, 4.S mm in diameter and 30 mg in 
weight, and none of them showed signs of capping after the friability test. This result is 
considered to be satisfactory. 
6.4.5.4 Effect of moisture on physical properties of S(+) Ibuprofen mini-matrices 
The effect of moisture on the properties of the mini-matrices maintained 
isothermally at 22"C was examined. The weight of the mini-matrices were individually 
determined after being kept in 10, 33 and 7S% relative humidity chambers, at 22·C, for 
2 week and 2 month periods. The average weight and standard deviation were 
calculated and are shown in Figure 6.9. 
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The weight of the mini-matrices, after long storage (2 months), varied in 
accordance with the relative humidity conditions during the study. This indicates that 
there is an exchange of water between the atmosphere and the matrix depending on 
the relative humidity of the environment. The weight of the mini-matrices maintained at 
10% and 33% relative humidity for 2 months (29.72±0.65 and 30.09±0.44 mg 
respectively) were lower than the weight of the freshly prepared mini-matrices 
(30.23±0.64 mg) indicating that drying had taken place. On the other hand, the weight 
of the mini-matrices maintained at 75% relative humidity for 2 months (31.24±0.58 mg) 
was higher than the freshly prepared mini-matrices indicating absorption of moisture. 
The freshly prepared mini-matrices contained moisture and when they were 
maintained at low relative humidity (10% relative humidity), this moisture was lost to 
the atmosphere. At high relative humidity (75% relative humidity), the mini-matrices 
absorbed moisture from the atmosphere. This process was continued until equilibrium 
was reached, exhibited by constant weight. At 33% relative humidity, the weight of 
mini-matrices after either short or long storage periods was the same. This meant that 
the moisture in the atmosphere and in the mini-matrices reached equilibrium within 2 
weeks. The moisture content in the mini-matrices and the atmospheric relative 
humidity should be similar, so as to prevent significant changes in tablet weight during 
the shelf life. At 10% and 75% relative humidity, the weights of the mini-matrices after 
short and long storage periods were different (Figure 6.9). This indicated that 
equilibrium between the moisture content in the mini-matrices and in the atmosphere 
was not reached within 2 weeks but the weight continued to increase up to 2 months. It 
appears that the movement of water molecules between the phases takes place 
gradually over extended periods until eventually equilibrium should be attained. 
However, most of this movement takes place during the initial 2 weeks. 
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igure 6.9. The weight of the mini-matrices containing S(+) ibuprofen, xanthan gum and 
lactose in a ratio of 1: 1: 1 stored in the 10, 33 and 75% relative humidity (RH) 
chambers, at 22°C, for 2 week and 2 month periods compared with the weight of the 
freshly prepared mini-matrices (mean values ±SD; n=20). 
The crushing strengths of the S(+) ibuprofen mini-matrices stored at 10, 33 and 
75% relative humidity, 22°C for 2 week and 2 month periods is shown in Figure 6.10. 
At high (75%) relative humidity, the crushing strengths of long storage mini-matrices 
(B .1±0.6 N) was higher than short storage mini-matrices (6 .1±0.B N). Whereas at 
medium (33%) and low (10%) relative humidity the crushing strengths of short and 
long storage mini-matrices (10.4±0.6 and 10.3±O.9 N for low relative humidity and 
11 .6±O.9 and 12.2±1.2 N for medium relative humidity) was similar. The rank order of 
the crushing strengths of mini-matrices stored at different relative humidity was 33% 
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>10% >75% relative humidity. This result indicated that moisture affected the crushing 
strengths of the mini-matrices. At low relative humidity, the mini-matrices lost their 
moisture content resulting in insufficient water to keep the ingredients bound together. 
The mini-matrices were brittle so the crushing strength was lower when compared with 
the mini-matrices stored at medium relative humidity. On the other hand, the mini-
matrices stored at high relative humidity had excessive water. The mini-matrices were 
softer and more easily crushed. This result indicated that an optimum moisture content 
is necessary in order to achieve the satisfactory crushing strength. 
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Figure 6.10. The crushing strengths of the mini-matrices comprised of S( +) ibuprofen, 
xanthan gum and lactose in a ratio of 1: 1: 1 stored in the 10, 33 and 75% relative 
humidity (RH) chambers, at 22'C, for 2 week and 2 month periods compared with the 
crushing strengths of the freshly prepared mini-matrices (mean values±SD; n = 20). 
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The percentage friabilities , the relative property of crushing strength , of these 
mini-matrices is shown in Figure 6.11 . The obviously high percentage of friability and 
also the remarkably low crushing strength (Figure 6.10) were observed with the mini-
matrices stored at high (75%) relative humidity. The friability of the mini-matrices 
stored at low (10%) and medium (33%) relative humidity was similar to the freshly 
prepared mini-matrices. This result was consistent with the crushing strength 
measurement (Figure 6.10) which showed only slightly different crushing strengths for 
mini-matrices maintained at 10% and 33% relative humidity and freshly prepared mini-
matrices. 
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Figure 6.11 . The percentage friabilities of mini-matrices containing S(+) ibuprofen, 
xanthan gum and lactose in a ratio of 1: 1: 1 stored in the 10, 33 and 75% relative 
humidity (RH) chambers, at 22"C, for 2 week and 2 month periods compared with the 
percentage friability of freshly prepared mini-matrices. 
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6.4.5.5 Effect of moisture on release characteristics 
The release profiles of the mini-matrices stored at various relative humidities 
(10, 33 and 75% relative humidity), 22·C, for a 2 month period are shown in Figure 
6.12. The values of release exponent (n), kinetic constant (k) and correlation 
coefficient (r) of these mini-matrices stored at various conditions and durations are 
shown in Table 6.4. The values of release rate with the correlation coefficient (r) are 
also shown in Table 6.5. The release mechanisms were still anomalous (non-Fickian) 
diffusion with n values of 0.640, 0.797 and 0.564 (Tables 6.4) and release rates of 
3.92, 4.26 and 2.82 %min-1I2 (Table 6.5) for 10%, 33% and 75% relative humidities, 
respectively. The drug release from mini-matrices stored at 75% relative humidity was 
nearly the same as the freshly prepared mini-matrices, while the mini-matrices stored 
at 10 and 33% relative humidities had faster release rates. The drug release rate of 
mini-matrices stored at 33% relative humidity was slower than that at 10% relative 
humidity for the first 6 hours and became faster in the second half of the dissolution 
time period. However, the overall release rates of both were similar. At high relative 
humidity, the equilibrium moisture content, i.e., the moisture content of the mini-
matrices that is in equilibrium with the atmosphere, was higher than at low relative 
humidity. This moisture will partially hydrate the gum. These mini-matrices can then 
hydrate and swell faster, when they are in contact with the dissolution medium, than 
matrices with low moisture content. This results in slow release rates. In addition, this 
result is consistent with the calculated n value = 0.564 which indicated that the 
dominant mechanism in drug release was diffusion. While for 10% and 33% relative 
humidities, the calculated n values = 0.640 and 0.797 respectively, indicated that both 
diffusion and polymer relaxation played a part in drug release. Although the moisture 
might slow the release rate of the mini-matrices, the risk of chemical instability and 
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also the physical properties of the final product at high relative humidity need to be 
considered. 
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Figure 6.12. Percentage of S( +) ibuprofen released against time from 8 mini-matrices 
(4.5 mm diameter) containing S(+) ibuprofen, xanthan gum and lactose in a ratio of 
1: 1: 1. The matrices were stored in the 10, 33 and 75% relative humidity (RH) 
chambers, at 22°C, for a 2 month period, and enclosed in a hard gelatin capsule. 
Results are compared with the release profile of freshly prepared mini-matrices (mean 
values ±SD; n=3). 
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Table 6.4. Release parameters from the encapsulated mini-matrices, containing S( +) ibuprofen, xanthan gum and lactose in a ratio of 1: 1: 1, 
after stored at various relative humidities and temperatures, using Equation 1.1 to derive the release exponent (n) and the kinetic constant (k) 
(mean values±SD; n=3). 
% Relative Temperature 2 week storage 2 month storage 
humidity (OC) Release Kinetic constant Correlation Release Kinetic constant Correlation 
exponent (n) (k) (min-n)x10-3 coefficient (r) exponent (n) (k) (min-")x10-3 coefficient (r) 
10 5 - - - - - -
22 0.867±O.092 5. 17±2.07 0.999 0.640±0.055 1S.68±4.91 0.999 
37 0.643±O.025 12.04±1.69 0.998 0.S74±O.039 21.93±6.12 0.999 
33 5 0.711±O.073 10.97±3.80 0.998 O. 885±O. 009 5.31±O.14 0.996 
22 0.653±O.100 15.52±8.60 0.997 0.797±O.111 6.82±3.90 0.998 
37 0.684±O.126 13.03±6.90 0.999 0.742±O.019 7.02±0.93 0.998 
75 5 - - - - - -
22 0.611±O.059 18.16±7.07 0.994 0.564±O.023 18.53±2.10 0.998 
37 0.578±O.005 19.95±0.09 0.996 0.655±O.089 14.62±7.30 0.995 
Release exponent of freshly prepared mini-matrices was 0.588±O.023. 
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Table 6.5. Release rates of encapsulated mini-matrices, containing S(+) ibuprofen, xanthan gum and lactose in a ratio of 1:1 :1, after stored in 
various relative humidities and temperatures (mean values±SD; n=3). 
% Relative Temperature 2 week storage 2 month storage 
humidity (0C) Release rate Correlation Release rate Correlation 
(%min-112) coefficient (r) (%min-112) coefficient (r) 
10 5 - - - -
22 5. 13±O.52 0.992 3. 92±0.16 0.996 
37 3.19±0.04 1.000 3.55±O.18 0.997 
33 5 4.02±O.36 0.998 3.51±O.23 0.999 
22 3.70±0.30 0.998 4.26±O.35 0.996 
37 3.80±0.78 0.998 3.62±O.02 0.999 
75 5 - - - -
22 3.46±O.02 0.998 2.82-+0.10 1.000 
37 3.29±O.07 0.999 3.62±O.39 1.000 
Release rate of freshly prepared mini-matrices was 2.96±0.13 % min . 
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6.4.5.6 Effect of temperature on physical properties of S(+) Ibuprofen mlnl-
matrices 
The effect of temperature (5, 22 and 37°C) on the properties of the mini-
matrices maintained at constant relative humidity (33%) was examined. The weights of 
the mini-matrices stored in the 33% relative humidity chambers, at various 
temperatures (5, 22 and 3iC), for 2 week and 2 month periods are shown in Figure 
6.13. The weights of the mini-matrices stored under various conditions were similar to 
each other and slightly lower than the weights of the freshly prepared mini-matrices. 
The weights were in the range of 29.80 to 30.11 mg. This implied that the moisture 
content in the freshly prepared mini-matrices was close to the moisture content at 33% 
relative humidity. This result is consistent with the result from the effect of moisture on 
the weights of the mini-matrices which showed little weight variation between freshly 
prepared mini-matrices and the mini-matrices stored at 33% relative humidity. 
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Figure 6.13. The weights of the mini-matrices containing S( +) ibuprofen, xanthan gum 
and lactose in a ratio of 1: 1: 1 stored in the 33% relative humidity chamber, at 5, 22 and 
3tC, for 2 week and 2 month periods compared with the weights of freshly prepared 
mini-matrices (mean values±SD; n = 20). 
The crushing strengths and the percentage friabilities of the mini-matrices 
stored in the 33% relative humidity chamber, at various temperatures (5, 22 and 3t C) , 
for 2 week and 2 month periods are shown in Figures 6.14 and 6.15 respectively . The 
crushing strength increased with increasing temperature and vice versa for the 
percentage friability . At higher temperatures, the mini-matrices lost more moisture to 
the atmosphere, resulting in the higher crushing strength and lower friability . 
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Figure 6.14. The crushing strengths of the mini-matrices containing S(+) ibuprofen, 
xanthan gum and lactose in a ratio of 1: 1: 1 stored in the 33% relative humidity 
chamber, at 5, 22 and 3tC, for 2 week and 2 month periods compared with the 
crushing strengths of freshly prepared mini-matrices (mean values±SD, n = 20) . 
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Figure 6.15. Percent friabilities of mini-matrices containing S(+) ibuprofen, xanthan 
gum and lactose in a ratio of 1: 1: 1 stored in the 33% relative humidity chamber, at 5, 
22 and 37°C, for 2 week and 2 month periods compared with the percent friability of 
freshly prepared mini-matrices. 
6.4.5.7 Effect of temperature on release characteristics 
The release profiles of mini-matrices stored in the 33% relative humidity 
chamber, at various temperatures (5, 22 and 3i C) , for a 2 month period are shown in 
Figure 6.16. The release mechanisms were still anomalous (non-Fickian) diffusion but 
approaching Case II transport with n values of 0.885, 0.797 and 0.742 (Table 6.4) and 
release rates of 3.51, 4.26 and 3.62 %mm1ll2 at 5, 22 and 3i c respectively (Table 
6.5). The release rates of these mini-matrices were higher than the release rate of 
freshly prepared mini-matrices, 2.96 % min-1/2 (Table 6.5). The release profiles of the 
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mini-matrices stored at 22 and 37°C were close to the release profile of freshly 
prepared mini-matrices for the first 2.5 and 4.5 hours respectively, and became higher 
later. These profiles implied that the mini-matrices had hydration rates fast enough to 
retard the release of the drug during initial stages. However, the release profile 
markedly increased later indicating that the increase of storage temperature might 
lower the swelling extent or enhance the erosion of the gum. The drug release profile 
from mini-matrices stored at 5°C was similar to the freshly-prepared mini-matrices but 
the release rate was higher. This result implied that low temperature might retard the 
hydration rate, decrease the swelling and/or enhance the erosion of the gum. 
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Figure 6.16. Percentage of S( +) ibuprofen released against time from 8 mini-matrices 
(4.5 mm diameter) containing S(+) ibuprofen, xanthan gum and lactose in a ratio of 
1: 1: 1. The matrices were stored in the 33% relative humidity chamber, at 5, 22 and 
37°C, for a 2 month period, and enclosed in a hard gelatin capsule. Results are 
compared with the release profile of freshly prepared mini-matrices (mean values ±SD; 
n=3). 
6.5 CONCLUSION 
S(+) ibuprofen mini-matrices can be produced by the wet granulation method 
using xanthan and karaya gums as the retarding agents. Excipients with good 
compressibility were needed in the formulation . Compression forces in the range of 11-
26 kN had little effect on the crushing strengths of mini-matrices. The crushing 
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strengths were in the range of 23.3-28.0 N. Xanthan gum produced a greater 
sustaining effect on the release of S(+) ibuprofen compared with karaya gum. The 
excipients used; lactose, Encompress® and AVicel®, affected the release rate of S(+) 
ibuprofen from encapsulated mini-matrices. The release rate from xanthan gum mini-
matrices containing lactose and Encompress® were very similar; 3.74 and 3.69 
%min-1/2 respectively, and slower than those containing Avicel®; 5.56 %min-1I2. The 
release mechanisms were anomalous with n values of 0.732, 0.644 and 0.881 for 
lactose, Encompress® and Avicel® respectively. From the contribution of Fickian 
diffusion and Relaxation, the release of S(+) ibuprofen from mini-matrices containing 
lactose and Encompress® in the initial stages was Fickian diffusion, gradually declining 
and changing to polymer relaxation in the later stages of the dissolution time period. 
For mini-matrices containing AVicel®, polymer relaxation was dominant throughout the 
dissolution time period. 
The release mechanism of S(+) ibuprofen from karaya gum mini-matrices 
containing lactose, Encompress® and Avicel® was Super-Case" with n values of 
1.143, 1.248 and 1.620 and release rates of 6.91, 7.79 and 10.18 %mm1l2, 
respectively. Polymer relaxation was dominant throughout the dissolution time period. 
The release of S(+) ibuprofen from S(+) ibuprofen: HPMC: lactose 1:1:1 was 
faster than xanthan gum mini-matrices but slower than karaya gum mini-matrices. The 
release mechanism was anomalous with a n value of 0.763 and a release rate of 4.80 
%min-112. Polymer relaxation was dominant throughout the dissolution time period. 
The release of S( +) ibuprofen from mini-matrices containing xanthan or HPMC 
and lactose depended greatly on the pH of the medium. This result was consistent with 
the pH solubility profile of S(+) ibuprofen (see Chapter 3). 
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The gums and excipients used in formulations 15A-C and 18A were unlikely to 
have any interaction with each other in the solid state, as shown by the DSC screening 
studies. 
All three polymers used, xanthan gum, karaya gum and HPMC, had a 
sustaining effect on the release of S(+) ibuprofen from the mini-matrix formulations. 
Xanthan gum and HPMC were particularly suitable with release exponents 
approaching zero-order (constant) release over 12 hour time periods in vitro, especially 
when using the pH change method. However the commercially available products, 
Brufen Retard® and Fenbid Spansule®, did not demonstrate suitable sustained release 
profiles under these in vitro dissolution study conditions. 
Isothermal storage of the mini-matrices at 22·C with different relative 
humidities, 10, 33 and 75%, for a 2 month period did not change the mechanism of the 
drug release from S(+) ibuprofen mini-matrices. At 10 and 33% relative humidities, 
there were small changes in the release rate, crushing strength, friability and weight of 
the mini-matrices. At 75% relative humidity, the crushing strength decreased whereas 
the friability and weight increased significantly. The release rate was close to the 
release rate of freshly prepared mini-matrices. 
After storage of the mini-matrices, at 33% relative humidity and various 
temperatures (5, 22 and 3iC), for 2 months, there was no change in the mechanisms 
of drug release. But there were small changes in release rate, crushing strength, 
friability and weight of the mini-matrices. 
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7.1 CONCLUSION 
CHAPTER 7 
OVERALL CONCLUSION 
Sustained-release drug delivery systems are developed in order to overcome 
the fluctuation in drug serum concentration, which may lead to low efficiency of 
treatment. Many methods are used to prepare sustained-release drug delivery 
systems. Each method has its own advantages and disadvantages that suit certain 
situations. This study attempted to prepare sustained-release diclofenac sodium and 
S(+) ibuprofen in the form of mini-matrices using the tabletting technique. A precise 
number of mini-matrices were enclosed in hard gelatin capsules to produce multiple 
unit dosage forms (MUDFs). 
Diclofenac sodium and S( +) ibuprofen sustained-release mini-matrices were 
prepared by the wet granulation method. Due to the low melting point of S(+) ibuprofen 
(53-55·C), a serious capping problem occurred during the compaction of mini-matrices. 
A suitable excipient was needed in the preparation of S(+) ibuprofen mini-matrices to 
improve the compression characteristics. From four natural hydrophilic gums studied 
(xanthan, karaya, locust bean and carrageenan gums), at 50% gum concentration, 
xanthan and karaya gums exhibited good retarding characteristics. These two gums 
delayed the release of the drug for up to ~ 12 hours. At low gum concentration (about 
33% wlw), karaya gum cannot retain its sustaining property. 
The release of the drug from the mini-matrices was regulated by drug diffusion 
and polymer relaxation which were both occurring simultaneously. The release rate of 
the drug increased with decreasing gum concentration and/or increasing the excipient 
concentration with the release mechanism changing from anomalous to Case II and 
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then to Super Case II transport. Solubility differences between the excipients did not 
affect the release rate. The stirring speed and the tablet volume had a relatively small 
effect on drug release. Xanthan gum mini-matrices produced a lower release rate than 
HPMC mini-matrices at both 33 and 50% wlw gum concentration. While karaya gum 
mini-matrices produced a lower release rate than HPMC mini-matrices only at 50% 
wlw gum concentration. 
Compression forces (11-26 kN) slightly affected the crushing strength of S(+) 
ibuprofen mini-matrices. S(+) ibuprofen mini-matrices were relatively stable to variation 
in temperature (5-3iC) and relative humidity (10-75%) over a 2 month time period. 
These results have shown that near zero-order release of diclofenac sodium 
and S(+) ibuprofen can be achieved using encapsulated mini-matrices. At low gum 
concentration, xanthan gum could sustain the release of the drug better than karaya 
gum. The release rate of the drugs is influenced by the gum concentration. 
The method of preparation can be applied to the other model drugs to produce 
sustained-release mini-matrices MUDFs. It is a simple and practical method for all who 
have tabletting facilities. The amount of gums and excipients used can be varied to 
obtain the optimum release profile for each model drug. 
7.2 SUGGESTION FOR FURTHER WORK 
In order to develop the formulation, further studies that should be considered 
are: 
• investigation of the optimum concentration of the gums that can retain their 
sustaining properties 
• microcrystalline cellulose loses its compaction property during the wet granulation 
method (Staniforth 1997), so for S(+) ibuprofen, using better compressibility 
excipients, e.g. silicified microcrystalline cellulose, or varying the method of 
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production, e.g. dry mixing excipient with the drug and gum granules, should be 
attempted in order to reduce the amount of excipient in the formulation 
• xanthan gum mini-matrices containing water soluble model drug should be studied 
in order to investigate the retarding property of xanthan gum 
• In vivo bioavailability should be investigated before launching these products. 
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